image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
26cc285aac7120c2adaf25b6c38baaac6cf226850b578a6a477b3f631ac18c02.png | complex | <table><tr><td rowspan="3">Variables</td><td>Overall</td><td rowspan="3"><i>p</i>-Value</td><td>Women</td><td rowspan="3"><i>p</i>-Value</td><td>Men</td><td rowspan="3"><i>p</i>-Value</td></tr><tr><td>N = 7504</td><td>N = 766</td><td>N = 6738</td></tr><tr><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td></tr><tr><td>Age (by five-year increment)</td><td>1.31 (1.24–1.39)</td><td><0.0001</td><td>1.36 (0.97–1.89)</td><td>0.074</td><td>1.30 (1.23–1.38)</td><td><0.0001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>25–29.9</td><td>2.18 (1.89–2.51)</td><td><0.0001</td><td>2.66 (0.95–7.45)</td><td>0.062</td><td>2.01 (1.74–2.32)</td><td><0.0001</td></tr><tr><td>≥30</td><td>5.68 (4.75–6.79)</td><td><0.0001</td><td>7.00 (1.46–33.6)</td><td>0.015</td><td>5.27 (4.40–6.31)</td><td><0.0001</td></tr><tr><td>Elevated blood pressure *</td><td>2.59 (2.24–3.00)</td><td><0.0001</td><td>2.29 (0.51–10.4)</td><td>0.28</td><td>2.36 (2.03–2.73)</td><td><0.0001</td></tr><tr><td>Waist circumference <sup>∫</sup></td><td>4.95 (4.27–5.73)</td><td><0.0001</td><td>4.39 (1.61–12.0)</td><td>0.0038</td><td>4.94 (4.26–5.74)</td><td><0.0001</td></tr><tr><td>Serum TG ≥ 150 mg/dL</td><td>4.61 (3.97–5.34)</td><td><0.0001</td><td>3.70 (1.02–13.5)</td><td>0.047</td><td>4.28 (3.68–4.97)</td><td><0.0001</td></tr><tr><td>FPG ≥ 100 mg/dL</td><td>1.94 (1.63–2.30)</td><td><0.0001</td><td>12.64 (4.34–36.8)</td><td><0.0001</td><td>1.74 (1.46–2.07)</td><td><0.0001</td></tr><tr><td>Low serum HDL <sup>$</sup></td><td>2.60 (2.24–3.02)</td><td><0.0001</td><td>2.93 (1.08–7.91)</td><td>0.034</td><td>2.72 (2.33–3.17)</td><td><0.0001</td></tr><tr><td>Total cholesterol ≥ 200 mg/dL</td><td>2.90 (2.50–3.37)</td><td><0.0001</td><td>1.39 (0.39–4.95)</td><td>0.61</td><td>2.86 (2.45–3.33)</td><td><0.0001</td></tr><tr><td>Current alcohol intake</td><td>1.32 (1.15–1.53)</td><td><0.0001</td><td>1.20 (0.38–3.77)</td><td>0.75</td><td>1.20 (1.04–1.39)</td><td>0.012</td></tr><tr><td>Metabolic syndrome (ATPIII)</td><td>5.90 (5.04–6.91)</td><td><0.0001</td><td>23.53 (8.09–68.5)</td><td><0.0001</td><td>5.36 (4.57–6.28)</td><td><0.0001</td></tr><tr><td>Metabolic syndrome (IDF)</td><td>6.35 (5.38–7.49)</td><td><0.0001</td><td>20.83 (6.93–62.64)</td><td><0.0001</td><td>5.81 (4.92–6.87)</td><td><0.0001</td></tr></table> |
e5dacfbd215abbdad8acc9106bb7f36c537ad089a8659dc0e45400e787639349.png | simple | <table><tr><td>Antibody (host, clonality, Company)</td><td>Purpose</td><td>Dilution</td></tr><tr><td>FGFR1 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGFR2 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGF7 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGF7 (rabbit, polyclonal, Abcam, Cambridge, UK)</td><td>WB</td><td>1:200</td></tr><tr><td>FGF10 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGF10 (goat, polyclonal, Peprotech Inc., Rocky Hill, NJ)</td><td>WB</td><td>1:200</td></tr><tr><td>p-p44/42 MAPK (Thr202/Tyr204) (rabbit, polyclonal, Cell Signaling, Beverly, MA)</td><td>WB</td><td>1:1,000</td></tr><tr><td>Akt (rabbit, polyclonal, Cell Signaling, Beverly, MA)</td><td>WB</td><td>1:1,000</td></tr><tr><td>p-Akt (Ser473) (rabbit, polyclonal, Cell Signaling, Beverly, MA)</td><td>WB</td><td>1:1,000</td></tr><tr><td>Actin (mouse, monoclonal, Amersham, Buckinghamshire, UK)</td><td></td><td></td></tr></table> |
16abdcae8b6427d58acf6294fe25b8c288d0307d6f775878cbfccce185e5e248.png | complex | <table><tr><td><i>N</i> = 54</td><td colspan="4">Test site</td></tr><tr><td></td><td>A</td><td>C2</td><td>L</td><td>C1</td></tr><tr><td>Average speed (km.h<sup>−1</sup>)</td><td>23.1 ± 1.3a<sup>*</sup></td><td>21.1 ± 1.0b</td><td>21.2 ± 0.8b</td><td>22.4 ± 0.9a</td></tr><tr><td>HR (beats.mn<sup>−1</sup>)</td><td>142.2 ± 15.2</td><td>140.0 ± 9.3</td><td>141.2 ± 13.7</td><td>146.9 ± 1</td></tr><tr><td>RMSSD (ms)</td><td>6.4 ± 2.7a<sup>*</sup></td><td>3.2 ± 1.0b</td><td>2.7 ± 1.3c</td><td>4.0 ± 1.6b</td></tr><tr><td>SD2 (ms)</td><td>38.3 ± 12.1</td><td>34.2 ± 23.2</td><td>23.7 ± 17.8</td><td>34.8 ± 16.7</td></tr><tr><td>LF (ms<sup>2</sup>)</td><td>12.6 ± 3.3</td><td>11.2 ± 3.9</td><td>6.9 ± 1.5</td><td>13.7 ± 5.8</td></tr><tr><td>HF (ms<sup>2</sup>)</td><td>9.3 ± 6.5</td><td>8.1 ± 5.1</td><td>8.7 ± 5.5</td><td>13.8 ± 6.6</td></tr><tr><td>LF/HF</td><td>1.6 ± 0.7</td><td>1.6 ± 0.6</td><td>1.1 ± 0.6</td><td>1.2 ± 0.6</td></tr><tr><td>LFnu (%)</td><td>60.1 ± 11.8</td><td>60.3 ± 8.9</td><td>48.4 ± 15.7</td><td>51.0 ± 14.4</td></tr><tr><td>HFnu (%)</td><td>39.9 ± 11.8</td><td>39.7 ± 8.9</td><td>51.6 ± 15.7</td><td>49.0 ± 14.4</td></tr></table> |
c72350f30549b497fec1c67d5a7d971cb6844e96c9db200ad02997d79d4451a2.png | simple | <table><tr><td>Characteristics</td><td>Controls n = 67</td><td>NSTEMI n = 38</td><td>STEMI n = 30</td></tr><tr><td>Age</td><td>66 ± 12</td><td>72 ± 15</td><td>72 ± 13</td></tr><tr><td>M/F</td><td>46/21</td><td>29/9</td><td>21/9</td></tr><tr><td>Diabetes Mellitus</td><td>8</td><td>8</td><td>4</td></tr><tr><td>Prior IHD</td><td>29</td><td>18</td><td>12</td></tr><tr><td>Hemoglobine, g/l</td><td>135 ± 15</td><td>132 ± 15</td><td>132 ± 16</td></tr><tr><td>Platelet count, ×10<sup>9</sup>/l</td><td>224 ± 74</td><td>218 ± 51</td><td>222 ± 66</td></tr><tr><td>Cholesterol mmol/l</td><td>-</td><td>4,67 ± 0,94</td><td>4,60 ± 0,79</td></tr><tr><td>Triglycerides mmol/l</td><td>-</td><td>1,19 ± 0,46</td><td>1,28 ± 0,94</td></tr><tr><td>BMI</td><td>-</td><td>24 ± 2,8</td><td>27 ± 3,2</td></tr></table> |
b271cb0457b1b5ffb5a0e9e347c662a6813c491c1415d74b01e8e6d4e80b5711.png | simple | <table><tr><td>Raw material</td><td>Cellulose</td><td>Hemicellulose</td><td>Lignin</td><td>Ash</td></tr><tr><td>Wheat straw</td><td>44.2 (1.8)</td><td>26.5 (1.9)</td><td>22.4 (1.7)</td><td>2.8 (0.6)</td></tr><tr><td>Rice straw</td><td>36.1 (2.6)</td><td>27.2 (3.2)</td><td>19.7 (2.5)</td><td>12.1 (2.8)</td></tr><tr><td>Poplar</td><td>39.2 (1.1)</td><td>18.8 (1.4)</td><td>29.6 (1.6)</td><td>1.5 (1.2)</td></tr></table> |
9afba184dea57942fc96ec313852f15774d9553984e735a2ec7290c4ddfc0834.png | complex | <table><tr><td colspan="4"></td><td colspan="5">Up/Down-regulated<sup>c</sup></td><td colspan="3">Regulated by</td></tr><tr><td></td><td>Gene<sup>a</sup></td><td>Enzyme<sup>b</sup></td><td>CAZy family</td><td>Δ<i>xlnR</i></td><td>Δ<i>araR</i></td><td>Δ<i>rhaR</i></td><td>Δ<i>galX</i></td><td>Δ<i>amyR</i></td><td>This study</td><td>Literature</td><td>Reference</td></tr><tr><td rowspan="2">E-1</td><td>An15g04900 (<i>eglD</i>)</td><td>LPMO</td><td>AA9</td><td>2.1</td><td>−1.2</td><td>−1.7</td><td>−1.6</td><td>−1.8</td><td>nd</td><td>nr</td><td>[38]</td></tr><tr><td>An03g00190 (<i>pelB</i>)</td><td>PEL</td><td>PL1</td><td>–</td><td>–</td><td>–</td><td>1.2</td><td>1.0</td><td>nd</td><td>nr</td><td>[73]</td></tr><tr><td rowspan="6">E-2</td><td>An07g09760</td><td>BGL</td><td>GH3</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>nd</td><td>nr</td><td>[38]</td></tr><tr><td>An08g01100</td><td>EXG</td><td>GH5</td><td>1.6</td><td>1.1</td><td>1.1</td><td>–</td><td>3.8</td><td>nd</td><td>nr</td><td>[38]</td></tr><tr><td>An11g03200 (<i>inuA</i>/<i>inuB</i>)</td><td>INU</td><td>GH32</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>nd</td><td>InuR</td><td>[8, 79]</td></tr><tr><td>An12g08280 (<i>inuE</i>/<i>inu1</i>)</td><td>INX</td><td>GH32</td><td>2.9</td><td>2.0</td><td>1.9</td><td>5.2</td><td>4.1</td><td>nd</td><td>InuR</td><td>[8]</td></tr><tr><td>An02g04900 (<i>pgaB</i>)</td><td>PGA</td><td>GH28</td><td>2.6</td><td>−2.3</td><td>–</td><td>2.2</td><td>−2.1</td><td>nd</td><td>GaaR</td><td>[15, 34, 80]</td></tr><tr><td>An08g11070 (<i>sucA</i>/<i>suc1</i>)</td><td>SUC</td><td>GH32</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>nd</td><td>InuR</td><td>[9, 81, 82]</td></tr></table> |
5c1a90fe2818afd05eeb8cdbe09cf1fe9db826fda7d7b417a883bba21d744777.png | complex | <table><tr><td>Year</td><td colspan="2">Public Hospitals</td><td>Public medic patients</td></tr><tr><td></td><td>Outpatients (95% CI)</td><td># of hospitalizations</td><td></td></tr><tr><td>1918</td><td>20.11 (16.43, 25.90)</td><td>12.20 (10.59, 14.38)</td><td>32.21* (28.48, 39.82)</td></tr><tr><td>1919</td><td>14.55 (11.89, 18.74)</td><td>36.70* (31.85, 43.27)</td><td>26.64* (22.70, 31.73)</td></tr><tr><td>1920</td><td>1.72 (1.40, 2.21)</td><td>19.83* (17.21, 23.38)</td><td>8.27 (7.09, 9.92)</td></tr></table> |
fd1164931ece75cada74d5df26877423f27210e5f7ef6ebcb2c5b89332d91480.png | complex | <table><tr><td colspan="2">Surface material</td><td>SBS</td><td>ARI</td></tr><tr><td rowspan="3">Enamel</td><td>Chi-square test</td><td>18.512</td><td>11.686</td></tr><tr><td> Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.003</td></tr><tr><td rowspan="3">SR Adoro</td><td>Chi-square test</td><td>0.281</td><td>1.636</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.869</td><td>0.441</td></tr><tr><td rowspan="3">Filtek Supreme XTE</td><td>Chi-square test</td><td>20.847</td><td>14.017</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.001</td></tr><tr><td rowspan="3">Wisil</td><td>Chi-square test</td><td>6.970</td><td>6.444</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.031</td><td>0.040</td></tr><tr><td rowspan="3">Dispersalloy</td><td>Chi-square test</td><td>9.223</td><td>6.691</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.010</td><td>0.035</td></tr><tr><td rowspan="3">Herador</td><td>Chi-square test</td><td>3.583</td><td>8.561</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.167</td><td>0.014</td></tr><tr><td rowspan="3">e.max Press</td><td>Chi-square test</td><td>23.086</td><td>11.600</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.003</td></tr><tr><td rowspan="3">ZirCAD</td><td>Chi-square test</td><td>16.423</td><td>15.612</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.000</td></tr><tr><td rowspan="3">Mark II</td><td>Chi-square test</td><td>9.762</td><td>19.815</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.008</td><td>0.000</td></tr></table> |
54489499a55fdf9487d86a179e00ededa3e3dcfa4f19216798a609ca6ec25cde.png | complex | <table><tr><td>Year</td><td>Number of districts</td><td colspan="2">Districts reporting at least one suspected case</td><td>Number of suspected cases reported</td><td colspan="2">Blood specimens collected</td><td colspan="2">Confirmed cases</td><td>Districts with confirmed cases</td></tr><tr><td></td><td><i>n</i></td><td><i> n </i></td><td> % </td><td><i>n</i></td><td><i> n </i></td><td> % </td><td><i> n </i></td><td> % </td><td></td></tr><tr><td>2003</td><td>144</td><td>52 </td><td>36.1</td><td>156</td><td>156</td><td>100</td><td>3</td><td>1.3</td><td>Bafia, Méri, Ntui</td></tr><tr><td>2004</td><td>159</td><td>80 </td><td>50.3</td><td>434</td><td>434</td><td>100</td><td>2</td><td>0.5</td><td>Ngaoundéré Rural</td></tr><tr><td>2005</td><td>159</td><td>88 </td><td>55.3</td><td>831</td><td>831</td><td>100</td><td>2</td><td>0.2</td><td>Yoko</td></tr><tr><td>2006</td><td>167</td><td>114</td><td>68.2</td><td>859</td><td>859</td><td>100</td><td>1</td><td>0.2</td><td>Messamena</td></tr></table> |
b121cc95893795522ef766b13edb6863fb6a407a2bb16326e454798f54842672.png | complex | <table><tr><td rowspan="2">Variable</td><td>Univariate</td><td colspan="2">Multivariate</td></tr><tr><td><i>p</i> value</td><td><i>p</i> value</td><td>HR (95% CI)</td></tr><tr><td>Male gender</td><td><0.0001</td><td>0.0104</td><td>1.42 (1.08–1.85)</td></tr><tr><td>Age > 55 years</td><td><0.0001</td><td><0.0001</td><td>8.33 (6.49–10.75)</td></tr><tr><td>Distant metastasis (<i>M</i>1)</td><td><0.0001</td><td><0.0001</td><td>6.06 (3.92–9.35)</td></tr><tr><td>Extrathyroid extension (Ex)</td><td><0.0001</td><td><0.0001</td><td>2.22 (1.74–2.82)</td></tr><tr><td>Tumor size (<i>T</i>)</td><td></td><td></td><td></td></tr><tr><td> >4.0 cm</td><td><0.0001</td><td><0.0001</td><td>2.27 (1.71–3.00)</td></tr><tr><td> 2.1–4.0 cm</td><td>0.8425</td><td>0.7321</td><td>1.04 (0.82–1.33)</td></tr><tr><td>Clinical node metastasis (<i>N</i>1)</td><td></td><td></td><td></td></tr><tr><td> >3.0 cm</td><td><0.0001</td><td><0.0001</td><td>2.64 (1.81–3.85)</td></tr><tr><td> <3.0 cm</td><td><0.0001</td><td>0.0025</td><td>1.52 (1.16–1.99)</td></tr><tr><td>Extranodal tumor extension (LN-Ex)</td><td><0.0001</td><td>0.0073</td><td>1.75 (1.16–2.64)</td></tr></table> |
439647234f2348fe499a423928fb1e0abd4e8357d6465fb83637f700468ef418.png | simple | <table><tr><td>Type of ZnO nanostructure</td><td>Turn-on field (V μm<sup>-1</sup>)</td><td>Threshold field (V μm<sup>-1</sup>)</td><td><i>β</i></td></tr><tr><td>Leaf-like (30 min)</td><td>2.94</td><td>4.35</td><td>2,800</td></tr><tr><td>Long NWs arrays (60 min)</td><td>3.69</td><td>5.72</td><td>2,526</td></tr><tr><td>Needle-like</td><td>3.87</td><td>5.65</td><td>2,284</td></tr></table> |
b7180e1705f50266cc9bcfabcaee0466d43a2ab98264b87b0a131518429493cd.png | simple | <table><tr><td>Patient no.</td><td>CSF leakage</td><td>Leakage pattern</td><td>Location of CSF leakage</td><td>Exact location of CSF leakage</td></tr><tr><td>1</td><td>+</td><td>Pseudodiverticular</td><td>Left T11/12</td><td>+</td></tr><tr><td>2</td><td>+</td><td>Gray rim</td><td>L1</td><td>+</td></tr><tr><td>3</td><td>−</td><td></td><td>−</td><td>−</td></tr><tr><td>4</td><td>+</td><td>Gray rim</td><td>T12/L1</td><td>+</td></tr><tr><td>5</td><td>+</td><td>Pseudodiverticular</td><td>Left L2/3 and L3/4</td><td>+</td></tr><tr><td>6</td><td>+</td><td>Gray rim</td><td>T3</td><td>+</td></tr><tr><td>7</td><td>+</td><td>Gray rim</td><td>From C5/6 to L1/2</td><td>Extensive</td></tr><tr><td>8</td><td>+</td><td>Gray rim</td><td>From C1/2 to T10/11</td><td>Extensive</td></tr><tr><td>9</td><td>+</td><td>Pseudodiverticular</td><td>Right L3/4 and L4/5</td><td>+</td></tr><tr><td>10</td><td>+</td><td>Gray rim</td><td>L4/5/S1</td><td>+</td></tr><tr><td>11</td><td>+</td><td>Gray rim and pseudodiverticular</td><td>From T12 to L2</td><td>Extensive</td></tr><tr><td>12</td><td>+</td><td>Gray rim</td><td>From cervical to upper T-spine</td><td>Extensive</td></tr><tr><td>13</td><td>+</td><td>Gray rim</td><td>T-spine</td><td>Extensive</td></tr><tr><td>14</td><td>+</td><td>Pseudodiverticular</td><td>Both T11/12</td><td>+</td></tr><tr><td>15</td><td>+</td><td>Gray rim</td><td>C5/6/7 and T7/8/9</td><td>Extensive</td></tr><tr><td>16</td><td>+</td><td>Pseudodiverticular</td><td>Right C5/6</td><td>+</td></tr><tr><td>17</td><td>+</td><td>Gray rim</td><td>T5/6</td><td>+</td></tr><tr><td>18</td><td>+</td><td>Gray rim and pseudodiverticular</td><td>From C4 to T4</td><td>Extensive</td></tr></table> |
2cf21bf0cbb132b0ce0512fe3344666f7f1a1bfafb0f3b19a18937884535b235.png | complex | <table><tr><td colspan="2">Variable</td><td>MetS= Yes, n (%)</td><td>COR (95% CI)</td><td><i>P-value</i></td><td>AOR (95% CI)</td><td><i>P-value</i></td></tr><tr><td rowspan="2">Gender</td><td>Men</td><td>44 (37.9)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>women</td><td>72 (62.1)</td><td>1.6 (0.97–2.74)</td><td><i>0.06</i></td><td>1.7 (0.66–4.4)</td><td><i>0.27</i></td></tr><tr><td rowspan="2">Residence:</td><td>Rural</td><td>20 (17.2)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>Urban</td><td>96 (82.8)</td><td>2.3 (1.2–4.2)</td><td><i>0.007</i></td><td>1.3 (0.54–3.1)</td><td><i>0.54</i></td></tr><tr><td rowspan="4">Age in years:</td><td>≤30</td><td>2 (1.7)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>31–45</td><td>31 (26.7)</td><td>5.7 (1.16–27.8)</td><td><i>0.03</i></td><td>5.8 (0.54–3.1)</td><td><i>0.08</i></td></tr><tr><td>46–60</td><td>41 (35.3)</td><td>4.8 (1.0–22.9)</td><td><i>0.05</i></td><td>4.5 (0.62–32.8)</td><td><i>0.14</i></td></tr><tr><td>≥61</td><td>42 (36.2)</td><td>6.8 (1.4–32.7)</td><td><i>0.02</i></td><td>8.2 (1.1–62.4)</td><td><i>0.04</i></td></tr><tr><td rowspan="3">Marital status:</td><td>Single</td><td>5 (4.3)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>Married</td><td>106 (91.4)</td><td>2.5 (1.1–74)</td><td><i>0.03</i></td><td>7.2 (1.4–35.9)</td><td><i>0.02</i></td></tr><tr><td>Divorced/widowed</td><td>5 (4.3)</td><td>13 (1.2–140.7)</td><td><i>0.02</i></td><td>16.4 (1.1–244.2)</td><td><i>0.04</i></td></tr><tr><td rowspan="5">Occupation:</td><td>Farmer</td><td>11 (9.5)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>Employed</td><td>36 (31.0)</td><td>2.2 (0.93–5.26)</td><td><i>0.07</i></td><td>0.86 (0.24–3.07)</td><td><i>0.81</i></td></tr><tr><td>Housewife</td><td>49 (42.2)</td><td>3.36 (1.4–7.9)</td><td><i>0.006</i></td><td>2.1 (0.56–7.93)</td><td><i>0.27</i></td></tr><tr><td>Retirement pension</td><td>11 (9.5)</td><td>4.1 (1.25–13.5)</td><td><i>0.02</i></td><td>5.3 (1.1–25.9)</td><td><i>0.04</i></td></tr><tr><td>Merchants</td><td>9 (7.8)</td><td>1.27 (0.42–3.8)</td><td><i>0.67</i></td><td>1.0 (0.22–4.76)</td><td><i>0.97</i></td></tr><tr><td rowspan="4">Monthly income:</td><td>No income/dependent</td><td>8 (6.9)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td><1000 birr</td><td>50 (43.1)</td><td>2.6 (1.1–61)</td><td><i>0.02</i></td><td>2.2 (0.74–6.55)</td><td><i>0.15</i></td></tr><tr><td>1001–2000 birr</td><td>31 (26.7)</td><td>6.0 (2.3–15.8)</td><td><i><0.0001</i></td><td>3.6 (1.1–12.5)</td><td><i>0.04</i></td></tr><tr><td>>2001 birr</td><td>27 (23.3)</td><td>4.2 (1.6–10.8)</td><td><i>0.003</i></td><td>5.8 (1.5–22.3)</td><td><i>0.01</i></td></tr><tr><td rowspan="4">BMI, Kg/m<sup>2</sup>:</td><td>Normal (18.5–24.9)</td><td>30 (25.9)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>Underweight (<18.5)</td><td>4 (3.4)</td><td>0.57 (0.15–2.19)</td><td><i>0.42</i></td><td>0.89 (0.17–4.5)</td><td><i>0.89</i></td></tr><tr><td>Overweight (25–29.9)</td><td>49 (42.2)</td><td>3.5 (1.9–6.4)</td><td><i><0.0001</i></td><td>2.8 (1.4–5.9)</td><td><i>0.005</i></td></tr><tr><td>Obese (≥30)</td><td>33 (28.4)</td><td>9.5 (3.9–22.9)</td><td><i><0.0001</i></td><td>10.7 (3.8–29.8)</td><td><i><0.0001</i></td></tr><tr><td rowspan="3">Duration since the diagnosis of HTN</td><td><5 years</td><td>73 (62.1)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>6–10 years</td><td>21 (18.1)</td><td>0.73 (0.38–1.38)</td><td><i>0.33</i></td><td>0.61 (0.27–1.38)</td><td><i>0.24</i></td></tr><tr><td>>11 years</td><td>22 (19.0)</td><td>2.5 (1.1–57)</td><td><i>0.02</i></td><td>2.0 (0.75–5.5)</td><td><i>0.16</i></td></tr><tr><td rowspan="2">Doing exercises regularly:</td><td>Yes</td><td>25 (21.6)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>No</td><td>91 (78.4)</td><td>1.7 (0.95–3.0)</td><td><i>0.07</i></td><td>1.9 (0.89–4.3)</td><td><i>0.09</i></td></tr><tr><td rowspan="3">FHCD</td><td>No</td><td>84 (72.4)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>Diabetes</td><td>12 (10.3)</td><td>2.5 (0.89–6.8)</td><td><i>0.08</i></td><td>1.4 (0.36–5.4)</td><td><i>0.62</i></td></tr><tr><td>Hypertension</td><td>20 (17.2)</td><td>2.1 (0.95–4.4)</td><td><i>0.06</i></td><td>2.3 (0.9–5.9)</td><td><i>0.08</i></td></tr><tr><td rowspan="3">Intensity of Physical activity:</td><td>Low</td><td>52 (44.8)</td><td>057 (0.26–1.22)</td><td><i>0.15</i></td><td>0.61 (0.22–1.74)</td><td><i>0.36</i></td></tr><tr><td>Moderate</td><td>43 (37.1)</td><td>0.61 (0.27–1.35)</td><td><i>0.22</i></td><td>0.5 (0.18–1.4)</td><td><i>0.19</i></td></tr><tr><td>High</td><td>21 (18.1)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr></table> |
77d3421194461b57440ab105601490b917c8d5be535aa073767a283cba3064fa.png | complex | <table><tr><td rowspan="2">Instrument</td><td colspan="2">Unprepared apical area (%)</td><td colspan="2">Unprepared coronal area (%)</td></tr><tr><td>Mean ± SD</td><td>Min-Max</td><td>Mean ± SD</td><td>Min-Max</td></tr><tr><td>ProTaper Next</td><td>11.03 ± .96</td><td>10.11–12.8</td><td>55.70 ± 1.25</td><td>53.26–57.19</td></tr><tr><td>WaveOne</td><td>12.06 ± 1.21</td><td>9.25–13.10</td><td>55.53 ± 1.01</td><td>53.48–57.24</td></tr><tr><td><i>P</i> value</td><td colspan="2">.683<sup>c</sup></td><td colspan="2">.684<sup>c</sup></td></tr></table> |
71a0f3fcdc8f3a61c6d345f8e3fc06afd30e7392315e793901893564cdc7feb5.png | simple | <table><tr><td>Heart evaluation parameters</td><td>CRT</td><td>IMRT</td></tr><tr><td>Average maximum heart dose (cGy)</td><td>5295.26</td><td>5209.87</td></tr><tr><td>Range (cGy)</td><td>4858.3–5743.8</td><td>4895.17–5862.8</td></tr><tr><td><i>P-</i>value</td><td>0.08</td><td>0.08</td></tr></table> |
e00918e7dcf1572b21b27f9a21d339ade2978aaea448ab4a51dce5e211961190.png | complex | <table><tr><td></td><td>All studies (<i>n </i>=<i> </i>102)</td><td>Randomized trials (<i>n </i>=<i> </i>25)</td><td>Nonrandomized studies (<i>n </i>=<i> </i>77)</td></tr><tr><td>Number of participants</td><td>66 386</td><td>7172</td><td>59 214</td></tr><tr><td>Age range of participants (years)</td><td>18–99</td><td>29–89</td><td>18–99</td></tr><tr><td colspan="4">Number of participating centres (%)</td></tr><tr><td>Single</td><td>58 (57)</td><td>13 (52)</td><td>45 (58)</td></tr><tr><td>Multiple</td><td>44 (43)</td><td>12 (48)</td><td>32 (42)</td></tr><tr><td>IRB or ethical approval reported (%)</td><td>52 (51)</td><td>14 (56)</td><td>38 (49)</td></tr><tr><td colspan="4">Tumour site (%)</td></tr><tr><td>Colon</td><td>10 (9)</td><td>2 (8)</td><td>7 (9)</td></tr><tr><td>Rectum</td><td>54 (53)</td><td>11 (44)</td><td>44 (55)</td></tr><tr><td>Mixed colon and rectum</td><td>38 (38)</td><td>12 (48)</td><td>26 (34)</td></tr><tr><td colspan="4">Surgical approach (%)</td></tr><tr><td>Laparoscopy</td><td>1 (1)</td><td>0</td><td>1 (1)</td></tr><tr><td>Hand‐assisted laparoscopy</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Open</td><td>5 (5)</td><td>1 (4)</td><td>4 (5)</td></tr><tr><td>Mixed</td><td>13 (12)</td><td>9 (36)</td><td>5 (6)</td></tr><tr><td>Not reported or incomplete information reported</td><td>83 (81)</td><td>15 (60)</td><td>67 (87)</td></tr><tr><td colspan="4">Neoadjuvant treatmenta (%)</td></tr><tr><td>Radiotherapy alone</td><td>20 (20)</td><td>9 (36)</td><td>11 (14)</td></tr><tr><td>Chemotherapy alone</td><td>0</td><td>0</td><td>0v (0.0)</td></tr><tr><td>Chemoradiotherapy</td><td>22 (22)</td><td>3 (12)</td><td>18 (24)</td></tr><tr><td>None</td><td>7 (7)</td><td>1 (4)</td><td>6 (8)</td></tr><tr><td>Not reported or incomplete information reported</td><td>53 (51)</td><td>12 (48)</td><td>42 (54)</td></tr><tr><td colspan="4">Adjuvant treatmenta (%)</td></tr><tr><td>Chemotherapy or chemoradiotherapy</td><td>56 (55)</td><td>16 (64)</td><td>40 (52)</td></tr><tr><td>None</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Not reported or incomplete information reported</td><td>46 (45)</td><td>9 (36)</td><td>37 (48)</td></tr><tr><td colspan="4">Number of PROMs reported</td></tr><tr><td>1</td><td>43</td><td>10</td><td>33</td></tr><tr><td>2</td><td>47</td><td>12</td><td>35</td></tr><tr><td>3</td><td>6</td><td>2</td><td>4</td></tr><tr><td>4</td><td>4</td><td>1</td><td>3</td></tr><tr><td>5</td><td>2</td><td>0</td><td>2</td></tr></table> |
f7a5eae316d8b0e3579dcf8e6b0d2a98593584c05accd3654a4c7fe4f6c54a9b.png | complex | <table><tr><td></td><td colspan="2">Right</td><td><i>p</i></td><td colspan="2">Left</td><td><i>p</i></td></tr><tr><td></td><td>Female</td><td>Male</td><td></td><td>Female</td><td>Male</td><td></td></tr><tr><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td></tr><tr><td>Cervical region</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Short-axis diameter (mm)</td><td>3.59±0.78</td><td>3.53±0.7</td><td>0.823</td><td>3.7±0.75</td><td>3.99±0.76</td><td>0.345</td></tr><tr><td>Long-axis diameter (mm)</td><td>11.35±4.04</td><td>10.85±2.6</td><td>0.717</td><td>11.75±2.52</td><td>11.85±2.95</td><td>0.931</td></tr><tr><td>S/L</td><td>0.34±0.12</td><td>0.34±0.1</td><td>0.926</td><td>0.33±0.08</td><td>0.35±0.07</td><td>0.403</td></tr><tr><td>Submandibular region</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Short-axis diameter (mm)</td><td>3.82±1.02</td><td>3.92±1.05</td><td>0.823</td><td>3.85±0.59</td><td>4.65±1.34</td><td>0.063</td></tr><tr><td>Long-axis diameter (mm)</td><td>12.45±3.55</td><td>13.26±5.3</td><td>0.654</td><td>12.18±2.32</td><td>11.68±1.51</td><td>0.533</td></tr><tr><td>S/L</td><td>0.33±0.12</td><td>0.32±0.1</td><td>0.836</td><td>0.32±0.07</td><td>0.40±0.12</td><td>0.055</td></tr><tr><td>Submental region</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Short-axis diameter (mm)</td><td>4.29±0.85</td><td>5.04±1.6</td><td>0.152</td><td>4.27±0.73</td><td>4.83±1.68</td><td>0.301</td></tr><tr><td>Long-axis diameter (mm)</td><td>13.85±3.15</td><td>16.64±5.6</td><td>0.147</td><td>15.45±2.65</td><td>16.98±6.29</td><td>0.445</td></tr><tr><td>S/L</td><td>0.33±0.12</td><td>0.31±0.07</td><td>0.665</td><td>0.28±0.07</td><td>0.29±0.06</td><td>0.741</td></tr></table> |
23b0c1acba3527d9b6ffb5a87effe5036b96a8e2647c74916e3a668d1aee8ee4.png | simple | <table><tr><td>Figure #</td><td>Algorithms Used</td><td>Initial Benefit</td><td>Acquired Benefit</td><td>Lost Benefit</td><td>Overall Distance</td><td>Solution Time (s)</td></tr><tr><td>11a</td><td>Greedy TA Heuristic MP</td><td>21,000</td><td>9479</td><td>11,521</td><td>2446</td><td>1.85</td></tr><tr><td>11b</td><td>Greedy TA Heuristic MP</td><td>21,000</td><td>9440</td><td>11,560</td><td>2462</td><td>2.73</td></tr></table> |
1731c8b6f31af474866153f4d6e97ca664254c811d43a2ccf0ea5019c5043c80.png | simple | <table><tr><td>Construct</td><td>Transgene</td><td>Progeny</td><td>n</td></tr><tr><td></td><td><i>ebEx498</i></td><td>92 ± 16</td><td>11</td></tr><tr><td></td><td><i>xyEx175</i></td><td>123 ± 15</td><td>10</td></tr><tr><td></td><td><i>xyEx177</i></td><td>115 ± 17</td><td>11</td></tr><tr><td></td><td><i>xyEx1</i></td><td>2 ± 1</td><td>10</td></tr><tr><td></td><td><i>xyEx2</i></td><td>1 ± 0.62</td><td>9</td></tr><tr><td></td><td><i>xyEx3</i></td><td>6 ± 2</td><td>9</td></tr><tr><td></td><td><i>xyEx27</i></td><td>11 ± 4</td><td>10</td></tr><tr><td></td><td><i>xyEx30</i></td><td>8 ± 4</td><td>10</td></tr><tr><td></td><td><i>xyEx34</i></td><td>17 ± 4</td><td>10</td></tr><tr><td></td><td><i>xyEx36</i></td><td>83 ± 15</td><td>9</td></tr><tr><td></td><td><i>xyEx37</i></td><td>110 ± 10</td><td>8</td></tr><tr><td></td><td><i>xyEx41</i></td><td>123 ± 15</td><td>10</td></tr><tr><td></td><td>N2 (wild type)</td><td>185 ± 5</td><td>10</td></tr><tr><td></td><td><i>spe-42(tn1231)</i></td><td>0</td><td>24</td></tr><tr><td></td><td><i>spe-42(tm2421)</i></td><td>0</td><td>15</td></tr></table> |
a83a7c7b7e975d5191c15743a6f3263a746c73733efc9d8c09af515a75b51d4f.png | simple | <table><tr><td>Epigenetic discovery</td><td>Health promotion research innovation domains</td><td>Example translational research questions</td></tr><tr><td>Individual variation in whether risk exposures negatively influence gene expression</td><td>Improving motivational potency of health communications</td><td>Evaluating relative benefit of validating beliefs about individual variability in extent of harm produced by risk behaviors on motivation</td></tr><tr><td>Intervention adherence can prompt measurable gene expression</td><td>Intervention targeting and tailoring</td><td>Comparative effectiveness of targeting relapse prevention approach based on gene expression profile following intervention participation</td></tr><tr><td>New technology to measure epigenetic processes (e.g., methylation) in saliva and blood samples</td><td>Novel biomarkers of intervention impact</td><td>Evaluate intervention adherence on gene expression in randomized effectiveness trials</td></tr></table> |
3bfe5d4510d5fea31b4eef28ed1789dcb1e162ecf59754dbed010751f335a6fc.png | simple | <table><tr><td></td><td>MCAA+</td><td>MCAA−</td><td>NHS</td><td>PLG+</td></tr><tr><td>Age (mean)</td><td>61.0</td><td>59.2</td><td>58.7</td><td>59.6</td></tr><tr><td>Age (SD)</td><td>10.5</td><td>13.3</td><td>3.7</td><td>12.3</td></tr><tr><td>M:F (ratio)</td><td>33:23 (1.43)</td><td>30: 21 (1.43)</td><td>25: 15 (1.67)</td><td>27: 18 (1.5)</td></tr></table> |
d8f298055d3fd8949d8ab6134c61a4388b21a086019977d4ff71390d773f153e.png | simple | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Age(year)</td><td>47</td><td>39</td><td>48</td></tr><tr><td>Follow-up(month)</td><td>70</td><td>54</td><td>5</td></tr><tr><td>Outcome</td><td>Favorable</td><td>Favorable</td><td>Favorable</td></tr><tr><td>Pre-operation upper-limb blood pressure(mm Hg)</td><td>125/65</td><td>135/65</td><td>145/50</td></tr><tr><td>Pre-operation lower-limb blood pressure(mm Hg)</td><td>100/55</td><td>110/50</td><td>125/45</td></tr><tr><td>Post-operation upper-limb blood pressure(mm Hg)</td><td>125/65</td><td>125/80</td><td>130/80</td></tr><tr><td>Post-operation lower-limb blood pressure(mm Hg)</td><td>130/70</td><td>130/80</td><td>130/75</td></tr></table> |
5609a019bf06a6edc758e8e15563f95850f5fae289ff12398230aa2443bd8c63.png | complex | <table><tr><td>Characteristic<sup>§</sup></td><td colspan="5">Levels of sCD40L</td></tr><tr><td></td><td colspan="2">High</td><td colspan="2">Medium-Low</td><td>p</td></tr><tr><td></td><td>No.</td><td>(%)</td><td>No.</td><td>%</td><td></td></tr><tr><td>Age:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <= 39</td><td>8</td><td>(40.0)</td><td>8</td><td>(20.0)</td><td></td></tr><tr><td> 40–54</td><td>9</td><td>(45.0)</td><td>14</td><td>(35.0)</td><td></td></tr><tr><td> >= 55</td><td>3</td><td>(15.0)</td><td>18</td><td>(45.0)</td><td>0.02</td></tr><tr><td>Sex:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Men</td><td>16</td><td>(80.0)</td><td>28</td><td>(68.3)</td><td></td></tr><tr><td> Women</td><td>4</td><td>(20.0)</td><td>13</td><td>(31.7)</td><td>0.51</td></tr><tr><td>T:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 1</td><td>4</td><td>(20.0)</td><td>9</td><td>(23.1)</td><td></td></tr><tr><td> 2A-2B</td><td>8</td><td>(40.0)</td><td>18</td><td>(46.2)</td><td></td></tr><tr><td> 3–4</td><td>8</td><td>(40.0)</td><td>12</td><td>(30.8)</td><td>0.78</td></tr><tr><td>N:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0</td><td>2</td><td>(10.0)</td><td>11</td><td>(28.9)</td><td></td></tr><tr><td> 1</td><td>10</td><td>(50.0)</td><td>12</td><td>(31.6)</td><td></td></tr><tr><td> 2–3</td><td>8</td><td>(40.0)</td><td>15</td><td>(39.5)</td><td>0.36</td></tr><tr><td>M:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0</td><td>13</td><td>(68.4)</td><td>38</td><td>(95.0)</td><td></td></tr><tr><td> 1</td><td>6</td><td>(31.6)</td><td>2</td><td>(5.0)</td><td>0.01</td></tr><tr><td>Stage:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> I-II</td><td>6</td><td>(31.6)</td><td>14</td><td>(42.4)</td><td></td></tr><tr><td> III-IVa-IVb</td><td>7</td><td>(36.8)</td><td>17</td><td>(51.5)</td><td></td></tr><tr><td> IVc</td><td>6</td><td>(31.6)</td><td>2</td><td>(6.1)</td><td>0.11</td></tr><tr><td>LMP-1 expression</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative cases</td><td>23</td><td>(95.8)</td><td>19</td><td>(70.4)</td><td></td></tr><tr><td> Positive cases</td><td>1</td><td>(4.2)</td><td>8</td><td>(29.6)</td><td>0.03</td></tr></table> |
30ebd356f36b9bbfe358ead734e61b2f9ed5688151b19e41a7ab56a8f1ec36ee.png | simple | <table><tr><td></td><td>df</td><td>AIC</td><td>BIC</td><td>logLik</td></tr><tr><td>m.rel.index</td><td>8</td><td>2043373</td><td>2043457</td><td>−1021678</td></tr><tr><td>m.freq.index</td><td>8</td><td>2043326</td><td>2043410</td><td>−1021655</td></tr></table> |
485c93a03463d6148659e430dfd854d05a1a5f15199cba49a8a8825b7695c100.png | simple | <table><tr><td>Time point (min)</td><td>42.5</td><td>47.5</td><td>52.5</td><td>57.5</td><td>62.5</td><td>72.5</td><td>72.5</td><td>77.5</td><td>82.5</td><td>87.5</td></tr><tr><td>Bias (%)</td><td>53</td><td>46</td><td>40</td><td>32</td><td>25</td><td>22</td><td>18</td><td>12</td><td>9</td><td>0</td></tr><tr><td>Factor 1</td><td>0.877</td><td>0.898</td><td>0.977</td><td>0.973</td><td>0.967</td><td>0.986</td><td>0.963</td><td>0.975</td><td>0.843</td><td>0.8573</td></tr><tr><td>Factor 2</td><td>0.453</td><td>0.423</td><td>−0.105</td><td>−0.068</td><td>−0.104</td><td>−0.116</td><td>−0.205</td><td>−0.102</td><td>−0.499</td><td>0.376</td></tr></table> |
6b459829f1d98533908472c6ec8a3522581da62849302bfd426afc7d49dc4fee.png | complex | <table><tr><td>Characteristic</td><td>Number (%)</td></tr><tr><td colspan="2">Age(months)</td></tr><tr><td> 0–11</td><td>166(24.3%)</td></tr><tr><td> 12–23</td><td>189(27.7%)</td></tr><tr><td> 24–35</td><td>101(14.7%)</td></tr><tr><td> 36–47</td><td>116(16.9%)</td></tr><tr><td> 48–59</td><td>112(16.4%)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>421(61.6%)</td></tr><tr><td> Female</td><td>263(38.4%)</td></tr><tr><td colspan="2">Season</td></tr><tr><td> Spring(January–March)</td><td>161(23.5%)</td></tr><tr><td> Summer(April–June)</td><td>252(36.8%)</td></tr><tr><td> Autumn(July–September)</td><td>123(18.0%)</td></tr><tr><td> Winter(October–December)</td><td>148(21.6%)</td></tr><tr><td colspan="2">Clinical Symptoms</td></tr><tr><td> Nausea</td><td>60(10.8%)</td></tr><tr><td> Vomiting</td><td>114(20.6%)</td></tr><tr><td> Abdominal pain</td><td>268(48.3%)</td></tr><tr><td> Fever(> 37.2 °C)</td><td>97(17.4%)</td></tr><tr><td> others</td><td>16(2.9%)</td></tr></table> |
263963797e794ce3ead9b00ce3e9f99b99dab26c0e052e7438403b48f4b01faf.png | complex | <table><tr><td> </td><td>Serology (serologicmarkers)<sup><i>∗</i></sup></td><td>Endoscopy of duodenum (mucosal morphologic alternations<sup><i>∗∗</i></sup>)</td><td>Genotype (genetic markers)</td></tr><tr><td rowspan="4"> </td><td>IgA anti-tissue transglutaminase antibodies (IgA anti-tTG, IgG anti-tTG antibodies)</td><td>Mucous membrane thickness</td><td rowspan="4"> HLA-typing</td></tr><tr><td>Anti-endomysial antibodies (AEA, IgA-anti-EMA)</td><td>Villus height</td></tr><tr><td>Anti-deamidated gliadin peptide (IgA anti-DGP, IgG anti-DGP)</td><td>Crypt depth</td></tr><tr><td> </td><td>Crypt-villus ratio</td></tr><tr><td><i>Limitations</i></td><td>Specificity and sensitivity of test method; the active period of the disease; long-term gluten-free diet</td><td>Similar histological pattern of some other diseases; long-term gluten-free diet</td><td>—</td></tr></table> |
e8ae8a8609c2fd0bef5d687ba3f7d1162ef5654894e6234b6eee6e03dba06adc.png | complex | <table><tr><td></td><td colspan="2">Caf1</td><td colspan="2">Ccr4</td></tr><tr><td></td><td>Gene</td><td>Synonyms</td><td>Gene</td><td>Synonyms</td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>POP2</td><td>CAF1</td><td>CCR4</td><td>FUN27, NUT21</td></tr><tr><td><i>Schizosaccharomyces pombe</i></td><td>caf1</td><td>pop2</td><td>CCR4</td><td></td></tr><tr><td><i>Caenorhabditis elegans</i></td><td>CCF-1</td><td></td><td>CCR-4</td><td></td></tr><tr><td><i>Drosophila melanogaster</i></td><td>Pop2</td><td>CAF1</td><td>Twin</td><td>CCR4</td></tr><tr><td><i>Xenopus laevis</i></td><td>Cnot7</td><td>caf1, caf-1</td><td>Cnot6</td><td>CCR4A</td></tr><tr><td></td><td>Cnot8</td><td>pop2, calif</td><td>Cnot6l</td><td>CCR4B</td></tr><tr><td><i>Danio rerio</i></td><td>Cnot7</td><td>zgc:153168</td><td>Cnot6</td><td>Zgc:65822</td></tr><tr><td></td><td>Cnot8</td><td>zgc:63844</td><td>Cnot6l</td><td>Zgc:111987</td></tr><tr><td><i>Mus musculus</i></td><td>Cnot7</td><td>Caf1</td><td>Cnot6</td><td></td></tr><tr><td></td><td>Cnot8</td><td></td><td>Cnot6l</td><td></td></tr><tr><td><i>Homo sapiens</i></td><td>CNOT7</td><td>Caf1; Caf1a</td><td>CNOT6</td><td>Ccr4; Ccr4a</td></tr><tr><td></td><td>CNOT8</td><td>Pop2; Calif; Caf1b</td><td>CNOT6L</td><td>Ccr4-like;</td></tr></table> |
458a0d1e2c182c150e73e3dc325b974122fcabf057001afc60302903abf0e302.png | complex | <table><tr><td colspan="2">Variables<sup>a</sup></td><td>High risk (n = 1170)</td><td>Not high risk (n = 563)</td><td><i>P</i> value<sup>*</sup></td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>463 (39.6)</td><td>372 (66.1)</td><td><0.001</td></tr><tr><td></td><td>Female</td><td>707 (60.4)</td><td>191 (33.9)</td><td></td></tr><tr><td colspan="2">Age (years) (M ± SD)</td><td>50.27 ± 10.83</td><td>50.46 ± 10.86</td><td>0.777</td></tr><tr><td></td><td>31- 45<sup>b</sup></td><td>459 (39.2)</td><td>212 (37.7)</td><td>0.737</td></tr><tr><td></td><td>46- 60</td><td>485 (41.5)</td><td>244 (43.3)</td><td></td></tr><tr><td></td><td>61 year& above</td><td>226 (19.3)</td><td>107 (19.0)</td><td></td></tr><tr><td colspan="2">Religion</td><td></td><td></td><td></td></tr><tr><td></td><td>Islam</td><td>796 (68.0)</td><td>377 (67.0)</td><td>0.386</td></tr><tr><td></td><td>Hindu</td><td>358 (30.6)</td><td>180 (32.0)</td><td></td></tr><tr><td></td><td>Christian</td><td>16 (1.4)</td><td>6 (1.1)</td><td></td></tr><tr><td colspan="2">Family size</td><td></td><td></td><td></td></tr><tr><td></td><td>Small (less than 4 persons)</td><td>564 (48.2)</td><td>274 (48.7)</td><td>0.275</td></tr><tr><td></td><td>Medium (5 – 8 persons)</td><td>541 (46.2)</td><td>273 (48.5)</td><td></td></tr><tr><td></td><td>Large (>9)</td><td>65 (5.6)</td><td>16 (2.8)</td><td></td></tr><tr><td colspan="2">Type of family</td><td></td><td></td><td></td></tr><tr><td></td><td>Nuclear family</td><td>982 (83.9)</td><td>475 (84.4)</td><td>0.815</td></tr><tr><td></td><td>Joint family</td><td>188 (16.1)</td><td>88 (15.6)</td><td></td></tr><tr><td colspan="2">Marital status</td><td></td><td></td><td></td></tr><tr><td></td><td>Never married/Divorced/ Separated/ Widowed</td><td>129 (11.5)</td><td>66 (11.7)</td><td>0.887</td></tr><tr><td></td><td>Married</td><td>1037 (88.6)</td><td>497 (88.3)</td><td></td></tr><tr><td colspan="2">Education</td><td></td><td></td><td></td></tr><tr><td></td><td>Illiterate/ Signature/Gonoshikha</td><td>512 (43.8)</td><td>249 (44.2)</td><td>0.729</td></tr><tr><td></td><td>Primary level</td><td>336 (28.7)</td><td>163 (29.0)</td><td></td></tr><tr><td></td><td>Secondary level and above</td><td>322 (27.5)</td><td>151 (26.8)</td><td></td></tr><tr><td colspan="2">Gross National Income (per capita, US$)</td><td></td><td></td><td></td></tr><tr><td></td><td>Low income (≤905)</td><td>345 (29.5)</td><td>150 (26.6)</td><td>0.175</td></tr><tr><td></td><td>Lower-middle income (906–3595)</td><td>818 (69.9)</td><td>410 (72.8)</td><td></td></tr><tr><td></td><td>Upper-middle income (3596–11115)</td><td>7 (0.6)</td><td>3 (0.5)</td><td></td></tr><tr><td colspan="2">Employment status</td><td></td><td></td><td></td></tr><tr><td></td><td>Unemployed/ sacked from the present job/ Retired</td><td>78 (6.7)</td><td>25 (4.4)</td><td>0.001</td></tr><tr><td></td><td>Office work/ Business/ Skilled labour</td><td>104 (8.9)</td><td>85 (15.1)</td><td></td></tr><tr><td></td><td>House maker/farmer</td><td>846 (72.3)</td><td>306 (54.4)</td><td></td></tr><tr><td></td><td>Rickshaw puller/day labour/ Others</td><td>142 (12.1)</td><td>147 (26.1)</td><td></td></tr></table> |
cb5dbc3068f2ffdff9330bb1de87d0678e2e27f8a5cb194e7f1effdbfd628713.png | simple | <table><tr><td>Factors</td><td>Have you ever attended VCT (N (%))</td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>No</td><td>χ<sup>2</sup></td><td>p-value</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td></tr><tr><td>Protestant</td><td>36(29.3)</td><td>87(70.7)</td><td>5.6</td><td>0.13</td></tr><tr><td>Catholic</td><td>39(37.1)</td><td>66(62.9)</td><td></td><td></td></tr><tr><td>Muslims</td><td>21(47.7)</td><td>23(52.3)</td><td></td><td></td></tr><tr><td>Others</td><td>11(29.7)</td><td>26(70.3)</td><td></td><td></td></tr><tr><td>Professional groups</td><td></td><td></td><td></td><td></td></tr><tr><td>Medical students (MD)</td><td>35(32.7)</td><td>65(32.2)</td><td>0.98</td><td>0.80</td></tr><tr><td>Nursing</td><td>33(30.8)</td><td>60(29.7)</td><td></td><td></td></tr><tr><td>Physiotherapist</td><td>14(13.1)</td><td>21(10.4)</td><td></td><td></td></tr><tr><td>Others</td><td>25(23.4)</td><td>56(27.7)</td><td></td><td></td></tr><tr><td>Age group</td><td></td><td></td><td></td><td></td></tr><tr><td>18–21</td><td>16(15)</td><td>31(15.3)</td><td>3.9</td><td>0.14</td></tr><tr><td>22–23</td><td>30(28)</td><td>78(38.6)</td><td></td><td></td></tr><tr><td>24–25</td><td>61(57)</td><td>93(46)</td><td></td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>38(35.5)</td><td>74(36.6)</td><td>0.04</td><td>0.85</td></tr><tr><td>Female</td><td>69(64.5)</td><td>128(63.4)</td><td></td><td></td></tr><tr><td>Ever had sex</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>106(99.1)</td><td>194(96)</td><td>2.26</td><td>0.17</td></tr><tr><td>No</td><td>1(0.9)</td><td>8(4.0)</td><td></td><td></td></tr></table> |
80eb5ade60a72ce9cae6eeb5e47f5e475f0e02fbdb0447f94bea58f3e9661bb9.png | simple | <table><tr><td></td><td>Total</td></tr><tr><td>No. of patients</td><td>394</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> Mean ± SD</td><td>57.0 ± 12.8</td></tr><tr><td> Range</td><td>28-94</td></tr><tr><td>Tumor size (cm)</td><td></td></tr><tr><td> ≤2.0</td><td>197 (50.0%)</td></tr><tr><td> 2.1-5.0</td><td>183 (46.5%)</td></tr><tr><td> >5.0</td><td>12 (3.1%)</td></tr><tr><td> Unknown</td><td>2 (0.4%)</td></tr><tr><td>No. of positive lymph nodes</td><td></td></tr><tr><td> 0</td><td>207 (52.5%)</td></tr><tr><td> 1-3</td><td>108 (27.4%)</td></tr><tr><td> 4-9</td><td>23 (5.9%)</td></tr><tr><td> ≥10</td><td>15 (3.8%)</td></tr><tr><td> Unknown</td><td>41 (10.4%)</td></tr><tr><td>Tumor grade</td><td></td></tr><tr><td> 1</td><td>111 (28.2%)</td></tr><tr><td> 2</td><td>113 (28.7%)</td></tr><tr><td> 3</td><td>146 (37.1%)</td></tr><tr><td> Unknown</td><td>24 (6.0%)</td></tr><tr><td>ERα</td><td></td></tr><tr><td> Negative</td><td>31(7.9%)</td></tr><tr><td> Positive</td><td>363 (92.1%)</td></tr><tr><td>PgR</td><td></td></tr><tr><td> Negative</td><td>86 (21.8%)</td></tr><tr><td> Positive</td><td>306 (77.7%)</td></tr><tr><td> Unknown</td><td>2 (0.5%)</td></tr><tr><td>HER2 status</td><td></td></tr><tr><td> Negative</td><td>278 (70.6%)</td></tr><tr><td> Positive</td><td>41 (10.4%)</td></tr><tr><td> Unknown</td><td>75 (19.0%)</td></tr><tr><td>Adjuvant therapy</td><td></td></tr><tr><td> None</td><td>30 (7.6%)</td></tr><tr><td> Endocrine therapy</td><td>177 (44.9%)</td></tr><tr><td> Chemotherapy</td><td>29 (7.4%)</td></tr><tr><td> Combined</td><td>155 (39.3%)</td></tr><tr><td> Unknown</td><td>3 (0.8%)</td></tr></table> |
4eb6feafbc39ac3cbf6c5960b3039c83fd5ad045ff2e44a0c784e3ce682fe224.png | simple | <table><tr><td>Patient number</td><td>Patient age</td><td>Early or late infection</td><td>Procedure</td><td>Time after first washout that NPWT was applied</td><td>Duration of NPWT</td><td>Number of NPWT changes</td><td>Long-term outcome</td></tr><tr><td>1</td><td>17 years</td><td>Late</td><td>Corrective surgery for severe scoliosis</td><td>0 days</td><td>21 days</td><td>3</td><td>Metalwork retained, no infection</td></tr><tr><td>2</td><td>46 years</td><td>Early</td><td>Instrumented lumbar spine fusion</td><td>0 days</td><td>14 days</td><td>2</td><td>Metalwork retained, no infection</td></tr><tr><td>3</td><td>43 years</td><td>Early</td><td>Instrumented lumbar spine fusion</td><td>0 days</td><td>14 days</td><td>2</td><td>Metalwork retained, no infection</td></tr><tr><td>4</td><td>41 years</td><td>Early</td><td>Instrumented anterior lumbar spine fusion</td><td>0 days</td><td>15 days</td><td>2</td><td>Metalwork retained, no infection</td></tr><tr><td>5</td><td>72 years</td><td>Early</td><td>Instrumented lumbar spine fusion</td><td>0 days</td><td>14 days</td><td>2</td><td>Metalwork retained, no infection </td></tr></table> |
37ba41baf7e871f5ac5d3ce2ddf958a739162e230c352122569fe846ee6ad9c5.png | simple | <table><tr><td>MAA Category</td><td>Commercial Agreement</td><td>Payment for Performance Agreement</td><td>Coverage with Evidence Development</td></tr><tr><td>Contract type</td><td>• Discount-based contract</td><td>• Permanent risk-shifting agreement (outcomes guarantee/insurance) applied on a per-patient basis</td><td>• Provisional agreement until new, clearly specified evidence develops from a cohort of patients</td></tr><tr><td>Collection and analysis of patient health outcomes data by the payer</td><td>• None</td><td>• Per patient</td><td>• Cohort of patients</td></tr><tr><td>Timeframe of the MAA</td><td>• Permanent/not linked to final decision-making</td><td>• Permanent/not linked to final decision-making based on new robust evidence</td><td>• Temporary/provisional until new evidence allows making a final decision</td></tr><tr><td>Underlying concept (payer perspective)</td><td>• Reducing pharmaceutical expenditure</td><td>• Avoiding inefficient expenditure on treating patients who do not respond to a drug and who cannot be identified <i>ex ante </i>(by permanently linking the payment to drug's performance in individual patients)</td><td>• Reducing uncertainty about drug's real-life effectiveness (by linking a final HTA, reimbursement and/or pricing decision to drug's performance in a cohort of patients, during a defined test period)</td></tr><tr><td>Examples</td><td>• Flat price per patient (regardless of the number of doses administered)• Cost Sharing• Rebate• Discount</td><td>• Payment for performance• Pay-back for non performance</td><td>• Temporary coverage on a condition that new evidence reduces uncertainty about a pre-specified health outcome:- Real-life effectiveness- Higher efficacy in a pre-specified subpopulation of patients- Long-term effect- Improved patient's adherence- Reduction of use of health care resources (e.g. hospitalization)</td></tr></table> |
79fc1464ddbea81683cf8c1a44051e6ea46857236ad6aad00fc47497d0846e9a.png | simple | <table><tr><td></td><td>All patients</td><td>Cases</td><td>Control</td></tr><tr><td>Samples</td><td>10,324</td><td>6,564</td><td>5,072<sup>b</sup></td></tr><tr><td>Identified CNVs</td><td>14,226<sup>a</sup></td><td>9,186</td><td>495,916</td></tr><tr><td>Type of CNVs:</td><td></td><td></td><td></td></tr><tr><td>Loss</td><td>7,554</td><td>5,101</td><td>343,489</td></tr><tr><td>Gain</td><td>6,672</td><td>4,085</td><td>152,427</td></tr><tr><td>Average CNV length (Kb)</td><td>3,336</td><td>3,014</td><td>31</td></tr><tr><td>Type of inheritance:</td><td></td><td></td><td></td></tr><tr><td>De novo constitutive</td><td>14,501</td><td>2,454</td><td></td></tr><tr><td>Inherited from normal parent</td><td>9,345</td><td>1,945</td><td></td></tr><tr><td>Inherited from parent with similar phenotype to child</td><td>1,345</td><td>240</td><td></td></tr><tr><td>Unknown</td><td>21,946</td><td>3,638</td><td></td></tr></table> |
04929abbdddd8373905cf506ae23ad50e313e9c673116f652d477ad9c81a9e98.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">Flexion</td><td colspan="3">Extension</td></tr><tr><td>Pre-operation</td><td>13 months after the operation</td><td>18 months after the operation</td><td>Pre-operation</td><td>13 months after the operation</td><td>18 months after the operation</td></tr><tr><td>Left hip</td><td>0°-25°</td><td>0°-85°</td><td>0°-110°</td><td rowspan="4">Flexion deformity</td><td>0°-15°</td><td>0°-15°</td></tr><tr><td>Right hip</td><td>0°-15°</td><td>0°-80°</td><td>0°-105°</td><td>0°-10°</td><td>0°-10°</td></tr><tr><td>Left knee</td><td>0°-15°</td><td>0°-100°</td><td>0°-125°</td><td>0°</td><td>0°</td></tr><tr><td>Right knee</td><td>0°-10°</td><td>0°-90°,</td><td>0°-127°</td><td>0°</td><td>0°</td></tr></table> |
f5285e92dbbfa8a398fba89abd500ccff30b8003ad7f28896855d878bbd20134.png | simple | <table><tr><td>Trait</td><td>Description (ability assessed)</td><td>CLDRC-RD (564)</td><td>UK-RD (958)</td><td>SLIC (498)</td><td>CLDRC-ADHD (163)</td></tr><tr><td>WRead</td><td>Reading real words</td><td>x (0.918)</td><td>x (0.918)</td><td>x (0.902)</td><td>x (0.871)</td></tr><tr><td>WSpell</td><td>Spelling real words</td><td>x (0.813)</td><td>x (0.852)</td><td>x (0.862)</td><td>x (0.764)</td></tr><tr><td>PD</td><td>Ability to convert letter strings into sounds, according to given phonetic rules</td><td>x (0.895, 0.861)*</td><td>x (0.809)</td><td></td><td>x (0.821, 0.729)*</td></tr><tr><td>PA</td><td>Ability to recognize and manipulate speech sounds (phonemes)</td><td>x (0.801)</td><td>x†</td><td></td><td>x (0.744)</td></tr><tr><td>OC</td><td>Ability to recognize a word as an orthographic unit and to retrieve the corresponding phonological form</td><td>x (0.764)</td><td>x (0.888)</td><td></td><td>x (0.644)</td></tr><tr><td>NWR</td><td>Ability to repeat nonsense words orally presented</td><td>x (0.493)</td><td></td><td>x (0.665)</td><td>x (0.355)</td></tr><tr><td>ELS</td><td>Sentence recalling and production (expressive domain of language)</td><td></td><td></td><td>x (0.856)</td><td></td></tr><tr><td>RLS</td><td>Listening and auditory comprehension (receptive domain of language)</td><td></td><td></td><td>x (0.837)</td><td></td></tr><tr><td>VIQ</td><td>Verbal reasoning</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>PIQ</td><td>Logical reasoning</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>PC1</td><td>Common variance in reading and language skills</td><td>544</td><td>914</td><td>245</td><td>159</td></tr><tr><td>IQ-adjusted PC1</td><td>Common variance in reading and language skills, not shared with general cognitive abilities</td><td>544</td><td>878</td><td>245</td><td>159</td></tr></table> |
227265bbd9a416bd00c19e002339c49f7310e830a12c705f56631f9c3e32bf66.png | simple | <table><tr><td> </td><td><i>T-cell development</i></td><td><i>Naive T-cell homeostasis</i></td><td><i>T-cell activation</i></td><td><i>T-cell differentiation</i></td><td><i>T-cell memory</i></td><td><i>References</i></td></tr><tr><td><i>Slc7a5</i><sup>–/–</sup> mice</td><td>No</td><td>No</td><td>T-cell activation↓</td><td>Th1 and Th17 cells↓</td><td>Not available</td><td><sup>11</sup></td></tr><tr><td><i>Slc1a5</i><sup>–/–</sup> mice</td><td>No</td><td>(1) For young micea: No (2) For older miceb: CD4<sup>+</sup> T cells↓CD44<sup>lo</sup>CD62L<sup>hi</sup> CD4<sup>+</sup> T cells↑</td><td>Activation of mTORC1 in T cellsc↓</td><td>Th1 and Th17 cells↓</td><td>(1) For young micea: No(2) For older miceb: Memory CD4<sup>+</sup> T cells↓</td><td><sup>10</sup></td></tr><tr><td><i>Slc6a1</i><sup>–/–</sup> mice</td><td>No</td><td>No</td><td>IL-2 secretion and CD69 expression in T cellsc ↑</td><td>Th1 cells↑</td><td>Not available</td><td><sup>9, 71</sup></td></tr></table> |
3229bac2195d4ebc7500856bdbe81d3d66d4e9f733e5c938b3b037e367af6436.png | simple | <table><tr><td>Term</td><td>Number of medications</td><td>Number of studies</td><td>References</td></tr><tr><td>Polypharmacy</td><td>≥ 2 for > 240 days (long term)</td><td>1</td><td>[101]</td></tr><tr><td></td><td>≥ 5 medications in the same month</td><td>1</td><td>[103]</td></tr><tr><td></td><td>> 5 medications for ≥ 90 days</td><td>1</td><td>[104]</td></tr><tr><td></td><td>≥ 5 medications in the same quarter of a year</td><td>1</td><td>[105]</td></tr><tr><td></td><td>≥ 5 medicines at hospital discharge</td><td>1</td><td>[106]</td></tr><tr><td></td><td>5 to 9 medicines on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)</td><td>1</td><td>[107]</td></tr><tr><td></td><td>5 to 9 medications for ≥ 90 days</td><td>1</td><td>[108]</td></tr><tr><td></td><td>5 to 9 medicines during hospital stay</td><td>1</td><td>[109]</td></tr><tr><td></td><td>≥ 10 medicines during hospital stay</td><td>1</td><td>[110]</td></tr><tr><td>Major polypharmacy</td><td>≥ 10 on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)</td><td>1</td><td>[107]</td></tr><tr><td>Hyperpolypharmacy</td><td>≥ 10 medications for ≥90 days</td><td>1</td><td>[108]</td></tr><tr><td>Excessive polypharmacy</td><td>≥ 10 medications in the same quarter of a year</td><td>1</td><td>[105]</td></tr><tr><td></td><td>≥ 10 medications during hospital stay</td><td>1</td><td>[109]</td></tr><tr><td>Persistent polypharmacy</td><td>≥ 5 medications for 181 days</td><td>1</td><td>[52]</td></tr><tr><td>Chronic polypharmacy</td><td>≥ 5 medications in 1 month for 6 months (consecutive or not) in a year</td><td>1</td><td>[111]</td></tr></table> |
931d390c5553904bf414c05b05cb9ba4580a527387764494ffa7bc12da06ddf2.png | simple | <table><tr><td>Category</td><td>Treatment group (<i>n</i> = 16)</td><td>Control group (<i>n</i> = 12)</td><td><i>P</i> value</td></tr><tr><td>Age (months)</td><td>136 (93–216)</td><td>140 (96–176)</td><td>0.82</td></tr><tr><td>Weight (kgs)</td><td>7.70 (1.44–27.82)</td><td>4.75 (1.63–29.09)</td><td>0.39</td></tr><tr><td>Coughing</td><td>8/16</td><td>7/12</td><td>0.78</td></tr><tr><td>Abdominal Distension</td><td>5/16</td><td>0/12</td><td>0.18</td></tr><tr><td>Respiratory Distress</td><td>13/16</td><td>10/12</td><td>0.73</td></tr><tr><td>Lethargy</td><td>8/16</td><td>5/12</td><td>0.67</td></tr><tr><td>Syncope</td><td>2/16</td><td>4/12</td><td>0.64</td></tr><tr><td>Exercise Intolerance</td><td>8/16</td><td>6/12</td><td>1.0</td></tr></table> |
0914f4a15df0cd49d7a9d9e73dfe9af02af7dcece8b853e921daf5e2215ab7e9.png | simple | <table><tr><td>Water Microbe</td><td>Amplified NuclearRibosomal Regions</td><td>Primer Sets (from 5' to 3')</td><td>PCR Program</td></tr><tr><td>Bacteria [19,20]</td><td>16S rRNA V4-V5 region</td><td>515F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT</td><td>95°C for 2 min, 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min</td></tr><tr><td>Fungi [21]</td><td>Internal transcribedspacer-1 (ITS1) region</td><td>1737F:GGAAGTAAAAGTCGTAACAAGG2043R:GCTGCGTTCTTCATCGATGC</td><td>95°C for 1 min, 30 cycles of 95°C for 10 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min</td></tr></table> |
c28f769c56f37a4ddbe0ea5afe53e41e8ec11d04a03b526266290c8d23b37f65.png | simple | <table><tr><td>whale</td><td>age/sex</td><td>year</td><td>tag duration (days)</td><td>min. latitude (° S)</td><td>max. SST (°C)</td></tr><tr><td>1</td><td>adult/female</td><td>2009</td><td>08 Jan–16 Jan (9)</td><td>64</td><td>2.3</td></tr><tr><td>2</td><td>adult/female</td><td>2009</td><td>14 Jan–27 Jan (14)</td><td>67</td><td>2.1</td></tr><tr><td>3</td><td>adult/female</td><td>2009</td><td>15 Jan–31 Jan (17)</td><td>60</td><td>2.9</td></tr><tr><td>4</td><td>adult/female</td><td>2009</td><td>24 Jan–13 Feb (21)</td><td>51</td><td>11.2</td></tr><tr><td>5</td><td>subadult/male</td><td>2010</td><td>13 Feb–24 Feb (12)</td><td>63</td><td>2.1</td></tr><tr><td>6</td><td>adult/female</td><td>2010</td><td>13 Feb–21 May (98)</td><td>30</td><td>22.4</td></tr><tr><td>7</td><td>adult/female</td><td>2010</td><td>13 Feb–01 Jun (109)</td><td>30</td><td>22.4</td></tr><tr><td>8</td><td>adult/male</td><td>2011</td><td>13 Jan–31 Jan (19)</td><td>67</td><td>1.8</td></tr><tr><td>9</td><td>adult/female</td><td>2011</td><td>13 Jan–25 Feb (44)</td><td>37</td><td>22.9</td></tr><tr><td>10</td><td>adult/female</td><td>2011</td><td>15 Jan–16 Apr (93)</td><td>36</td><td>20.9</td></tr><tr><td>11</td><td>adult/female</td><td>2011</td><td>15 Jan–22 Apr (99)</td><td>30</td><td>24.2</td></tr><tr><td>12</td><td>adult/female</td><td>2011</td><td>24 Jan–13 Feb (21)</td><td>65</td><td>1.9</td></tr></table> |
7465703eaf50cec176937fec5ed5c1b31501568dc6a463cdb15aea6fca3e6239.png | simple | <table><tr><td>Age (yrs)</td><td>Weight (kg)</td><td>Gender</td><td>Ethnicity</td><td>Indication</td><td>Target INR</td><td>Drug Interaction(s)</td><td>Therapeutic warfarin dose (mg/d)</td><td>Reference</td></tr><tr><td>69</td><td>79.8</td><td>Female </td><td>Japanese</td><td>AFib</td><td>1.5–20</td><td>NR</td><td>0.5</td><td>[8]</td></tr><tr><td>71</td><td>82</td><td>Male </td><td>White</td><td>AFib</td><td>2.0–3.0</td><td>Amiodarone </td><td>0.9</td><td>[11]</td></tr><tr><td>58</td><td>70</td><td>Male </td><td>Japanese</td><td>AFib</td><td>NR</td><td>Propafenone </td><td>0.25–0.75</td><td>[12]</td></tr><tr><td>68</td><td>70</td><td>Female </td><td>Chinese</td><td>AFib</td><td>2.0–3.0</td><td>NR</td><td>0.63</td><td>[13]</td></tr><tr><td>50</td><td>88</td><td>Male </td><td>Chinese</td><td>AFib</td><td>2.0–3.0</td><td>NR</td><td>1.25</td><td>[13]</td></tr><tr><td>74</td><td>54</td><td>Female </td><td>White</td><td>AFib</td><td>2.0–3.0</td><td>Amiodarone/Atorvastatin</td><td>0.5</td><td>Present case</td></tr></table> |
60a84dd3c0f72497af355c2146c73492341c2c66a93d5281ace6bcce69af006e.png | complex | <table><tr><td></td><td>N</td><td>%</td></tr><tr><td>Clozapine</td><td>9</td><td>39</td></tr><tr><td>Other antipsychotics</td><td>14</td><td>61</td></tr><tr><td> Traditional antipsychotics</td><td>6</td><td>26</td></tr><tr><td> Atypical antipsychotics</td><td>8</td><td>35</td></tr><tr><td>Mood stabilizers</td><td>5</td><td>22</td></tr><tr><td>Clozapine dose</td><td colspan="2">481 ± 218 mg (range 300 - 900)</td></tr><tr><td>Serum level of clozapine</td><td colspan="2">1671 ± 1164 μmol/l (range 326 - 3333)</td></tr></table> |
c1dc7e27f960418fe1009d2cdceb319ed569e5dbc952fcf3220bb79c3873a60c.png | complex | <table><tr><td rowspan="2">Barrier</td><td colspan="2">1<sup>st</sup> Barrier</td><td colspan="2">2<sup>nd</sup> Barrier</td><td colspan="2">3<sup>rd</sup> Barrier</td><td>Total</td></tr><tr><td>Freq</td><td>%</td><td>Freq</td><td>%</td><td>Freq</td><td>%</td><td><i>N</i></td></tr><tr><td>Delay before care is received</td><td>59</td><td>10.9</td><td>35</td><td>6.5</td><td>9</td><td>1.7</td><td>103</td></tr><tr><td>Long distance to treatment centres</td><td>6</td><td>1.1</td><td>24</td><td>4.5</td><td>11</td><td>2</td><td>41</td></tr><tr><td>Financial challenges</td><td>68</td><td>12.6</td><td>24</td><td>4.4</td><td>19</td><td>3.5</td><td>111</td></tr><tr><td>Job insecurity</td><td>14</td><td>2.6</td><td>7</td><td>1.3</td><td>5</td><td>0.9</td><td>26</td></tr><tr><td>No challenge</td><td>198</td><td>36.7</td><td>350</td><td>64.8</td><td>418</td><td>77.4</td><td>966</td></tr><tr><td>Shortage of drugs and other commodities</td><td>72</td><td>13.3</td><td>34</td><td>6.3</td><td>12</td><td>2.2</td><td>118</td></tr><tr><td>Fear of side effects</td><td>26</td><td>4.8</td><td>8</td><td>1.5</td><td>2</td><td>0.4</td><td>36</td></tr><tr><td>Stigmatisation</td><td>7</td><td>1.3</td><td>6</td><td>1.1</td><td>3</td><td>0.6</td><td>16</td></tr><tr><td>Total</td><td>540</td><td>100</td><td>540</td><td>100</td><td>540</td><td>100</td><td>1620</td></tr></table> |
beef9b9ee451acf4bfe5fa1c66f7cc9b8622d6640a15b29b13dc6d6b941de55e.png | simple | <table><tr><td>Variable</td><td>Unadjusted</td><td>Adjusted for CRP/AGP <sup>2</sup></td></tr><tr><td>Participants (<i>n</i>) <sup>3</sup></td><td>770</td><td>770</td></tr><tr><td>Hb concentration, g/dL <sup>4</sup></td><td>9.6 (9.5,9.8)</td><td>-</td></tr><tr><td>Anemia, Hb < 10.5 g/dL (2nd trimester) or 11.0 g/dL (1st, 3rd trimester)</td><td>601 (79.0)</td><td>-</td></tr><tr><td>Mild anemia (Hb 10.0–10.4 or 10.9 g/dL)</td><td>173 (22.7)</td><td>-</td></tr><tr><td>Moderate anemia (Hb 7.0–9.9 g/dL)</td><td>402 (52.8)</td><td>-</td></tr><tr><td>Severe anemia (Hb < 7.0 g/dL)</td><td>26 (3.4)</td><td>-</td></tr><tr><td>Ferritin, μg/L</td><td>30.5 (28.5, 32.7)</td><td>27.3 (25.8, 28.8)</td></tr><tr><td>Iron deficiency, ferritin < 15 μg/L</td><td>137 (17.8)</td><td>159 (20.7)</td></tr><tr><td>sTfR, mg/L</td><td>7.8 (7.5, 8.1)</td><td>-</td></tr><tr><td>Iron deficiency, sTfR > 8.3 mg/L</td><td>275 (35.7)</td><td>-</td></tr><tr><td>pZn, μg/dL</td><td>51.7 (51.0, 52.4)</td><td>52.3 (51.6, 53.0)</td></tr><tr><td>Zinc deficiency, pZn < 50 μg/dL <sup>5</sup></td><td>311 (43.4)</td><td>292 (40.7)</td></tr><tr><td>RBP, μmol/L</td><td>1.05 (1.03, 1.08)</td><td>1.07 (1.05, 1.10)</td></tr><tr><td>RBP < 0.70 μmol/L</td><td>68 (8.8)</td><td>57 (7.4)</td></tr><tr><td>Inadequate or marginal status, RBP < 1.32 μmol/L</td><td>622 (80.8)</td><td>614 (79.7)</td></tr><tr><td>B<sub>12</sub>, pmol/L</td><td>169.9 (165.1, 174.9)</td><td>-</td></tr><tr><td>Inadequate status, B<sub>12</sub> < 148 pmol/L</td><td>259 (34.8)</td><td>-</td></tr><tr><td>Marginal status, B<sub>12</sub>, 148–221 pmol/L</td><td>324 (43.5)</td><td>-</td></tr><tr><td>Folate, nmol/L</td><td>10.5 (10.1, 10.9)</td><td>-</td></tr><tr><td>Inadequate status, folate < 10 nmol/L</td><td>328 (44.3)</td><td>-</td></tr><tr><td>Micronutrient deficiency anemia <sup>6</sup></td><td></td><td></td></tr><tr><td>Iron deficiency anemia (Anemia + ferritin < 15 μg/L)</td><td>124 (16.3)</td><td>142 (18.7)</td></tr><tr><td>Iron deficiency anemia (Anemia + sTfR > 8.3 mg/L)</td><td>250 (32.9)</td><td>-</td></tr><tr><td>B<sub>12</sub> deficiency anemia (Anemia + B12 < 148 pmol/L)</td><td>208 (28.3)</td><td>-</td></tr><tr><td>Folate-deficiency anemia (Anemia + and folate < 10 nmol/L)</td><td>265 (36.4)</td><td>-</td></tr><tr><td>Multiple micronutrient (MNN) deficiency <sup>7</sup></td><td></td><td></td></tr><tr><td>0</td><td>25 (3.6)</td><td>24 (3.5)</td></tr><tr><td>1</td><td>131 (19.0)</td><td>131 (19.0)</td></tr><tr><td>2</td><td>212 (30.8)</td><td>222 (32.3)</td></tr><tr><td>3</td><td>173 (25.2)</td><td>164 (23.8)</td></tr><tr><td>4</td><td>114 (16.6)</td><td>114 (16.6)</td></tr><tr><td>5</td><td>33 (4.8)</td><td>33 (4.8)</td></tr><tr><td>AGP, g/L</td><td>0.39 (0.38,0.40)</td><td>-</td></tr><tr><td>AGP > 1 g/L</td><td>23 (3.0)</td><td>-</td></tr><tr><td>CRP, mg/L</td><td>2.2 (2.0, 2.4)</td><td>-</td></tr><tr><td>CRP > 5 mg/L</td><td>189 (24.6)</td><td>-</td></tr><tr><td>Malaria antigenemia (elevated HRP2) <sup>8</sup></td><td>97 (12.6)</td><td>-</td></tr></table> |
e347910cf9ef5315c661266d76a6e15caba4e9870a7ec300776fb401bec454fe.png | complex | <table><tr><td rowspan="2">Country</td><td rowspan="2">Year of data collection</td><td colspan="6">Male</td><td colspan="8">Female</td></tr><tr><td>lung</td><td>stomach</td><td>large bowel</td><td>prostate</td><td>kidney</td><td>urinary bladder</td><td>lung</td><td>stomach</td><td>large bowel</td><td>breast</td><td>cervix</td><td>ovary</td><td>kidney</td><td>urinary bladder</td></tr><tr><td>Croatia</td><td>2005</td><td>63.7</td><td>17.7</td><td>43.5</td><td>38.7</td><td>11.1</td><td>18.4</td><td>13.6</td><td>6.9</td><td>23.4</td><td>55.8</td><td>9.2</td><td>11.7</td><td>4.7</td><td>4.1</td></tr><tr><td>Czech Republic</td><td>2005</td><td>58.2</td><td>11.2</td><td>58.7</td><td>59.5</td><td>22.6</td><td>22.3</td><td>15.5</td><td>5.8</td><td>28.8</td><td>61.7</td><td>13.3</td><td>12.4</td><td>9.8</td><td>6.0</td></tr><tr><td>Hungary</td><td>2002</td><td>94.6</td><td>20.5</td><td>56.6</td><td>34.0</td><td>14.7</td><td>19.6</td><td>24.9</td><td>9.5</td><td>33.7</td><td>63.0</td><td>15.7</td><td>11.1</td><td>6.6</td><td>5.1</td></tr><tr><td>Poland</td><td>2006</td><td>60.2</td><td>12.8</td><td>29.3</td><td>27.3</td><td>9.1</td><td>15.9</td><td>14.5</td><td>4.9</td><td>17.2</td><td>44.5</td><td>11.5</td><td>11.1</td><td>4.7</td><td>3.0</td></tr><tr><td>Romania</td><td>2002</td><td>50.0</td><td>17.6</td><td>22.0</td><td>16.8</td><td>5.5</td><td>15.4</td><td>8.5</td><td>6.8</td><td>14.4</td><td>44.3</td><td>23.9</td><td>9.4</td><td>2.8</td><td>3.3</td></tr><tr><td>Central Serbia</td><td>2004</td><td>64.2</td><td>12.9</td><td>33.7</td><td>20.1</td><td>6.5</td><td>17.4</td><td>18.4</td><td>7.2</td><td>20.9</td><td>57.9</td><td>24.3</td><td>10.9</td><td>3.8</td><td>4.2</td></tr><tr><td>Slovakia</td><td>2004</td><td>55.8</td><td>16.1</td><td>55.5</td><td>33.9</td><td>14.9</td><td>15.9</td><td>10.4</td><td>7.0</td><td>27.7</td><td>49.7</td><td>15.2</td><td>11.5</td><td>6.6</td><td>4.1</td></tr></table> |
f4d2eeab02360850a1151f154ab38444f0a7524a58f448dbda8fa95e4b325e95.png | complex | <table><tr><td>Parameters</td><td>Lead (Pb)</td><td>Cadmium (Cd)</td><td>Zinc (Zn)</td><td>Iron (Fe)</td><td>References</td></tr><tr><td>Water concentration (ppm)</td><td>0.33 ± 0.03</td><td>0.02 ± 0.00*</td><td>0.01 ± 0.00**</td><td>2.61 ± 0.07**</td><td>This study</td></tr><tr><td>Liver concentration (ppm)</td><td>0.35 ± 0.04</td><td>0.04 ± 0.00*</td><td>2.17 ± 0.30**</td><td>11.66 ± 1.32**</td><td>This study</td></tr><tr><td>Bioaccumulation factor</td><td>1.06</td><td>2.00</td><td>217.00</td><td>4.46</td><td>This study</td></tr><tr><td rowspan="2">Maximum acceptable water limit (ppm)</td><td>0.01</td><td>0.003</td><td>3.00</td><td>0.30</td><td>NIS (2007)</td></tr><tr><td>0.01</td><td>0.01</td><td>5.00</td><td>0.30</td><td>WHO (2003) [24]</td></tr><tr><td>Maximum acceptable liver limit (mgkg<sup>-1</sup>)</td><td>0.01</td><td>0.01</td><td>5.00</td><td>0.30</td><td>WHO (2003) [24]</td></tr></table> |
0e559518f626ffc1660d1446264f3fb46fa135e211bc85f9dfaa73a63e8e4c50.png | complex | <table><tr><td>Factor</td><td colspan="2">Prokaryotic community (<i>P</i>/R)</td><td></td><td colspan="2">Fungal community (<i>P</i>/R)</td></tr><tr><td></td><td>Chao1 (Richness)</td><td>Shannon</td><td></td><td>Chao1 (Richness)</td><td>Shannon</td></tr><tr><td>Na</td><td>0.489/-0.006</td><td>0.592/-0.033</td><td></td><td>0.280/0.042</td><td>0.067/0.156</td></tr><tr><td>S</td><td>0.001/0.526</td><td>0.001/0.610</td><td></td><td>0.320/0.012</td><td>0.319/0.029</td></tr><tr><td>P</td><td>0.021/0.100</td><td>0.214/0.049</td><td></td><td>0.067/0.181</td><td>0.188/0.080</td></tr><tr><td>Ca</td><td>0.223/0.026</td><td>0.085/0.088</td><td></td><td>0.690/-0.056</td><td>0.004/0.228</td></tr><tr><td>K</td><td>0.007/0.118</td><td>0.150/0.080</td><td></td><td>0.340/0.053</td><td>0.431/0.006</td></tr><tr><td>Mg</td><td>0.002/0.156</td><td>0.002/0.350</td><td></td><td>0.646/-0.075</td><td>0.158/0.103</td></tr><tr><td>Fe</td><td>0.001/0.238</td><td>0.047/0.136</td><td></td><td>0.494/-0.027</td><td>0.404/0.007</td></tr><tr><td>Al</td><td>0.001/0.225</td><td>0.020/0.165</td><td></td><td>0.347/0.029</td><td>0.356/0.023</td></tr><tr><td>As</td><td>0.878/-0.049</td><td>0.627/-0.042</td><td></td><td>0.143/0.146</td><td>0.776/-0.078</td></tr><tr><td>B</td><td>0.549/-0.012</td><td>0.269/0.033</td><td></td><td>0.299/0.031</td><td>0.784/-0.079</td></tr><tr><td>Ba</td><td>0.001/0.287</td><td>0.012/0.196</td><td></td><td>0.001/0.467</td><td>0.261/0.044</td></tr><tr><td>Cd</td><td>0.461/0.001</td><td>0.553/-0.030</td><td></td><td>0.017/0.362</td><td>0.514/-0.019</td></tr><tr><td>Co</td><td>0.001/0.245</td><td>0.012/0.187</td><td></td><td>0.414/0.013</td><td>0.491/-0.011</td></tr><tr><td>Cr</td><td>0.001/0.295</td><td>0.011/0.201</td><td></td><td>0.421/-0.012</td><td>0.455/-0.003</td></tr><tr><td>Cu</td><td>0.317/0.017</td><td>0.627/-0.037</td><td></td><td>0.591/-0.071</td><td>0.971/-0.156</td></tr><tr><td>Ga</td><td>0.001/0.270</td><td>0.009/0.206</td><td></td><td>0.342/0.008</td><td>0.215/0.064</td></tr><tr><td>Ge</td><td>0.200/0.033</td><td>0.072/0.144</td><td></td><td>0.322/-0.008</td><td>0.969/-0.125</td></tr><tr><td>Hg</td><td>0.001/0.167</td><td>0.159/0.072</td><td></td><td>0.417/-0.009</td><td>0.326/0.024</td></tr><tr><td>Li</td><td>0.259/0.022</td><td>0.475/-0.002</td><td></td><td>0.332/0.035</td><td>0.148/0.101</td></tr><tr><td>Mn</td><td>0.001/0.218</td><td>0.062/0.121</td><td></td><td>0.337/0.026</td><td>0.266/0.047</td></tr><tr><td>Ni</td><td>0.004/0.167</td><td>0.025/0.158</td><td></td><td>0.462/-0.021</td><td>0.216/0.072</td></tr><tr><td>Pt</td><td>0.918/-0.056</td><td>0.454/-0.025</td><td></td><td>0.524/-0.044</td><td>0.574/-0.047</td></tr><tr><td>Sr</td><td>0.417/0.004</td><td>0.177/0.064</td><td></td><td>0.712/-0.064</td><td>0.001/0.433</td></tr><tr><td>Ti</td><td>0.001/0.282</td><td>0.009/0.225</td><td></td><td>0.225/0.079</td><td>0.195/0.062</td></tr><tr><td>Zn</td><td>0.813/-0.041</td><td>0.931/-0.092</td><td></td><td>0.979/-0.117</td><td>0.837/-0.110</td></tr><tr><td>Rb</td><td>0.136/0.051</td><td>0.398/0.01</td><td></td><td>0.094/0.178</td><td>0.139/0.097</td></tr><tr><td>TCE</td><td>0.985/-0.076</td><td>0.899/-0.084</td><td></td><td>0.177/0.099</td><td>0.091/0.122</td></tr><tr><td>pH</td><td>0.779/-0.035</td><td>0.849/-0.07</td><td></td><td>0.396/0.015</td><td>0.390/0.016</td></tr><tr><td>Moisture</td><td>0.004/0.158</td><td>0.057/0.101</td><td></td><td>0.005/0.275</td><td>0.281/0.043</td></tr><tr><td>Longitude</td><td>0.020/0.129</td><td>0.006/0.162</td><td></td><td>0.930/-0.075</td><td>0.287/0.021</td></tr><tr><td>Latitude</td><td>0.007/0.160</td><td>0.047/0.107</td><td></td><td>0.836/-0.065</td><td>0.205/0.046</td></tr></table> |
7bdc4d8018002a3f3caac8535d9e206c68b6e8566d828037c6a37d3ef2e80424.png | simple | <table><tr><td>Fatty acid</td><td>Overall <i>N</i> = 3196</td><td>Male <i>N</i> = 1434</td><td>Female <i>N</i> = 1762</td><td><i>P</i> value*</td></tr><tr><td>Myristic, C14:0</td><td>0.31 (0.08)</td><td>0.29 (0.07)</td><td>0.32 (0.09)</td><td><0.0001</td></tr><tr><td>Palmitic, C16:0</td><td>21.29 (1.24)</td><td>21.24 (1.21)</td><td>21.34 (1.26)</td><td>0.031</td></tr><tr><td>Stearic, C18:0</td><td>18.11 (0.95)</td><td>18.20 (0.89)</td><td>18.04 (1.00)</td><td><0.0001</td></tr><tr><td>Lignoceric, C24:0</td><td>0.43 (0.16)</td><td>0.44 (0.16)</td><td>0.42 (0.16)</td><td>0.012</td></tr><tr><td>Palmitoleic, C16:1</td><td>0.35 (0.19)</td><td>0.31 (0.18)</td><td>0.39 (0.19)</td><td><0.0001</td></tr><tr><td>Oleic, C18:1</td><td>13.88 (1.06)</td><td>13.90 (1.06)</td><td>13.85 (1.06)</td><td>0.23</td></tr><tr><td>Eicosenoic, C20:1</td><td>0.27 (0.11)</td><td>0.28 (0.12)</td><td>0.27 (0.10)</td><td><0.0001</td></tr><tr><td>Nervonic, C24:1</td><td>0.45 (0.15)</td><td>0.46 (0.15)</td><td>0.43 (0.15)</td><td><0.0001</td></tr><tr><td>trans Palmitoleic, C16:1 trans</td><td>0.17 (0.05)</td><td>0.16 (0.05)</td><td>0.17 (0.05)</td><td>0.0052</td></tr><tr><td>trans Oleic, C18:1 trans</td><td>1.62 (0.55)</td><td>1.62 (0.57)</td><td>1.61 (0.54)</td><td>0.56</td></tr><tr><td>trans Linoleic, C18:2 trans</td><td>0.25 (0.08)</td><td>0.24 (0.08)</td><td>0.25 (0.08)</td><td>0.0021</td></tr><tr><td>alpha-Linolenic, C18:3n3</td><td>0.19 (0.10)<sup>†</sup></td><td>0.17 (0.09)</td><td>0.20 (0.11)</td><td><0.0001</td></tr><tr><td>Eicosapentaenoic (EPA), C20:5n3</td><td>0.74 (0.46)<sup>†</sup></td><td>0.71 (0.42)</td><td>0.76 (0.49)</td><td>0.0011</td></tr><tr><td>Docosapentaenoic, C22:5n3</td><td>2.74 (0.46)</td><td>2.80 (0.46)</td><td>2.70 (0.45)</td><td><0.0001</td></tr><tr><td>Docosahexaenoic (DHA), C22:6n3</td><td>4.88 (1.38)</td><td>4.82 (1.39)</td><td>4.92 (1.37)</td><td>0.043</td></tr><tr><td>Linoleic, C18:2n6</td><td>11.19 (1.74)</td><td>11.03 (1.63)</td><td>11.33 (1.81)</td><td><0.0001</td></tr><tr><td>gamma-Linolenic, C18:3n6</td><td>0.08 (0.09)</td><td>0.08 (0.12)</td><td>0.09 (0.07)</td><td>0.089</td></tr><tr><td>Eicosadienoic, C20:2n6</td><td>0.28 (0.05)</td><td>0.28 (0.05)</td><td>0.28 (0.05)</td><td>0.23</td></tr><tr><td>Eicosatrienoic, C20:3n6</td><td>1.59 (0.36)</td><td>1.59 (0.36)</td><td>1.59 (0.35)</td><td>0.66</td></tr><tr><td>Arachidonic, C20:4n6</td><td>16.78 (1.62)</td><td>16.79 (1.57)</td><td>16.77 (1.66)</td><td>0.66</td></tr><tr><td>Docosatetraenoic, C22:4n6</td><td>3.76 (0.83)</td><td>3.92 (0.83)</td><td>3.63 (0.81)</td><td><0.0001</td></tr><tr><td>Docosapentaenoic, C22:5n6</td><td>0.66 (0.19)</td><td>0.67 (0.19)</td><td>0.64 (0.19)</td><td><0.0001</td></tr></table> |
9997778607d72ceb7ab82835009ffbac248ce2b073822896418a4e3db5eeb659.png | simple | <table><tr><td>Factor</td><td>Effect on efficiency</td><td>Implications</td></tr><tr><td>Decreased morale</td><td>Decrease</td><td>Increase staff support and supervision, plan for retention, access to ART</td></tr><tr><td>Increased experience</td><td>Increase</td><td>Plan to increase retention to keep experienced staff</td></tr><tr><td>Increased training</td><td>Increase long term (short-term training time may decrease efficiency)</td><td>Plan for quality training on-hire (practical and didactic), continuing education, work to integrate into preclinical education in health services</td></tr><tr><td>Staff flexibility</td><td>Potentially increase</td><td>Provide education and support to encourage staff willing to expand/change roles to increase efficiency of the overall programme</td></tr></table> |
d892e0c31b84afedcd8e2e13edcd1abf97761462d9a7793085acd751754d8f47.png | complex | <table><tr><td></td><td colspan="3">Number</td></tr><tr><td></td><td>Round 1</td><td>Round 2</td><td>Round 3</td></tr><tr><td>Participant response rate</td><td>34/49 (70%)</td><td>33/34 (97%)</td><td>32/33 (97%)</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>8 (23.5%)</td><td>8 (24.2%)</td><td>7 (21.9%)</td></tr><tr><td> Female</td><td>26 (76.4%)</td><td>25 (75.8%)</td><td>25 (78.1%)</td></tr><tr><td>Age (years)</td><td></td><td></td><td></td></tr><tr><td> 30–40</td><td>6 (17.6%)</td><td>5 (15.1%)</td><td>5 (15.6%)</td></tr><tr><td> 41–50</td><td>14 (41.2%)</td><td>14 (42.4%)</td><td>14 (43.8%)</td></tr><tr><td> 51–60</td><td>14 (41.2%)</td><td>14 (42.4%)</td><td>13 (40.6%)</td></tr><tr><td>Work experience (years)</td><td></td><td></td><td></td></tr><tr><td> 5–15</td><td>25 (73.5%)</td><td>24 (72.7%)</td><td>23 (71.9%)</td></tr><tr><td> 16–25</td><td>8 (23.5%)</td><td>8 (24.2%)</td><td>8 (25%)</td></tr><tr><td> 26–30</td><td>1 (2.9%)</td><td>1 (3.03%)</td><td>1 (3.1%)</td></tr><tr><td>Education level</td><td></td><td></td><td></td></tr><tr><td> Bachelor's degree</td><td>13 (38.2%)</td><td>13 (39.4%)</td><td>12 (37.5%)</td></tr><tr><td> Master's degree</td><td>17 (50%)</td><td>16 (48.5%)</td><td>16 (50%)</td></tr><tr><td> PhD</td><td>4 (11.8%)</td><td>4 (12.1%)</td><td>4 (12.5%)</td></tr><tr><td>Profession</td><td></td><td></td><td></td></tr><tr><td> Nurse</td><td>24 (70.6%)</td><td>24 (72.7%)</td><td>23 (71.9%)</td></tr><tr><td> Physician</td><td>3 (8.8%)</td><td>3 (9.1%)</td><td>3 (9.4%)</td></tr><tr><td> Psychiatrist</td><td>2 (5.9%)</td><td>2 (6.0%)</td><td>2 (6.3%)</td></tr><tr><td> Psychologist</td><td>2 (5.9%)</td><td>1 (3.0%)</td><td>1 (3.1%)</td></tr><tr><td> Social worker</td><td>1 (2.9%)</td><td>1 (3.0%)</td><td>1 (3.1%)</td></tr><tr><td> Alcoholics Anonymous membership</td><td>1 (2.9%)</td><td>1 (3.0%)</td><td>1 (3.1%)</td></tr><tr><td> Health officer</td><td>1 (2.9%)</td><td>1 (3.0%)</td><td>1 (3.1%)</td></tr><tr><td>Region</td><td></td><td></td><td></td></tr><tr><td> North</td><td>6 (17.64%)</td><td>6 (18.18%)</td><td>6 (18.78%)</td></tr><tr><td> South</td><td>4 (11.76%)</td><td>4 (12.12%)</td><td>4 (12.52%)</td></tr><tr><td> Central</td><td>4 (11.76%)</td><td>4 (12.12%)</td><td>3 (9.39%)</td></tr><tr><td> Northeast</td><td>20 (58.8%)</td><td>19 (57.57%)</td><td>19 (59.47%)</td></tr></table> |
4243adae04103dba490259a59cb47fe757faf9ec1ec63ec55c46267bafa30055.png | simple | <table><tr><td>Compounds</td><td><i>E</i><sub>e</sub>/au</td><td>(Δ<i>E</i><sub>b</sub>) kcal/mol</td><td><i>E</i><sub>BSSE</sub></td><td>(Δ<i>E</i><sub>b-bsse</sub>) kcal/mol</td><td><i>E</i><sub>c</sub></td><td>(Δ<i>E</i><sub>cb</sub>) kcal/mol</td><td><i>H</i>\au</td><td>Δ<i>H</i> kcal/mol</td></tr><tr><td>L-Dopa</td><td>−705.45367</td><td></td><td></td><td></td><td>−705.25677</td><td></td><td>−705.24186</td><td></td></tr><tr><td>LD-W1</td><td>−781.92896</td><td>−10.559</td><td>−781.91194</td><td>−0.11922</td><td>−781.70706</td><td>−8.206</td><td>−781.68921</td><td>−8.788</td></tr><tr><td>LD-W2</td><td>−781.91946</td><td>−4.598</td><td>−781.91112</td><td>−0.63377</td><td>−781.69836</td><td>−2.783</td><td>−781.68007</td><td>−3.026</td></tr><tr><td>LD-W3</td><td>−781.92633</td><td>−8.905</td><td>−781.90779</td><td>−2.72335</td><td>−781.70373</td><td>−5.939</td><td>−781.68652</td><td>−7.073</td></tr><tr><td>Water</td><td>−76.45846</td><td></td><td></td><td></td><td>−76.43716</td><td></td><td>−76.43339</td><td></td></tr></table> |
a5fff2874247418b90506c571ede32e808c2a1f4e3984cacfe224f7c0e000f79.png | simple | <table><tr><td></td><td>A/CPA patients</td><td>Pure APA patients</td><td><i>P</i> value</td></tr><tr><td>Number of cases</td><td>22</td><td>392</td><td></td></tr><tr><td>Age (years)</td><td>40.32 ± 6.37</td><td>38.37 ± 7.76</td><td>0.1255</td></tr><tr><td>Age range (years)</td><td>26–51</td><td>19–58</td><td></td></tr><tr><td>Female, <i>n</i> (%)</td><td>14, 63.64%</td><td>219, 52.87%</td><td>0.3252</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.45 ± 3.22</td><td>25.28 ± 3.44</td><td>0.8111</td></tr><tr><td>Tumor size (mm)</td><td>24.50 ± 11.34</td><td>18.92 ± 7.98</td><td>0.0318<sup>∗</sup></td></tr><tr><td>SBP (mmHg)</td><td>181.4 ± 31.55</td><td>180.6 ± 26.57</td><td>0.8180</td></tr><tr><td>DBP (mmHg)</td><td>108.2 ± 13.26</td><td>109.2 ± 14.87</td><td>0.7071</td></tr><tr><td>Duration of HT (years)</td><td>11.91 ± 8.26</td><td>9.46 ± 7.30</td><td>0.1489</td></tr><tr><td>Stroke, <i>n</i> (%)</td><td>3 (13.64%)</td><td>22 (5.61%)</td><td>0.1242</td></tr><tr><td>Heart disease, <i>n</i> (%)</td><td>8 (36.36%)</td><td>41 (10.46%)</td><td>0.0003<sup>†</sup></td></tr><tr><td>CVE history, <i>n</i> (%)</td><td>11 (50%)</td><td>63 (16.07%)</td><td><0.0001<sup>†</sup></td></tr><tr><td>Glucose intolerance/diabetes, <i>n</i> (%)</td><td>13 (59.09%)</td><td>85 (21.68%)</td><td><0.0001<sup>†</sup></td></tr><tr><td>Lipid metabolic disorder, <i>n</i> (%)</td><td>9 (40.91%)</td><td>108 (27.55%)</td><td>0.1757</td></tr><tr><td>Osteopenia/osteoporosis, <i>n</i> (%)</td><td>3 (13.64%)</td><td>4 (1.02%)</td><td><0.0001<sup>†</sup></td></tr><tr><td>Metabolic syndrome, <i>n</i> (%)</td><td>8 (36.36%)</td><td>72 (18.37%)</td><td>0.0375<sup>∗</sup></td></tr><tr><td>Cortisol excess screening, <i>n</i> (%)<sup>‡</sup></td><td>22 (100%)</td><td>392 (100%)</td><td>—</td></tr><tr><td>Confirmation test performed, <i>n</i> (%)<sup>§</sup></td><td>22 (100%)</td><td>264 (67.35%)</td><td>—</td></tr><tr><td>Aldosterone excess screening, <i>n</i> (%)</td><td>22 (100%)</td><td>392 (100%)</td><td>—</td></tr><tr><td>Confirmation test performed, <i>n</i> (%)</td><td>22 (100%)</td><td>392 (100%)</td><td>—</td></tr></table> |
929778d428d4c570632bbd69c9e1e989db0d6bc286344344e305be5b1eab21f6.png | complex | <table><tr><td rowspan="2">Error type and antimicrobial</td><td rowspan="2">Organism</td><td rowspan="2">No. of errors</td><td colspan="2">MIC<sup><i>a</i></sup></td><td colspan="2">AST result<sup><i>b</i></sup></td><td colspan="2">Breakpoint<sup><i>a</i></sup></td><td colspan="2">Reportable range<sup><i>a</i></sup></td></tr><tr><td>AXDX</td><td>REF</td><td>AXDX</td><td>REF</td><td>S</td><td>R</td><td>Low</td><td>High</td></tr><tr><td>Very major errors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Daptomycin</td><td>Staphylococcus aureus</td><td>1</td><td>0.5</td><td>≥2</td><td>S</td><td>NS</td><td>1</td><td>N/A</td><td>0.25</td><td>2</td></tr><tr><td>Erythromycin</td><td>Staphylococcus warneri<sup><i>c</i></sup></td><td>1</td><td>0.25</td><td>≥16</td><td>S</td><td>R</td><td>0.5</td><td>8</td><td>0.125</td><td>16</td></tr><tr><td>Cefoxitin (MRSA/MRS)</td><td>Staphylococcus epidermidis</td><td>4</td><td>N/A</td><td>N/A</td><td>NEG</td><td>POS</td><td>4</td><td>8</td><td>4</td><td>8</td></tr><tr><td></td><td>Staphylococcus haemolyticus</td><td>1</td><td>N/A</td><td>N/A</td><td>NEG</td><td>POS</td><td>4</td><td>8</td><td>4</td><td>8</td></tr><tr><td>Erythromycin-clindamycin (MLSb)</td><td>Staphylococcus warneri</td><td>1</td><td>N/A</td><td>N/A</td><td>NEG</td><td>POS</td><td>2</td><td>4</td><td>2</td><td>4</td></tr><tr><td>Major errors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ampicillin</td><td>Enterococcus faecium</td><td>1</td><td>16</td><td>8</td><td>R</td><td>S</td><td>8</td><td>16</td><td>2</td><td>32</td></tr><tr><td>Daptomycin</td><td>Enterococcus faecium</td><td>1</td><td>≥8</td><td>2</td><td>NS</td><td>S</td><td>4</td><td>N/A</td><td>1</td><td>8</td></tr><tr><td rowspan="2">Doxycycline<sup><i>c</i></sup></td><td>Staphylococcus hominis subsp. <i>hominis</i></td><td>1</td><td>16</td><td>4</td><td>R</td><td>S</td><td>4</td><td>16</td><td>1</td><td>32</td></tr><tr><td>Staphylococcus aureus</td><td>4</td><td>≥32</td><td>2</td><td>R</td><td>S</td><td>4</td><td>16</td><td>1</td><td>32</td></tr><tr><td>Erythromycin</td><td>Staphylococcus aureus</td><td>1</td><td>≥16</td><td>0.25</td><td>R</td><td>S</td><td>0.5</td><td>8</td><td>0.125</td><td>16</td></tr><tr><td rowspan="2">Cefoxitin (MRSA/MRS)</td><td>Staphylococcus epidermidis</td><td>1</td><td>N/A</td><td>N/A</td><td>POS</td><td>NEG</td><td>4</td><td>8</td><td>4</td><td>8</td></tr><tr><td>Staphylococcus aureus</td><td>1</td><td>N/A</td><td>N/A</td><td>POS</td><td>NEG</td><td>4</td><td>8</td><td>4</td><td>8</td></tr><tr><td>Erythromycin-clindamycin (MLSb)</td><td>Staphylococcus epidermidis</td><td>1</td><td>N/A</td><td>N/A</td><td>POS</td><td>NEG</td><td>2</td><td>4</td><td>2</td><td>4</td></tr><tr><td></td><td>Staphylococcus warneri</td><td>1</td><td>N/A</td><td>N/A</td><td>POS</td><td>NEG</td><td>2</td><td>4</td><td>2</td><td>4</td></tr><tr><td rowspan="5">TMP-SMX<sup><i>c</i></sup><sup>,</sup><sup><i>d</i></sup></td><td rowspan="4">Staphylococcus aureus</td><td>1</td><td>≥8</td><td>2</td><td>R</td><td>S</td><td>2</td><td>4</td><td>0.5</td><td>8</td></tr><tr><td>2</td><td>≥8</td><td>≤0.5</td><td>R</td><td>S</td><td>2</td><td>4</td><td>0.5</td><td>8</td></tr><tr><td>2</td><td>4</td><td>1</td><td>R</td><td>S</td><td>2</td><td>4</td><td>0.5</td><td>8</td></tr><tr><td>2</td><td>4</td><td>≤0.5</td><td>R</td><td>S</td><td>2</td><td>4</td><td>0.5</td><td>8</td></tr><tr><td>Staphylococcus lugdunensis</td><td>3</td><td>4</td><td>≤0.5</td><td>R</td><td>S</td><td>2</td><td>4</td><td>0.5</td><td>8</td></tr></table> |
091d042282da17f2ce87a05ebd1c805ce7ad00a23a143417ea9c2b7f7eb42a77.png | complex | <table><tr><td></td><td>Target population (<i>n</i> = 5)</td><td>Key stakeholders (<i>n</i> = 5)</td></tr><tr><td>Gender</td><td>Male (4)</td><td>Male (3)</td></tr><tr><td>Age</td><td>21–34 years 
(mean: 26 years)</td><td>23–38 years 
(mean: 29 years)</td></tr><tr><td rowspan="4">Educational status</td><td>Primary (1)</td><td>High-school (2)</td></tr><tr><td>Secondary (2)</td><td>Bachelors (2)</td></tr><tr><td>High-school (1)</td><td>Masters (1)</td></tr><tr><td>Bachelors (1)</td><td></td></tr><tr><td rowspan="4">Countries visited</td><td>Malaysia (2)</td><td rowspan="4">n/a</td></tr><tr><td>Saudi Arabia (1)</td></tr><tr><td>Qatar (1)</td></tr><tr><td>UAE (1)</td></tr><tr><td rowspan="4">Occupation</td><td>Domestic service (1)</td><td>Coordinator (1)</td></tr><tr><td>Driver (1)</td><td>Counselor (2)</td></tr><tr><td>Construction (2)</td><td>Field worker (2)</td></tr><tr><td>Cook (1)</td><td></td></tr><tr><td>Work experience</td><td>3–8 years 
(mean: 5.2 years)</td><td>1–6 years 
(mean: 4.4 years)</td></tr></table> |
9671248b31598833e9ce5af8c9810a2d92ae27260ba5db866e0262906c65d357.png | simple | <table><tr><td> </td><td>No. (%)</td></tr><tr><td>State of health</td><td> </td></tr><tr><td>Good</td><td>349 (37.0)</td></tr><tr><td>Poor</td><td>595 (63.0)</td></tr><tr><td>Emotional status</td><td> </td></tr><tr><td>Blank</td><td>144 (15.3)</td></tr><tr><td>Unhappy (ever)</td><td>99 (10.5)</td></tr><tr><td>Ordinary</td><td>343 (36.3)</td></tr><tr><td>happy</td><td>348 (36.9)</td></tr><tr><td>No response</td><td>10 (1.1)</td></tr><tr><td>Smoking</td><td> </td></tr><tr><td>No</td><td>925 (98.0)</td></tr><tr><td><5 cigarettes per day</td><td>11 (1.2)</td></tr><tr><td>6 ~ 10 cigarettes per day</td><td>5 (0.5)</td></tr><tr><td>11 ~ 20 cigarettes per day</td><td>3 (0.3)</td></tr><tr><td>Alcohol use</td><td> </td></tr><tr><td>No</td><td>856 (90.7)</td></tr><tr><td><1 time per week</td><td>63 (6.7)</td></tr><tr><td>1 ~ 2 times per week</td><td>18 (1.9)</td></tr><tr><td>3 ~ 6 times per week</td><td>6 (0.6)</td></tr><tr><td>≥1 time per day</td><td>1 (0.1)</td></tr><tr><td>Religion</td><td> </td></tr><tr><td>No</td><td>580 (61.4)</td></tr><tr><td>Yes</td><td>364 (38.6)</td></tr><tr><td>Exercise regularly</td><td> </td></tr><tr><td>No</td><td>487 (51.6)</td></tr><tr><td>Yes</td><td>457 (48.4)</td></tr><tr><td>Exercise duration (years)</td><td> </td></tr><tr><td><3</td><td>93 (9.9)</td></tr><tr><td>3 ~ 5</td><td>116 (12.3)</td></tr><tr><td>6 ~ 10</td><td>118 (12.5)</td></tr><tr><td>>10</td><td>74 (7.8)</td></tr><tr><td>No response</td><td>46 (4.9)</td></tr></table> |
53cda5a4147d2039c24fe6b2733ac8017a4f49b4b839f12ddc1292ab9045a5cc.png | complex | <table><tr><td rowspan="2"></td><td>Total Median Costs</td><td></td><td></td><td></td><td>MRI</td><td></td><td>No MRI</td><td></td></tr><tr><td colspan="4">(<i>N</i> = 53,653)</td><td colspan="2">(<i>N</i> = 10,776)</td><td colspan="2">(<i>N</i> = 42,877)</td></tr><tr><td>Characteristics<sup>b</sup> of women</td><td>N</td><td>%</td><td>Median</td><td>IQR ($)</td><td>Median</td><td>IQR ($)</td><td>Median</td><td>IQR ($)</td></tr><tr><td>Total</td><td>53,653</td><td>100 %</td><td>$1,353</td><td>(818–2,042)</td><td>$2,251</td><td>(1,783–2,971)</td><td>$1,152</td><td>(708–1,727)</td></tr><tr><td>Stage</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0</td><td>8,533</td><td>16 %</td><td>$1,721</td><td>(1,232–2,368)</td><td>$2,627</td><td>(2,090–3,228)</td><td>$1,524</td><td>(1,160–2,085)</td></tr><tr><td> I</td><td>25,146</td><td>47 %</td><td>$1,393</td><td>(878–2,080)</td><td>$2,255</td><td>(1,799–2,985)</td><td>$1,190</td><td>(781–1,751)</td></tr><tr><td> II</td><td>14,328</td><td>27 %</td><td>$1,106</td><td>(627–1,838)</td><td>$2,093</td><td>(1,662–2,776)</td><td>$891</td><td>(547–1,442)</td></tr><tr><td> III</td><td>3,838</td><td>7 %</td><td>$1,008</td><td>(535–1,76)</td><td>$2,078</td><td>(1,631–2,775)</td><td>$825</td><td>(452–1,345)</td></tr><tr><td> IV</td><td>503</td><td>1 %</td><td>$927</td><td>(449–1,685)</td><td>$2,023</td><td>(1,690–2,791)</td><td>$738</td><td>(405–1,294)</td></tr><tr><td> Unknown</td><td>1,305</td><td>2 %</td><td>$1,310</td><td>(815–1,938)</td><td>$2,118</td><td>(1,620–2,743)</td><td>$1,176</td><td>(741–1,712)</td></tr><tr><td>Histology (invasive)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Ductal</td><td>33,134</td><td>62 %</td><td>$1,259</td><td>(751–1,953)</td><td>$2,186</td><td>(1,742–2,892)</td><td>$1,068</td><td>(664–1,641)</td></tr><tr><td> Lobular</td><td>5,005</td><td>9 %</td><td>$1,359</td><td>(765–2,061)</td><td>$2,155</td><td>(1,736–2,837)</td><td>$1,025</td><td>(615–1,576)</td></tr><tr><td> Mixed</td><td>3,177</td><td>6 %</td><td>$1,346</td><td>(795–2,094)</td><td>$2,264</td><td>(1,774–2,968)</td><td>$1,058</td><td>(656–1,580)</td></tr><tr><td> Other</td><td>3,804</td><td>7 %</td><td>$1,232</td><td>(714–1,877)</td><td>$2,178</td><td>(1,623–2,927)</td><td>$1,078</td><td>(648–1,674)</td></tr><tr><td>Grade</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> High</td><td>12,125</td><td>24 %</td><td>$1,392</td><td>(877–2,083)</td><td>$2,284</td><td>(1,811–3,050)</td><td>$1,191</td><td>(772–1,754)</td></tr><tr><td> Intermediate</td><td>22,522</td><td>45 %</td><td>$1,351</td><td>(822–2,054)</td><td>$2,238</td><td>(1,776–2,944)</td><td>$1,129</td><td>(708–1,715)</td></tr><tr><td> Low</td><td>15,133</td><td>30 %</td><td>$1,289</td><td>(726–1,969)</td><td>$2,212</td><td>(1,747–2,899)</td><td>$1,100</td><td>(636–1,676)</td></tr><tr><td>Nodal Status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Positive</td><td>11,009</td><td>25 %</td><td>$1,119</td><td>(623–1,851)</td><td>$2,113</td><td>(1,652–2,842)</td><td>$890</td><td>(534–1,439)</td></tr><tr><td> Negative</td><td>32,952</td><td>75 %</td><td>$1,379</td><td>(847–2,074)</td><td>$2,242</td><td>(1,788–2,951)</td><td>$1,158</td><td>(739–1,734)</td></tr><tr><td>ER Status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Positive</td><td>40,999</td><td>84 %</td><td>$1,367</td><td>(827–2,061)</td><td>$2,249</td><td>(1,787–2,971)</td><td>$1,152</td><td>(716–1,732)</td></tr><tr><td> Negative</td><td>7,978</td><td>16 %</td><td>$1,263</td><td>(728–1,960)</td><td>$2,231</td><td>(1,747–2,935)</td><td>$634</td><td>(634–1,633)</td></tr><tr><td>Size</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <1 cm</td><td>12,455</td><td>25 %</td><td>$1,569</td><td>(1,090–2,253)</td><td>$2,451</td><td>(1,967–3,184)</td><td>$1,369</td><td>(987–1,936)</td></tr><tr><td> 1 to <2 cm</td><td>19,135</td><td>39 %</td><td>$1,348</td><td>(824–2,031)</td><td>$2,187</td><td>(1,745–2,925)</td><td>$1,127</td><td>(723–1,716)</td></tr><tr><td> 2 to <5 cm</td><td>15,281</td><td>31 %</td><td>$1,098</td><td>(610–1,826)</td><td>$2,097</td><td>(1,660–2,798)</td><td>$891</td><td>(532–1,459)</td></tr><tr><td> 5+ cm</td><td>2,620</td><td>5 %</td><td>$1,057</td><td>(535–1,870)</td><td>$2,133</td><td>(1,719–2,810)</td><td>$840</td><td>(438–1,420)</td></tr><tr><td>Primary Treatment</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mastectomy</td><td>19,650</td><td>37 %</td><td>$1,267</td><td>(696–1,955)</td><td>$2,265</td><td>(1,746–3,028)</td><td>$1,053</td><td>(602–1,686)</td></tr><tr><td> BCS<sup>c</sup> without Radiation</td><td>12,972</td><td>24 %</td><td>$1,362</td><td>(838–2,035)</td><td>$2,285</td><td>(1,782–2,955)</td><td>$1,198</td><td>(744–1,744)</td></tr><tr><td> BCS<sup>c</sup> with Radiation</td><td>21,031</td><td>39 %</td><td>$1,413</td><td>(909–2,126)</td><td>$2,230</td><td>(1,801–2,925)</td><td>$1,201</td><td>(602–1,762)</td></tr><tr><td>Number of days in Diagnostic/preoperative Window</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <= Median (25 days)</td><td>27,779</td><td>52 %</td><td>$1,172</td><td>(685–1,768)</td><td>$2,009</td><td>(1,626–2,543)</td><td>$1,056</td><td>(633–1,588)</td></tr><tr><td> > Median (25 days)</td><td>25,874</td><td>48 %</td><td>$1,593</td><td>(998–2,354)</td><td>$2,392</td><td>(1,878–3,229)</td><td>$1,272</td><td>(828–1,915)</td></tr></table> |
39f134e0b5c80700b46267f05160cc8ca5a1953e43113bb81429f7a75f8457b6.png | simple | <table><tr><td>Reason of Intake</td><td>Cat</td><td>Dog</td></tr><tr><td>Stray</td><td>100 (80.6%)</td><td>58 (47.5%)</td></tr><tr><td>People Issues (allergic, relocating, etc.)</td><td>5 (4.0%)</td><td>16 (13.1%)</td></tr><tr><td>Deceased Caretaker</td><td>3 (2.4%)</td><td>1 (0.8%)</td></tr><tr><td>Negligence</td><td>2 (1.6%)</td><td>0 (0%)</td></tr><tr><td>Abandoned (chip and no reclaim)</td><td>0 (0%)</td><td>9 (7.4%)</td></tr><tr><td>Animal Illness</td><td>13 (10.5%)</td><td>27 (22.1%)</td></tr><tr><td>Behavior</td><td>1 (11.9%)</td><td>11 (9.0%)</td></tr></table> |
7385c8fe1af7e5548cc3311b922a637e7b721de44e136d648434dbdcc96836b2.png | simple | <table><tr><td>Time steps</td><td>Experiment-1</td><td>Experiment-2</td><td>Experiment-3</td><td>Experiment-4</td></tr><tr><td><i>t</i><sub>0</sub></td><td>75.12%</td><td>92.80%</td><td>55.02%</td><td>67.90%</td></tr><tr><td><i>t</i><sub>1</sub></td><td>78.07%</td><td>95.40%</td><td>80.01%</td><td>72.42%</td></tr><tr><td><i>t</i><sub>2</sub></td><td>78.39%</td><td>94.64%</td><td>75.42%</td><td>53.79%</td></tr><tr><td><i>t</i><sub>3</sub></td><td>78.76%</td><td>95.56%</td><td>95.72%</td><td>61.30%</td></tr><tr><td><i>t</i><sub>4</sub></td><td>78.33%</td><td>95.89%</td><td>79.17%</td><td>55.70%</td></tr><tr><td><i>t</i><sub>5</sub></td><td>81.11%</td><td>94.89%</td><td>31.97%</td><td>68.11%</td></tr><tr><td><i>t</i><sub>6</sub></td><td>59.72%</td><td>96.02%</td><td>66.80%</td><td>72.33%</td></tr><tr><td><i>t</i><sub>7</sub></td><td>55.60%</td><td>96.12%</td><td>91.19%</td><td>63.88%</td></tr><tr><td><i>t</i><sub>8</sub></td><td>57.41%</td><td>96.08%</td><td>75.35%</td><td>79.23%</td></tr><tr><td><i>t</i><sub>9</sub></td><td>57.12%</td><td>96.23%</td><td>74.83%</td><td>62.25%</td></tr><tr><td><i>t</i><sub>10</sub></td><td>50.26%</td><td>97.07%</td><td>54.56%</td><td>63.04%</td></tr><tr><td><i>t</i><sub>11</sub></td><td>57.20%</td><td>97.71%</td><td>49.06%</td><td>49.57%</td></tr><tr><td><i>t</i><sub>12</sub></td><td>55.68%</td><td>97.33%</td><td>58.64%</td><td>68.43%</td></tr><tr><td><i>t</i><sub>13</sub></td><td>84.71%</td><td>97.74%</td><td>95.73%</td><td>67.83%</td></tr><tr><td><i>t</i><sub>14</sub></td><td>87.05%</td><td>97.82%</td><td>72.06%</td><td>51.28%</td></tr><tr><td><i>t</i><sub>15</sub></td><td>85.03%</td><td>97.11%</td><td>83.78%</td><td>79.36%</td></tr><tr><td><i>t</i><sub>16</sub></td><td>81.62%</td><td>97.56%</td><td>95.87%</td><td>68.08%</td></tr><tr><td><i>t</i><sub>17</sub></td><td>85.39%</td><td>97.59%</td><td>97.00%</td><td>50.38%</td></tr><tr><td><i>t</i><sub>18</sub></td><td>82.83%</td><td>96.38%</td><td>53.05%</td><td>68.15%</td></tr><tr><td><i>t</i><sub>19</sub></td><td>81.01%</td><td>96.52%</td><td>43.29%</td><td>53.84%</td></tr><tr><td><i>t</i><sub>20</sub></td><td>27.91%</td><td>63.11%</td><td>31.24%</td><td>36.31%</td></tr><tr><td><i>t</i><sub>21</sub></td><td>29.84%</td><td>67.49%</td><td>35.47%</td><td>39.92%</td></tr><tr><td><i>t</i><sub>22</sub></td><td>27.96%</td><td>63.14%</td><td>27.56%</td><td>34.19%</td></tr><tr><td><i>t</i><sub>23</sub></td><td>28.86%</td><td>66.94%</td><td>22.00%</td><td>41.38%</td></tr><tr><td>Figure</td><td>Figure 13(a)</td><td>Figure 13(b)</td><td>Figure 14(a)</td><td>Figure 14(b)</td></tr></table> |
0d4061eb372ecbcf9be5875c374e79c96c424a1cacb8f57bd30394ee48d890ff.png | complex | <table><tr><td>Target</td><td>Species</td><td>Dilution</td><td>Reference</td></tr><tr><td colspan="4">Primary antibodies</td></tr><tr><td> Nrf2</td><td>Rabbit</td><td>1:100</td><td>ab31163; Abcam, UK</td></tr><tr><td> AhR</td><td>Rabbit</td><td>1:200</td><td>sc-5579; H-211; Santa Cruz, Heidelberg, Germany</td></tr><tr><td colspan="4">Secondary antibodies</td></tr><tr><td> Anti-rabbit</td><td>Goat</td><td>1:2000</td><td>AS09 633; Agrisera, Vännas, Sweden</td></tr></table> |
79409dac05db8ada4d3d6f873f18a11ff09224f500e4d32b824c6c03c0c836e6.png | complex | <table><tr><td> </td><td colspan="2">1a</td><td> </td><td colspan="2">7b</td></tr><tr><td>Position</td><td><i>δ</i><sub>C</sub></td><td><i>δ</i><sub>H</sub> (<i>J</i> Hz)</td><td>Position</td><td><i>δ</i><sub>C</sub></td><td><i>δ</i><sub>H</sub> (<i>J</i> Hz)</td></tr><tr><td>1a</td><td>43.8</td><td>1.12, m</td><td>2</td><td>161.6</td><td> </td></tr><tr><td>1b</td><td> </td><td>1.18, m</td><td>3</td><td>87.5</td><td>5.65, s</td></tr><tr><td>2a</td><td>18.7</td><td>1.53, m</td><td>4</td><td>169.1</td><td> </td></tr><tr><td>2b</td><td> </td><td>1.76, m</td><td>5</td><td>149.2</td><td> </td></tr><tr><td>3a</td><td>38.3</td><td>1.20, m</td><td>6</td><td>107.7</td><td>7.26, s</td></tr><tr><td>3b</td><td> </td><td>1.69, m</td><td>7</td><td>131.4</td><td> </td></tr><tr><td>4</td><td>39.2</td><td> </td><td>8</td><td>143.7</td><td> </td></tr><tr><td>5</td><td>45.9</td><td>1.80, m</td><td>9</td><td>132.1</td><td> </td></tr><tr><td>6</td><td>69.3</td><td>5.67, m</td><td>10</td><td>105.9</td><td> </td></tr><tr><td>7a</td><td>28.8</td><td>2.12, m</td><td>11</td><td>65.4</td><td>4.67, d (6.5)</td></tr><tr><td>7b</td><td> </td><td>2.47, m</td><td>12</td><td>119.8</td><td>5.47, d (6.5)</td></tr><tr><td>8</td><td>37.0</td><td>2.87, t (8.0)</td><td>13</td><td>137.3</td><td> </td></tr><tr><td>9</td><td>50.7</td><td>2.40, m</td><td>14</td><td>18.1</td><td>1.74, s</td></tr><tr><td>10</td><td>35.7</td><td> </td><td>15</td><td>25.5</td><td>1.76, s</td></tr><tr><td>11a</td><td>69.4</td><td>4.28,dd (5.5,10)</td><td>16</td><td>61.2</td><td>4.80, d (4.0)</td></tr><tr><td>11b</td><td> </td><td>4.47, d (9.5)</td><td>17</td><td>56.7</td><td>3.94, s</td></tr><tr><td>12</td><td>181.2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>13</td><td>20.3</td><td>0.88, s</td><td> </td><td> </td><td> </td></tr><tr><td>14a</td><td>71.2</td><td>3.03, d (6.5)</td><td> </td><td> </td><td> </td></tr><tr><td>14b</td><td> </td><td>3.56, d (6.0)</td><td> </td><td> </td><td> </td></tr><tr><td>15</td><td>19.1</td><td>1.43, s</td><td> </td><td> </td><td> </td></tr><tr><td>1′</td><td>168.1</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>2′</td><td>132.0</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3′</td><td>130.6</td><td>7.95,dd (1.5,7.0)</td><td> </td><td> </td><td> </td></tr><tr><td>4′</td><td>129.6</td><td>7.48, d (8.0)</td><td> </td><td> </td><td> </td></tr><tr><td>5′</td><td>134.1</td><td>7.60, t (7.5)</td><td> </td><td> </td><td> </td></tr><tr><td>6′</td><td>129.6</td><td>7.47, d (7.5)</td><td> </td><td> </td><td> </td></tr><tr><td>7′</td><td>130.6</td><td>7.97, dd (1.5,7.0)</td><td> </td><td> </td><td> </td></tr></table> |
7ec2619cc8d54d69ebc622cbc55b254a8e871d93b6ed9fef88026a398acd4165.png | simple | <table><tr><td>Tumor and normal cells</td><td>Cis-3M-RESIC<sub>50</sub> (μM)<sup>*</sup></td><td>ResveratrolIC<sub>50</sub> (μM)<sup>*</sup></td></tr><tr><td>Unstimulated human peripheral T cells</td><td>>10.0</td><td>N.D</td></tr><tr><td>PHA-stimulated human peripheral T cells<sup>**</sup></td><td>0.23</td><td>N.D</td></tr><tr><td>Human acute T cell leukemia Jurkat E6.1</td><td>0.07</td><td>110.1</td></tr><tr><td>Human acute T cell leukemia Jurkat (JT/Neo)</td><td>0.08</td><td>97.5</td></tr><tr><td>Human acute T cell leukemia Jurkat (JT/BCL-2)</td><td>>10.0</td><td>>250.0</td></tr><tr><td>Human monoblastoid U937</td><td>0.08</td><td>86.6</td></tr><tr><td>Human promyelocytic leukemia HL-60</td><td>0.08</td><td>60.5</td></tr><tr><td>Human cervical carcinoma HeLa</td><td>0.17</td><td>193.4</td></tr></table> |
d40bfefd7ccad9ceab6e894d6ec8b99dd6b75fac022a1275cf1633cbddb99af3.png | simple | <table><tr><td>Variable</td><td>Categories</td><td>Unadjusted Odd ratio (CI)</td></tr><tr><td>Fistula size</td><td>Large (> 3 cm)</td><td>5.33(0.93-30.50)</td></tr><tr><td></td><td>Medium (1-3 cm)</td><td>0.63(1.39-2.86)</td></tr><tr><td></td><td>Small (< 3 cm)</td><td>1</td></tr><tr><td>Level of vaginal scarring</td><td>Moderate severe</td><td>NA</td></tr><tr><td></td><td>Mild or no scarring</td><td>1</td></tr><tr><td>Urethral involvement</td><td>Circumferential</td><td>10.50 (1.39-79.13)*</td></tr><tr><td></td><td>Partial/Juxta</td><td>5 (1.14-22.00)*</td></tr><tr><td></td><td>Urethral involvement</td><td></td></tr><tr><td></td><td>No urethral involvement</td><td>1</td></tr><tr><td>Class of Fistula</td><td>Type II b</td><td>5.56(1.34-23.02)*</td></tr><tr><td></td><td>Type II a</td><td>O.625(0.06-6.30)</td></tr><tr><td></td><td>Type I</td><td>1</td></tr><tr><td>Previous Repair</td><td>Yes</td><td>4.8(1.27-18.11)*</td></tr><tr><td></td><td>No</td><td>1</td></tr></table> |
bdc9ec0d0cd0ce381b73aff8a30be0b228233e8b0f1dc42daeceec476e71fd4f.png | complex | <table><tr><td></td><td>Adult <i>n</i> (%) (<i>n</i> = 186)<sup>a</sup></td><td>Paediatric <i>n</i> (%) (<i>n</i> = 17)<sup>a</sup></td><td><i>p</i>-value</td></tr><tr><td>Pulmonary TB</td><td>125 (67)</td><td>14 (82)</td><td>0.198</td></tr><tr><td> Multidrug-resistant TB</td><td>7 (6)</td><td>2 (14)</td><td>0.099</td></tr><tr><td colspan="4">Method TB detected</td></tr><tr><td> Screening performed at arrival</td><td>35 (19)</td><td>7 (41)</td><td>0.029</td></tr><tr><td> During contact tracing of another TB patient</td><td>14 (8)</td><td>4 (24)</td><td>0.026</td></tr><tr><td> Sought care for symptoms or by chance</td><td>137 (74)</td><td>6 (35)</td><td><0.01</td></tr><tr><td colspan="4">Time from arrival to Finland to diagnosis of TB</td></tr><tr><td>< 3 months</td><td>39 (21)</td><td>9 (53)</td><td><0.01</td></tr><tr><td> 3–23 months</td><td>51 (27)</td><td>4 (24)</td><td>0.73</td></tr><tr><td>≥ 24 months</td><td>80 (43)</td><td>4 (24)</td><td>0.119</td></tr><tr><td> Unknown</td><td>16 (9)</td><td>0 (0)</td><td>0.254</td></tr><tr><td colspan="4">Person had resided in</td></tr><tr><td> Reception centre in Finland</td><td>27 (15)</td><td>8 (47)</td><td><0.01</td></tr><tr><td> Refugee camp abroad</td><td>25 (13)</td><td>5 (29)</td><td>0.076</td></tr><tr><td>No TB-related symptoms</td><td>40 (22)</td><td>10 (59)</td><td><0.01</td></tr></table> |
c1c0c92e3c70740dc067896ea690521b088f751521ed71334965fb3f7694b899.png | simple | <table><tr><td> ISTH score</td><td>Predicted score from PT</td><td>Predicted score from PT + APTT</td><td>Predicted score from PT/APTT</td></tr><tr><td>2</td><td>3.44</td><td>3.37</td><td>3.70</td></tr><tr><td>2</td><td>3.48</td><td>3.49</td><td>3.43</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><tr><td>2</td><td>3.36</td><td>3.32</td><td>3.40</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><tr><td>2</td><td>3.38</td><td>3.39</td><td>3.23</td></tr></table> |
49285aa3003552accc7dbcd8b5d251fd4308d6bc784eb74eb5e0900cf0a59614.png | complex | <table><tr><td>Scale</td><td colspan="3">Men</td><td colspan="3">Women</td><td><i>d</i> (Men-Women)</td></tr><tr><td></td><td>α</td><td><i>M</i></td><td><i>SD</i></td><td>α</td><td><i>M</i></td><td><i>SD</i></td><td></td></tr><tr><td>Vigor</td><td>0.89</td><td>3.03</td><td>0.89</td><td>0.88</td><td>2.87</td><td>0.91</td><td>0.17</td></tr><tr><td>Calmness</td><td>0.88</td><td>3.90</td><td>0.66</td><td>0.88</td><td>3.90</td><td>0.71</td><td>0.00</td></tr><tr><td>Mature personality</td><td>0.93</td><td>3.90</td><td>0.58</td><td>0.93</td><td>3.93</td><td>0.61</td><td>−0.05</td></tr><tr><td>Impulsiveness</td><td>0.65</td><td>2.57</td><td>0.52</td><td>0.68</td><td>2.46</td><td>0.57</td><td>0.18</td></tr><tr><td>Self confidence</td><td>0.78</td><td>3.60</td><td>0.60</td><td>0.81</td><td>3.32</td><td>0.67</td><td>0.41</td></tr><tr><td>Culture</td><td>0.85</td><td>3.39</td><td>0.67</td><td>0.83</td><td>3.61</td><td>0.64</td><td>−0.32</td></tr><tr><td>Sociability</td><td>0.85</td><td>3.18</td><td>0.67</td><td>0.84</td><td>3.15</td><td>0.68</td><td>0.06</td></tr><tr><td>Leadership</td><td>0.82</td><td>2.81</td><td>0.82</td><td>0.82</td><td>2.56</td><td>0.84</td><td>0.29</td></tr><tr><td>Social sensitivity</td><td>0.83</td><td>3.71</td><td>0.63</td><td>0.85</td><td>3.99</td><td>0.64</td><td>−0.42</td></tr><tr><td>Tidiness</td><td>0.88</td><td>3.49</td><td>0.71</td><td>0.88</td><td>3.61</td><td>0.74</td><td>−0.17</td></tr></table> |
9ad4cc74acef76c4b6d88aa3241b4719fcc40379cfd225d90f0723ecfd213c76.png | complex | <table><tr><td colspan="2"> </td><td>All participants(<i>N</i> = 2,467)</td></tr><tr><td colspan="2">Age, years</td><td>58.3 (15.7)</td></tr><tr><td colspan="2">Sex, women, <i>n</i></td><td>1,438 (58.3%)</td></tr><tr><td colspan="2">Regular exercise,<sup>a</sup><i>n</i></td><td>831 (33.8%)</td></tr><tr><td>Smoking</td><td>Current smoker, <i>n</i></td><td>381 (15.5%)</td></tr><tr><td> </td><td>Ex-smoker, <i>n</i></td><td>460 (18.7%)</td></tr><tr><td colspan="2">Alcohol consumption, g/week</td><td>72.1 (133.7)</td></tr><tr><td colspan="2">Body mass index, kg/m<sup>2</sup></td><td>23.1 (3.4)</td></tr><tr><td colspan="2">Systolic blood pressure, mm Hg</td><td>132.1 (19.4)</td></tr><tr><td colspan="2">Diastolic blood pressure, mm Hg</td><td>79.4 (11.1)</td></tr><tr><td colspan="2">HbA1c (NGSP), %</td><td>5.8 (0.8)</td></tr><tr><td colspan="2">Total cholesterol, mg/dL</td><td>206.3 (35.1)</td></tr><tr><td colspan="2">HDL cholesterol, mg/dL</td><td>62.6 (16.0)</td></tr><tr><td colspan="2">Hypertension,<sup>b</sup><i>n</i></td><td>1,158 (46.9%)</td></tr><tr><td colspan="2">Diabetes mellitus,<sup>c</sup><i>n</i></td><td>254 (10.3%)</td></tr><tr><td colspan="2">Hypercholesterolemia,<sup>d</sup><i>n</i></td><td>1,030 (41.8%)</td></tr><tr><td colspan="2">Low HDL cholesterol,<sup>e</sup><i>n</i></td><td>181 (7.3%)</td></tr></table> |
21b25826035432386722bd00b194f3d301024c386e263f06d6010144a911c70d.png | simple | <table><tr><td>Characteristic</td><td>No. of participants (<i>n</i> = 15)</td></tr><tr><td>Age [median (range)]</td><td>47 (33–59)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Male</td><td>8</td></tr><tr><td>Female</td><td>7</td></tr><tr><td>Ethnicity</td><td></td></tr><tr><td>White British</td><td>13</td></tr><tr><td>Other</td><td>2</td></tr><tr><td>Profession</td><td></td></tr><tr><td>Surgeon</td><td>5</td></tr><tr><td>Clinical oncologist</td><td>3</td></tr><tr><td>Specialist nurse</td><td>4</td></tr><tr><td>Research nurse</td><td>1</td></tr><tr><td>Specialist radiographer</td><td>1</td></tr><tr><td>Speech and language therapist</td><td>1</td></tr><tr><td>Geographic area of sample, no.</td><td></td></tr><tr><td>North West England</td><td>4</td></tr><tr><td>North East England</td><td>2</td></tr><tr><td>South West England</td><td>1</td></tr><tr><td>London</td><td>4</td></tr><tr><td>South East England</td><td>3</td></tr><tr><td>Wales</td><td>1</td></tr></table> |
0f8f8eba032d6ac99c875a2af0d95de31ad4e835caa0054ca30b92feccf5dc25.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Ethiopia</td><td colspan="2">Kenya</td></tr><tr><td>Urban</td><td>Rural</td><td>Urban</td><td>Rural</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td> 15–24</td><td>15.9</td><td>15.9</td><td>12.5</td><td>10.3</td></tr><tr><td> 25–34</td><td>37.3</td><td>33.4</td><td>39.1</td><td>34.1</td></tr><tr><td> 35–44</td><td>29.2</td><td>28.7</td><td>28.8</td><td>32.3</td></tr><tr><td> 45+</td><td>17.6</td><td>21.9</td><td>19.6</td><td>23.3</td></tr><tr><td> <i>p</i>-Value</td><td>0.000</td><td>0.000</td><td>0.000</td><td>0.000</td></tr><tr><td>Marital status</td><td></td><td></td><td></td><td></td></tr><tr><td> Single</td><td>55.4</td><td>51.8</td><td>50.2</td><td>49.7</td></tr><tr><td> Married</td><td>42.7</td><td>45.5</td><td>45.9</td><td>49.6</td></tr><tr><td> Widow/divorced</td><td>1.9</td><td>2.7</td><td>3.9</td><td>0.7</td></tr><tr><td> <i>p</i>-Value</td><td>0.598</td><td>0.55</td><td>0.577</td><td>0.208</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td></tr><tr><td> Christian</td><td>49.2</td><td>24.2</td><td>77.2</td><td>82.8</td></tr><tr><td> Moslem</td><td>50.1</td><td>72.0</td><td>16.5</td><td>9.1</td></tr><tr><td> Other</td><td>0.7</td><td>3.8</td><td>6.4</td><td>8.2</td></tr><tr><td> <i>p</i>-Value</td><td>0.000</td><td>0.000</td><td>0.000</td><td>0.000</td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td></tr><tr><td> Nil</td><td>12.9</td><td>49.0</td><td>14.0</td><td>16.0</td></tr><tr><td> Primary</td><td>40.0</td><td>45.1</td><td>46.8</td><td>49.6</td></tr><tr><td> Secondary</td><td>27.1</td><td>3.9</td><td>29.6</td><td>19.5</td></tr><tr><td> Higher</td><td>20.0</td><td>2.0</td><td>9.5</td><td>14.8</td></tr><tr><td> <i>p</i>-value</td><td>0.000</td><td>0.000</td><td>0.000</td><td>0.000</td></tr><tr><td>Occupation</td><td></td><td></td><td></td><td></td></tr><tr><td> Agriculture</td><td>59.5</td><td>57.8</td><td>18.8</td><td>23.9</td></tr><tr><td> Managerial</td><td>8.8</td><td>9.1</td><td>17.2</td><td>28.0</td></tr><tr><td> Sales/service</td><td>13.6</td><td>15.2</td><td>11.4</td><td>29.7</td></tr><tr><td> Manual</td><td>10.1</td><td>10.4</td><td>27.5</td><td>14.0</td></tr><tr><td> Unemployed</td><td>8.0</td><td>7.6</td><td>25.1</td><td>4.4</td></tr><tr><td> <i>p</i>-Value</td><td>0.449</td><td>0.000</td><td>0.000</td><td>0.002</td></tr><tr><td>Wealth status</td><td></td><td></td><td></td><td></td></tr><tr><td> Poorest</td><td>2.1</td><td>36.6</td><td>40.1</td><td>59.8</td></tr><tr><td> Poorer</td><td>0.5</td><td>19.1</td><td>11.9</td><td>6.6</td></tr><tr><td> Middle</td><td>0.7</td><td>16.4</td><td>7.8</td><td>3.6</td></tr><tr><td> Richer</td><td>6.9</td><td>19.8</td><td>37.4</td><td>28.2</td></tr><tr><td> Richest</td><td>89.7</td><td>8.0</td><td>2.8</td><td>1.8</td></tr><tr><td> <i>p</i>-Value</td><td>0.017</td><td>0.000</td><td>0.000</td><td>0.000</td></tr><tr><td>Drinks alcohol</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>47.4</td><td>47.5</td><td>37.8</td><td>35.4</td></tr><tr><td> Yes</td><td>52.6</td><td>52.5</td><td>62.2</td><td>64.6</td></tr><tr><td> <i>p</i>-Value</td><td>0.821</td><td>0.274</td><td>0.000</td><td>0.000</td></tr></table> |
65743b0ce55a789cc9169a3b02acd0f88f574a30dc5c4c3cedb6dcbdc4550e28.png | complex | <table><tr><td>Data</td><td>Characteristics</td><td>Description</td></tr><tr><td rowspan="3">Classes of deprivation</td><td>Group 1: low deprivation</td><td>Census block with high median income, low proportion of households without a car, low proportion with non-owner-occupied primary residences</td></tr><tr><td>Group 2: moderate deprivation</td><td>Census block with median income average, medium proportion of households without a car, medium proportion with non-owner-occupied primary residences</td></tr><tr><td>Group 3: high deprivation</td><td>Census block with low median income, high proportion of households without a car, high proportion with non-owner-occupied primary residences</td></tr></table> |
ca07b1f1fa34fb65011864367c298872676e891c63eed51a8d97c2a0d6da20da.png | complex | <table><tr><td></td><td></td><td></td><td colspan="2">95% Confidence Interval for odds</td></tr><tr><td></td><td>P value</td><td>OR</td><td>Lower</td><td>Upper</td></tr><tr><td>Gender(female)</td><td></td><td></td><td>1.259</td><td>5.725</td></tr><tr><td>Jobless</td><td><.001</td><td>1.870</td><td>1.412</td><td>2.478</td></tr><tr><td>Illegal Income</td><td>.001</td><td>1.617</td><td>1.217</td><td>2.150</td></tr><tr><td>Substance use of family members</td><td>.005</td><td>1.471</td><td>1.125</td><td>1.925</td></tr><tr><td>pleasure/enjoyment as cause of first injection</td><td>.001</td><td>1.583</td><td>1.209</td><td>2.074</td></tr><tr><td>First place of drug use (Roofless public places)</td><td>.003</td><td>1.558</td><td>1.157</td><td>2.097</td></tr><tr><td>First place of drug use (Roofed public places)</td><td>.019</td><td>1.621</td><td>1.084</td><td>2.424</td></tr><tr><td>Alone injection</td><td><.001</td><td>.515</td><td>.388</td><td>.682</td></tr><tr><td>Groin injection</td><td>.013</td><td>1.642</td><td>1.111</td><td>2.427</td></tr><tr><td>Testis injection</td><td>.022</td><td>1.573</td><td>1.068</td><td>2.318</td></tr><tr><td>Nonfatal overdose</td><td><.001</td><td>1.686</td><td>1.282</td><td>2.216</td></tr><tr><td>Arresting in past year</td><td>.022</td><td>1.385</td><td>1.049</td><td>1.829</td></tr></table> |
c8eaf89bb451435fc6376374d0370e126a01eebe043598efb32bb86835c342c5.png | complex | <table><tr><td></td><td colspan="4">Position at foot contact (deg)</td></tr><tr><td></td><td>Flexion</td><td>Ext. tibial rot.</td><td colspan="2">Varus</td></tr><tr><td>ICC</td><td>0.93</td><td>0.94</td><td colspan="2">0.95</td></tr><tr><td>SEM (deg)</td><td>1.80</td><td>1.42</td><td colspan="2">0.61</td></tr><tr><td></td><td colspan="4">Displacement during landing (deg)</td></tr><tr><td></td><td>Flexion</td><td>Int. tibial rot.</td><td>Varus</td><td>Valgus</td></tr><tr><td>ICC</td><td>0.96</td><td>0.87</td><td>0.64</td><td>0.86</td></tr><tr><td>SEM (deg)</td><td>1.41</td><td>2.18</td><td>1.22</td><td>0.39</td></tr><tr><td></td><td colspan="4">Electromyographic data (%MVC)</td></tr><tr><td></td><td colspan="2">Rectus femoris</td><td colspan="2">Hamstrings</td></tr><tr><td>ICC</td><td colspan="2">0.79</td><td colspan="2">0.62</td></tr><tr><td>SEM (%)</td><td colspan="2">10.84</td><td colspan="2">9.49</td></tr></table> |
26c8d51ee97393aa2429bc008432a43f191fec1b403ff520546fd64a33757bf5.png | simple | <table><tr><td></td><td>Metric</td><td><i>F</i></td><td><i>R</i><sup>2</sup></td><td><i>p</i> value*</td></tr><tr><td>HC (<i>n</i> = 29)vsRTT (<i>n</i> = 50)</td><td>Unweighted UniFrac</td><td>6.84</td><td>0.08</td><td>≤0.003</td></tr><tr><td></td><td>Weighted UniFrac</td><td>15.6</td><td>0.16</td><td>≤0.003</td></tr><tr><td></td><td>Bray-Curtis</td><td>6.94</td><td>0.08</td><td>≤0.003</td></tr><tr><td>HC (<i>n</i> = 29)vsRTT-C (<i>n</i> = 34)</td><td>Unweighted UniFrac</td><td>5.59</td><td>0.08</td><td>≤0.003</td></tr><tr><td></td><td>Weighted UniFrac</td><td>12.1</td><td>0.16</td><td>≤0.003</td></tr><tr><td></td><td>Bray-Curtis</td><td>5.39</td><td>0.08</td><td>≤0.003</td></tr><tr><td>HC (<i>n</i> = 29)vsRTT-NC (<i>n</i> = 14)</td><td>Unweighted UniFrac</td><td>5.27</td><td>0.11</td><td>≤0.003</td></tr><tr><td></td><td>Weighted UniFrac</td><td>8.75</td><td>0.17</td><td>≤0.003</td></tr><tr><td></td><td>Bray-Curtis</td><td>5.47</td><td>0.11</td><td>≤0.003</td></tr><tr><td>RTT-C (<i>n</i> = 34)vsRTT-NC (<i>n</i> = 14)</td><td>Unweighted UniFrac</td><td>1.31</td><td>0.02</td><td>0.180</td></tr><tr><td></td><td>Weighted UniFrac</td><td>1.10</td><td>0.02</td><td>0.687</td></tr><tr><td></td><td>Bray-Curtis</td><td>1.76</td><td>0.03</td><td>0.180</td></tr></table> |
4f9dc11712b09d0a7d6e90e54df26f9910a0c6896e4bad3fc7185527bb585da7.png | complex | <table><tr><td></td><td></td><td>CECA22*</td><td>CECA10</td><td>CECA6</td><td>CECA4</td></tr><tr><td colspan="2">N° of items</td><td>22</td><td>10</td><td>6</td><td>4</td></tr><tr><td colspan="2">Scoring distribution</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Valid observations</td><td>132</td><td>133</td><td>134</td><td>134</td></tr><tr><td colspan="2">Mean</td><td>44.9</td><td>44.6</td><td>38.8</td><td>53.4</td></tr><tr><td colspan="2">SD</td><td>17.5</td><td>22.3</td><td>23.9</td><td>29.3</td></tr><tr><td colspan="2">Percentile 50</td><td>43.7</td><td>40</td><td>37.5</td><td>53.1</td></tr><tr><td colspan="2">% scoring 0</td><td>0</td><td>0</td><td>5</td><td>3 (2.2%)</td></tr><tr><td colspan="2">% scoring 100</td><td>0</td><td>1</td><td>2</td><td>8 (5.9%)</td></tr><tr><td colspan="2">Correlation item-global scoring</td><td>0.21–0.72</td><td>0.53–0.73</td><td>0.65–0.79</td><td>0.78–0.89</td></tr><tr><td colspan="2">Reliability (Cronbach's alpha)</td><td>0.87</td><td>0.86</td><td>0.84</td><td>0.86</td></tr><tr><td>Results of Rasch analysis</td><td>Person separation</td><td>2.28</td><td>2.21</td><td>1.87</td><td>1.79</td></tr><tr><td></td><td>Person reliability</td><td>0.84</td><td>0.83</td><td>0.78</td><td>0.76</td></tr></table> |
bde03731d9c8752a3742857fd39619c1930069c52e7a10802356251891cbda84.png | simple | <table><tr><td></td><td>Insomnia (<i>N</i> = 17)</td><td>Controls (<i>N</i> = 15)</td><td><i>p</i>-values</td></tr><tr><td>HbA1c (%)</td><td>5.3 (0.3)</td><td>5.4 (0.3)</td><td>>0.05</td></tr><tr><td>Fasting blood glucose (mg/dl)</td><td>97.6 (8.2)</td><td>96.3 (10.3)</td><td>>0.05</td></tr><tr><td>Blood glucose after 30 min (mg/dl)</td><td>138.7 (22.1)</td><td>156. 9 (30.3)</td><td>>0.05</td></tr><tr><td>Blood glucose after 60 min (mg/dl)</td><td>120.3 (20.8)</td><td>135.9 (49.9)</td><td>>0.05</td></tr><tr><td>Blood glucose after 120 min (mg/dl)</td><td>100.5 (14.8)</td><td>105.1 (28.7)</td><td>>0.05</td></tr><tr><td>Area under the curve for glucose (mg/dl)</td><td>14,043. 8 (1,319.7)</td><td>15,422.0 (3,710.5)</td><td>>0.05</td></tr></table> |
a66f46c43900efdb7ca3ab1df1d49aa668bd745844b7831549e85b1243043223.png | simple | <table><tr><td>Toxicity</td><td>Grade</td><td>ACRT</td><td>STRT1</td><td>STRT2</td><td>Total</td><td><i>p</i>-value</td></tr><tr><td></td><td></td><td>(45 Gy)</td><td>(60-63 Gy)</td><td>(> 63 Gy)</td><td></td><td></td></tr><tr><td></td><td></td><td>n = 154</td><td>n = 99</td><td>n = 239</td><td></td><td></td></tr><tr><td>Esophagitis</td><td>0-1</td><td>107(89.9%)</td><td>80(88.9%)</td><td>82(90.1%)</td><td>269(89.7%)</td><td>0.958</td></tr><tr><td></td><td>≥ 2</td><td>12(10.1%)</td><td>10(11.1%)</td><td>9(9.9%)</td><td>31(10.3%)</td><td></td></tr><tr><td>Dysphagia</td><td>0-1</td><td>110(92.4%)</td><td>75(83.3%)</td><td>80(87.9%)</td><td>265(88.3%)</td><td>0.126</td></tr><tr><td></td><td>≥ 2</td><td>9(7.6%)</td><td>15(16.7%)</td><td>11(12.1%)</td><td>35(11.7%)</td><td></td></tr><tr><td>Pneumonitis</td><td>0-1</td><td>105(88.2%)</td><td>71(78.9%)</td><td>71(78.0%)</td><td>247(82.3%)</td><td>0.093</td></tr><tr><td></td><td>≥ 2</td><td>14(11.8%)</td><td>19(21.1%)</td><td>20(22.0%)</td><td>53(17.7%)</td><td></td></tr><tr><td>Radiation Dermatitis</td><td>0-1</td><td>117(98.3%)</td><td>79(87.8%)</td><td>78(85.7%)</td><td>274(91.3%)</td><td>0.002</td></tr><tr><td></td><td>≥ 2</td><td>2(1.7%)</td><td>11(12.2%)</td><td>13(14.3%)</td><td>26(8.7%)</td><td></td></tr><tr><td>Nausea/Vomiting</td><td>0-1</td><td>115(96.6%)</td><td>79(87.8%)</td><td>87(95.6%)</td><td>281(93.7%)</td><td>0.022</td></tr><tr><td></td><td>≥ 2</td><td>4(3.4%)</td><td>11(12.2%)</td><td>13(14.3%)</td><td>26(8.7%)</td><td></td></tr><tr><td>Weight loss</td><td>0-1</td><td>115(96.6%)</td><td>81(90.0%)</td><td>90(98.9%)</td><td>286(95.3%)</td><td>0.020</td></tr><tr><td></td><td>≥ 2</td><td>4(3.4%)</td><td>9(10.0%)</td><td>1(1.1%)</td><td>14(4.7%)</td><td></td></tr></table> |
e1d1f80626cf58259487b9ebf1578afd8bb947aa1feab4f51d40d5cb36fc8b38.png | simple | <table><tr><td>S. No</td><td>Lubricant</td><td>Speed (kmph)</td><td>Load (N)</td></tr><tr><td>1</td><td>Racer-4</td><td>40-60</td><td>10-50</td></tr><tr><td>2</td><td>Racer-4 + 0.05% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>3</td><td>Racer-4 + 0.1% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>4</td><td>Racer-4 + 0.2% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>5</td><td>Racer-4 + 0.05% TiO<sub>2</sub></td><td>40-60</td><td>20-80</td></tr></table> |
d0455f7f1045812c43caf3caa0253c58a45911f59647bce413045538321b6ab1.png | complex | <table><tr><td>Factors</td><td colspan="2">Simple regression</td><td colspan="3">Multiple regression</td></tr><tr><td> </td><td>Unstandardizedcoefficient(B)</td><td>P value</td><td>Unstandardizedcoefficient(B)</td><td>Standardizedcoefficient(beta)</td><td>P value</td></tr><tr><td>Gly1057Asp polymorphism in IRS-2</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Asp/Asp(n = 41)</td><td>reference</td><td> </td><td>reference</td><td>reference</td><td> </td></tr><tr><td> Gly/Gly(n = 69) + Gly/Asp(n = 80)</td><td>0.007</td><td>0.902</td><td>−0.023</td><td>−0.029</td><td>0.678</td></tr><tr><td>Age(year)</td><td>−0.002</td><td>0.245</td><td>−0.003</td><td>−0.107</td><td>0.147</td></tr><tr><td>Diabetes mellitus</td><td>0.194</td><td><0.001</td><td>0.151</td><td>0.213</td><td>0.003</td></tr><tr><td>Hypertension</td><td>0.103</td><td>0.037</td><td>0.078</td><td>0.115</td><td>0.121</td></tr><tr><td>Male</td><td>0.019</td><td>0.697</td><td>−0.032</td><td>−0.048</td><td>0.574</td></tr><tr><td>Smoking</td><td>0.013</td><td>0.800</td><td>−0.012</td><td>−0.017</td><td>0.830</td></tr><tr><td>Total cholesterol(mmol/L)</td><td>0.033</td><td>0.197</td><td>0.040</td><td>0.114</td><td>0.103</td></tr><tr><td>Serum creatinine(μmol/L)</td><td>0.002</td><td>0.019</td><td>0.003</td><td>0.206</td><td>0.007</td></tr><tr><td>Body mass index(kg/m<sup>2</sup>)</td><td>0.023</td><td><0.001</td><td>0.017</td><td>0.189</td><td>0.008</td></tr></table> |
0ad0c0d2dad0e58b7167353448a1d3e405d0dabdbdef6d875875a6a0c1ebdd06.png | complex | <table><tr><td rowspan="3">Spice</td><td colspan="6">Frequency of dishes prepared</td></tr><tr><td colspan="2">Daily</td><td colspan="2">Weekly</td><td colspan="2">Monthly</td></tr><tr><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.D (Median)</td></tr><tr><td>Chillies</td><td>157</td><td>2.1 ± 1.3 (1.8)</td><td>186</td><td>3.8 ± 3.88 (2.32)</td><td>21</td><td>3.0 ± 1.92 (2.25)</td></tr><tr><td>Turmeric</td><td>156</td><td>0.6 ± 0.46 (0.66)</td><td>171</td><td>0.82 ± 0.53 (0.72)</td><td>24</td><td>0.73 ± 0.46 (0.6)</td></tr><tr><td>Cumin</td><td>61</td><td>1.22 ± 1.14 (1.0)</td><td>125</td><td>1.85 ± 1.78 (1.2)</td><td>12</td><td>1.66 ± 1.07 (1.4)</td></tr><tr><td>Coriander</td><td>27</td><td>0.8 ± 0.65 (0.5)</td><td>62</td><td>1.5 ± 1.74 (0.84)</td><td>7</td><td>2.47 ± 2.22 (3.5)</td></tr><tr><td>Mustard</td><td>34</td><td>0.55 ± 0.31 (0.5)</td><td>81</td><td>1.24 ± 0.95 (1.0)</td><td>7</td><td>1.65 ± 1.2 (1.12)</td></tr><tr><td>Cloves</td><td>-</td><td>-</td><td>105</td><td>0.33 ± 0.62 (0.11)</td><td>16</td><td>0.48 ± 0.68 (0.12)</td></tr><tr><td>Cardamom</td><td>6</td><td>0.67 ± 0.64 (0.63)</td><td>134</td><td>0.37 ± 0.57 (0.25)</td><td>18</td><td>0.5 ± 0.36 (0.32)</td></tr><tr><td>Cinnamon</td><td>-</td><td>-</td><td>102</td><td>0.74 ± 0.83 (0.5)</td><td>15</td><td>1.03 ± 0.83 (0.8)</td></tr><tr><td>Caraway</td><td>-</td><td>-</td><td>94</td><td>1.1 ± 1.07 (0.7)</td><td>18</td><td>1.22 ± 0.89 (0.92)</td></tr><tr><td>Black pepper</td><td>28</td><td>0.69 ± 0.87 (0.5)</td><td>64</td><td>1.07 ± 1.16 (0.5)</td><td>16</td><td>1.07 ± 0.81 (0.72)</td></tr><tr><td>Nutmeg</td><td>-</td><td>-</td><td>23</td><td>0.11 ± 0.07 (0.11)</td><td>7</td><td>0.22 ± 0.19 (0.14)</td></tr><tr><td>Mace</td><td>-</td><td>-</td><td>18</td><td>0.19 ± 0.13 (0.16)</td><td>5</td><td>0.27</td></tr><tr><td>Asafoetida</td><td>17</td><td>0.37 ± 0.16 (0.4)</td><td>16</td><td>0.72 ± 0.49 (0.5)</td><td></td><td>-</td></tr><tr><td>Fenugreek</td><td>-</td><td>-</td><td>25</td><td>0.68 ± 0.65 (0.4)</td><td>4</td><td>2.04</td></tr><tr><td>Carom seeds</td><td>-</td><td>-</td><td>13</td><td>0.69 ± 0.64 (0.45)</td><td>5</td><td>0.66</td></tr></table> |
1f704a92d2e1e9cca9fe78076d42c9e96bcb29311ae00c82d502421fe9b7beed.png | simple | <table><tr><td> </td><td>NC</td><td>MCI</td><td>AD</td></tr><tr><td>NC</td><td>15/16</td><td>1/1</td><td>0/0</td></tr><tr><td>MCI</td><td>2/1</td><td>14/16</td><td>3/1</td></tr><tr><td>AD</td><td>0/0</td><td>3/1</td><td>14/16</td></tr></table> |
28ab9395f57c2ef3d41d97c508f9b209023c09a236eaea00f557f7f15ab8c6c7.png | complex | <table><tr><td>Category</td><td>Part A</td><td>Part B</td><td>Part C</td><td>Total</td></tr><tr><td rowspan="2">Preferred Term</td><td>(<i>N</i> = 12)</td><td>(<i>N</i> = 10)</td><td>(<i>N</i> = 10)</td><td>(<i>N</i> = 32)</td></tr><tr><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Subjects with Any Adverse Event</td><td>1 (8.3)</td><td>3 (30.0)</td><td>7 (70.0)</td><td>11 (34.4)</td></tr><tr><td>Subjects with Any Study Drug Related Adverse Event</td><td>0 (0.0)</td><td>0 (0.0)</td><td>1 (10.0)</td><td>1 (3.1)<sup>a</sup></td></tr><tr><td>Subjects with Any Serious Adverse Event</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Subjects with Any Study Drug Related Serious Adverse Event</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Subjects with Any Adverse Event Leading to Discontinuation</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr></table> |
f92145ebeb69407c1ab817972590e5d45a0807f3bd377d0d020c0e733f627ae4.png | simple | <table><tr><td></td><td>Phe-free milk</td><td>Phe-free amino acid powder (A-1)</td><td>Low Phe peptide powder (MP-11)</td></tr><tr><td>Protein (g)</td><td>15.8</td><td>93.7</td><td>75</td></tr><tr><td>Fat (g)</td><td>17.1</td><td>0</td><td>0</td></tr><tr><td>Carbohydrate (g)</td><td>60.4</td><td>0</td><td>7.2</td></tr><tr><td>Ash content (g)</td><td>3.68</td><td>2.9</td><td>7.4</td></tr><tr><td>Water substance (g)</td><td>2.97</td><td>3.4</td><td>2.8</td></tr><tr><td>Energy (kcal)</td><td>458</td><td>375</td><td>329</td></tr><tr><td>Phe (mg)</td><td>0</td><td>0</td><td>280</td></tr><tr><td>Ca (mg)</td><td>360</td><td>0</td><td>1100</td></tr><tr><td>Mg (mg)</td><td>34</td><td>0</td><td>300</td></tr><tr><td>Na (mg)</td><td>168</td><td>880</td><td>620</td></tr><tr><td>K (mg)</td><td>440</td><td>0</td><td>1400</td></tr><tr><td>P (mg)</td><td>270</td><td>0</td><td>600</td></tr><tr><td>Cl (mg)</td><td>320</td><td>1900</td><td>300</td></tr><tr><td>Fe (mg)</td><td>6</td><td>0</td><td>15</td></tr><tr><td>Zn (mg)</td><td>2.5</td><td>0</td><td>20</td></tr><tr><td>Cu (μg)</td><td>280</td><td>0</td><td>1000</td></tr><tr><td>I (μg)</td><td>25</td><td>0</td><td>150</td></tr><tr><td>Se (μg)</td><td>1</td><td>2</td><td>11</td></tr><tr><td>Vit A (IU)</td><td>1500</td><td>0</td><td>0</td></tr><tr><td>Vit B1 (mg)</td><td>0.36</td><td>0</td><td>0</td></tr><tr><td>Vit B2 (mg)</td><td>0.6</td><td>0</td><td>0</td></tr><tr><td>Vit B6 (mg)</td><td>0.4</td><td>0</td><td>0</td></tr><tr><td>Vit B12</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Vit C (mg)</td><td>48</td><td>0</td><td>0</td></tr><tr><td>Vit D (IU)</td><td>300</td><td>0</td><td>0</td></tr><tr><td>Vit E (mg)</td><td>4.38</td><td>0</td><td>0</td></tr><tr><td>Ca pantothenate (mg)</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Niacin (mg)</td><td>5</td><td>0</td><td>0</td></tr><tr><td>Folate (mg)</td><td>0.1</td><td>0</td><td>0</td></tr><tr><td>Choline (mg)</td><td>50</td><td>0</td><td>0</td></tr><tr><td>Biotin (μg)</td><td>0</td><td>0</td><td>0.6</td></tr></table> |
b0917f259b6ef369df22d690199c689e07a5579cac44674ec5ede18da4e91ce3.png | complex | <table><tr><td> </td><td colspan="2">Prevalence per 10,000</td><td colspan="2">Crude incidence per 10,000</td><td colspan="2">Mortality per 100,000</td><td colspan="2">Fatality per 1,000</td></tr><tr><td>Age</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td></tr><tr><td>0-17 years</td><td>44.05</td><td>42.61-45.49</td><td>3.96</td><td>3.52-4.39</td><td>10.21</td><td>8.01-12.41</td><td>3.59</td><td>1.37-5.81</td></tr><tr><td>0-12 months</td><td>25.73</td><td>21.23-30.24</td><td>25.73</td><td>21.23-30.24</td><td>0.56*</td><td>0.35*-0.77*</td><td>19.23</td><td>4.74-33.72</td></tr><tr><td>1-17 years</td><td>45.22</td><td>43.71-46.72</td><td>4.26</td><td>3.80-4.73</td><td>7.29</td><td>6.69-7.90</td><td>2.98</td><td>0.92-5.04</td></tr><tr><td><i>1-14 years</i></td><td><i>46.25</i></td><td><i>44.58-47.93</i></td><td><i>4.41</i></td><td><i>3.89-4.92</i></td><td><i>8.00</i></td><td><i>7.30-8.69</i></td><td><i>3.10</i></td><td><i>0.81-5.39</i></td></tr><tr><td><i>15-17 years</i></td><td><i>40.26</i></td><td><i>36.84-43.68</i></td><td><i>3.57</i></td><td><i>2.55-4.59</i></td><td><i>3.93</i></td><td><i>2.86-5.00</i></td><td><i>2.36</i></td><td><i>0.00-6.99</i></td></tr><tr><td>18-64 years</td><td>31.34</td><td>30.72-31.96</td><td>3.70</td><td>3.48-3.91</td><td>9.03</td><td>7.97-10.09</td><td>3.70</td><td>2.33-5.07</td></tr><tr><td>over 65 years</td><td>17.68</td><td>16.83-18.53</td><td>2.90</td><td>2.56-3.25</td><td>28.51</td><td>25.10-31.91</td><td>26.79</td><td>17.49-36.10</td></tr><tr><td>TOTAL</td><td>33.09</td><td>32.56-33.62</td><td>3.85</td><td>3.67-4.03</td><td>13.04</td><td>12.02-14.06</td><td>5.99</td><td>4.58-7.40</td></tr></table> |
2e189bc0a8b3f3f04b1f3dd5ff3a8883bb820c07a6db6148647e6f49596378f2.png | complex | <table><tr><td rowspan="2">Compound Administered</td><td rowspan="2">Subject ID</td><td colspan="2"><i>R-</i>baclofen (ng/mL) </td><td colspan="2"><i>S-</i>baclofen (ng/mL) </td><td colspan="2"><i>S-</i>M1 (ng/mL) </td></tr><tr><td>Plasma</td><td>Urine</td><td>Plasma</td><td>Urine</td><td>Plasma</td><td>Urine</td></tr><tr><td rowspan="7">Racemic Baclofen 10 mg</td><td>P1-01 </td><td>45.2</td><td>1880</td><td>35.6</td><td>1400</td><td>24.9</td><td>254</td></tr><tr><td>P1-04 </td><td>42.4</td><td>1030</td><td>39.9</td><td>806</td><td>27.5</td><td>146</td></tr><tr><td>P1-06 </td><td>35.5</td><td>1120</td><td>31.2</td><td>892</td><td>19.5</td><td>183</td></tr><tr><td>P1-07 </td><td>36.9</td><td>1230</td><td>32.1</td><td>857</td><td>18.7</td><td>142</td></tr><tr><td>P2-02 </td><td>42.7</td><td>514</td><td>35.9</td><td>460</td><td>25.1</td><td>75.1</td></tr><tr><td>P2-05 </td><td>40.3</td><td>652</td><td>34.1</td><td>553</td><td>16.4</td><td>99.4</td></tr><tr><td>P2-08 </td><td>37.5</td><td>552</td><td>31.6</td><td>457</td><td>20.1</td><td>95</td></tr><tr><td></td><td>Mean</td><td>40.1</td><td>997</td><td>34.3</td><td>775</td><td>21.7</td><td>142</td></tr><tr><td></td><td>SD</td><td>3.6</td><td>482</td><td>3.1</td><td>333</td><td>4.1</td><td>61.6</td></tr><tr><td rowspan="7">STX209 5mg</td><td>P1-02 </td><td>40.1</td><td>1610</td><td>- </td><td>370* </td><td>- </td><td>- </td></tr><tr><td>P1-03 </td><td>37.7</td><td>866</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td>P1-05 </td><td>36.4</td><td>1730</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td>P1-08 </td><td>31.3</td><td>892</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td>P2-01 </td><td>35.1</td><td>942</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td>P2-06 </td><td>35.4</td><td>446</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td>P2-07 </td><td>31.6</td><td>422</td><td>- </td><td>- </td><td>- </td><td>- </td></tr><tr><td></td><td>Mean</td><td>35.4</td><td>987</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>SD</td><td>3.2</td><td>513</td><td></td><td></td><td></td><td></td></tr></table> |
01e0785d8520e8d4c70ef62618b45678eb6a1bda0a495dbba058d91b5388c06e.png | simple | <table><tr><td></td><td>25 JIA patientswith secondary LOE</td><td>28 JIA patientswithout secondary LOE</td></tr><tr><td>median age (range)</td><td>14.4 (6.0-27.0) years</td><td>13.8 (7.6-21.5) years</td></tr><tr><td>Sex</td><td>21 female, 4 male</td><td>18 female, 10 male</td></tr><tr><td>median ADM dose (range)</td><td>25.8 (10.7-58.8) mg/m<sup>2</sup> every other week</td><td>24.3 (6.6-37.1) mg/m<sup>2</sup> every other week</td></tr><tr><td>median duration of anti-TNF therapy (range)</td><td>2.2 (0.2-6.0) years</td><td>1.3 (0.2-10.4) years</td></tr><tr><td>MTX comedication</td><td>12/25 (48.0%)</td><td>15/28 (53.6%)</td></tr><tr><td>median MTX dose (range)</td><td>10.0 (3.9-12.1) mg/m<sup>2</sup> weekly</td><td>10.8 (7.7-13.4) mg/m<sup>2</sup> weekly</td></tr></table> |
6a364e70dd1969dad09472c87f37afe3b4889f61f9928ae10c62bb8d5176c6ff.png | simple | <table><tr><td>ETIOLOGY</td><td>NO. OF PATIENTS</td><td>PERCENTAGE</td></tr><tr><td>ONCOLOGICAL RES.</td><td>75</td><td>42.1%</td></tr><tr><td>TMJ ANKYLOSIS</td><td>35</td><td>19.6%</td></tr><tr><td>POST-TRAUMATIC</td><td>44</td><td>24.7%</td></tr><tr><td>OSTEOMYELITIS OF MANDIBLE</td><td>24</td><td>13.5%</td></tr><tr><td>TOTAL</td><td>178</td><td>100 %</td></tr></table> |
3bb89bcba0539bd0b616fae3ac782015caea7b6a62dbdea091e9ef8510c5af4f.png | simple | <table><tr><td>Factor</td><td>Estimate</td><td>SE</td><td>Chi-square</td><td><i>P</i> value</td></tr><tr><td>F14</td><td>0.0197</td><td>0.0184</td><td>1.14</td><td>0.2857</td></tr><tr><td>F3</td><td>0.1558</td><td>0.0304</td><td>26.34</td><td><0.0001</td></tr><tr><td>F9</td><td>0.0498</td><td>0.0185</td><td>7.22</td><td>0.0072</td></tr></table> |
79ee8e401c979524f2174a03629bb6ee38aee278bae8bfb2b96473d24ba97ebf.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">PM6</td><td colspan="2">PM7</td></tr><tr><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td></tr><tr><td><i>Isolated molecule</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Plumbagin</td><td>−84.56</td><td></td><td>−87.09</td><td></td></tr><tr><td>BCD</td><td>−1614.25</td><td></td><td>−1648.53</td><td></td></tr><tr><td>MBCD</td><td>−1543.64</td><td></td><td>−1573.87</td><td></td></tr><tr><td>HPBCD</td><td>−1659.94</td><td></td><td>−1701.90</td><td></td></tr><tr><td><i>Inclusion Complex</i></td><td></td><td></td><td></td><td></td></tr><tr><td>BCD-I</td><td>−1704.99</td><td>−6.18</td><td>−1768.09</td><td>−32.47</td></tr><tr><td>BCD-II</td><td>−1704.97</td><td>−6.15</td><td>−1765.72</td><td>−30.10</td></tr><tr><td>BCD-I–BCD-II</td><td></td><td>−0.03</td><td></td><td>−2.37</td></tr><tr><td>MBCD-I</td><td>−1636.23</td><td>−8.03</td><td>−1702.37</td><td>−41.41</td></tr><tr><td>MBCD-II</td><td>−1640.97</td><td>−12.78</td><td>−1699.12</td><td>−38.17</td></tr><tr><td>MBCD-I–MBCD-II</td><td></td><td>4.75</td><td></td><td>−3.24</td></tr><tr><td>HPBCD-I</td><td>−1753.57</td><td>−9.08</td><td>−1820.19</td><td>−31.21</td></tr><tr><td>HPBCD-II</td><td>−1750.20</td><td>−5.70</td><td>−1829.73</td><td>−40.75</td></tr><tr><td>HPBCD-I–HPBCD-II</td><td></td><td>−3.38</td><td></td><td>9.54</td></tr></table> |
4e38fb8255717b7151af9fd219fbacda737d7860013ba2e439413192bd8bfae3.png | complex | <table><tr><td> </td><td><i>Control</i></td><td><i>Intervention</i></td><td><i>Comparison</i></td><td><i>Treatment effect</i></td><td><i>P value</i></td></tr><tr><td>Maternal</td><td>n = 75</td><td>n = 79</td><td> </td><td>(95% CI)</td><td> </td></tr><tr><td>GDM</td><td>24 (32%)</td><td>22 (28%)</td><td>Risk difference</td><td>−4% (−19 to 13)</td><td>0.574</td></tr><tr><td> </td><td> </td><td> </td><td>Risk ratio</td><td colspan="2">0.87 (0.54 to 1.41)</td></tr><tr><td>Neonatal</td><td>n = 84</td><td>n = 86</td><td> </td><td> </td><td> </td></tr><tr><td>LGA</td><td>7 (8%)</td><td>7 (8%)</td><td>Risk difference</td><td>0% (−8 to 8)</td><td>0.982</td></tr><tr><td> </td><td> </td><td> </td><td>Risk ratio</td><td>0.99 (0.36 to 2.7)</td><td> </td></tr><tr><td>>4 Kg</td><td>16 (19%)</td><td>13 (15%)</td><td>Risk difference</td><td>−4% (−15 to 8)</td><td>0.518</td></tr></table> |
bb93a2ed6ac8034ba5626f2d54ea43315954f29e10dc23cb9c23931d69d88575.png | simple | <table><tr><td>Green alga/land plant</td><td>Size (bp)</td><td>IR size (bp)</td><td>Genes (no.) <sup>a</sup></td><td>Introns (no.) <sup>b</sup></td><td>GenBank accession no.</td></tr><tr><td>Charophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Chara vulgaris</i></td><td>184,933</td><td>10,919</td><td>127</td><td>2/16</td><td>GenBank:NC_008097</td></tr><tr><td><i>Chaetosphaeridium globosum</i></td><td>131,183</td><td>12,431</td><td>125</td><td>1/17</td><td>GenBank:NC_004115</td></tr><tr><td><i>Chlorokybus atmophyticus</i></td><td>152,254</td><td>7,640</td><td>138</td><td>1/0</td><td>GenBank:DQ422812</td></tr><tr><td><i>Mesostigma viride</i></td><td>118,360</td><td>6,057</td><td>137</td><td>0</td><td>GenBank:NC_002186</td></tr><tr><td><i>Staurastrum punctulatum</i></td><td>157,089</td><td>-</td><td>121</td><td>1/7</td><td>GenBank:NC_008116</td></tr><tr><td><i>Zygnema circumcarinatum</i></td><td>165,372</td><td>-</td><td>125</td><td>1/12</td><td>GenBank:NC_008117</td></tr><tr><td>Land Plants</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Acorus calamus</i></td><td>153,821</td><td>25,697</td><td>110</td><td>1/20</td><td>GenBank:NC_007407</td></tr><tr><td><i>Amborella trichopoda</i></td><td>162,686</td><td>26,651</td><td>111</td><td>1/20</td><td>GenBank:NC_005086</td></tr><tr><td><i>Anthoceros formosae</i></td><td>161,162</td><td>15,744</td><td>120</td><td>2/20</td><td>GenBank:NC_004543</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>154,478</td><td>26,264</td><td>110</td><td>1/20</td><td>GenBank:NC_000932</td></tr><tr><td><i>Atropa belladonna</i></td><td>156,687</td><td>17,031</td><td>111</td><td>1/20</td><td>GenBank:NC_004561</td></tr><tr><td><i>Calycanthus floridus</i></td><td>153,337</td><td>23,296</td><td>111</td><td>1/20</td><td>GenBank:NC_004993</td></tr><tr><td><i>Cucumis sativus</i></td><td>155,293</td><td>24,753</td><td>111</td><td>1/20</td><td>GenBank:NC_007144</td></tr><tr><td><i>Eucalyptus globulus</i></td><td>160,286</td><td>26393</td><td>109</td><td>1/20</td><td>GenBank:NC_008115</td></tr><tr><td><i>Huperzia lucidula</i></td><td>154,373</td><td>15,314</td><td>119</td><td>1/20</td><td>GenBank:NC_006861</td></tr><tr><td><i>Lactuca sativa</i></td><td>152,765</td><td>25,033</td><td>111</td><td>1/20</td><td>GenBank:NC_007578</td></tr><tr><td><i>Lotus japonicus</i></td><td>150,519</td><td>25,156</td><td>109</td><td>1/20</td><td>GenBank:NC_002694</td></tr><tr><td><i>Marchantia polymorpha</i></td><td>121,024</td><td>10,058</td><td>120</td><td>1/19</td><td>GenBank:NC_001319</td></tr><tr><td><i>Nicotiana tabacum</i></td><td>155,939</td><td>25,341</td><td>110</td><td>1/20</td><td>GenBank:NC_001879</td></tr><tr><td><i>Nymphaea alba</i></td><td>159,930</td><td>25,177</td><td>111</td><td>1/20</td><td>GenBank:NC_006050</td></tr><tr><td><i>Oenothera elata</i></td><td>163,935</td><td>27,807</td><td>109</td><td>1/18</td><td>GenBank:NC_002693</td></tr><tr><td><i>Oryza sativa</i></td><td>134,525</td><td>20,799</td><td>108</td><td>1/17</td><td>GenBank:NC_001320</td></tr><tr><td><i>Panax ginseng</i></td><td>156,318</td><td>26,071</td><td>111</td><td>1/20</td><td>GenBank:NC_006290</td></tr><tr><td><i>Phalaenopsis aphrodite</i></td><td>148,964</td><td>23,787</td><td>99</td><td>1/18</td><td>GenBank:NC_007499</td></tr><tr><td><i>Physcomitrella patens</i></td><td>122,890</td><td>9,589</td><td>116</td><td>1/20</td><td>GenBank:NC_005087</td></tr><tr><td><i>Pinus thunbergii</i></td><td>119,707</td><td>-</td><td>106</td><td>1/15</td><td>GenBank:NC_001631</td></tr><tr><td><i>Saccharum officinarum</i></td><td>141,182</td><td>22795</td><td>108</td><td>1/17</td><td>GenBank:NC_006084</td></tr><tr><td><i>Spinacia oleracea</i></td><td>150,725</td><td>25,073</td><td>110</td><td>1/19</td><td>GenBank:NC_002202</td></tr><tr><td><i>Triticum aestivum</i></td><td>134,545</td><td>20,703</td><td>108</td><td>1/17</td><td>GenBank:NC_002762</td></tr><tr><td><i>Zea mays</i></td><td>140,384</td><td>22,748</td><td>108</td><td>1/17</td><td>GenBank:NC_001666</td></tr><tr><td>Prasinophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Nephroselmis olivacea</i></td><td>200,799</td><td>46,137</td><td>128</td><td>0</td><td>GenBank:NC_000927</td></tr><tr><td>Trebouxiophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Chlorella vulgaris</i></td><td>150,613</td><td>-</td><td>112</td><td>3/0</td><td>GenBank:NC_001865</td></tr><tr><td>Ulvophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Oltmannsiellopsis viridis</i></td><td>151,933</td><td>18,510</td><td>104</td><td>5/0</td><td>GenBank:NC_008099</td></tr><tr><td><i>Pseudendoclonium akinetum</i></td><td>195,867</td><td>6,039</td><td>105</td><td>27/0</td><td>GenBank:NC_008114</td></tr><tr><td>Chlorophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Chlamydomonas reinhardtii</i></td><td>203,827</td><td>22,211</td><td>94</td><td>5/2</td><td>GenBank:NC_005353</td></tr><tr><td><i>Scenedesmus obliquus</i></td><td>161,452</td><td>12,022</td><td>96</td><td>7/2</td><td>GenBank:NC_008101</td></tr><tr><td><i>Stigeoclonium helveticum</i></td><td>223,902</td><td>-</td><td>97</td><td>16/5</td><td>GenBank:DQ630521</td></tr></table> |
4726a7749ed05fac64b7a00b16b63edcb8474a09416406486c3989f1c40865af.png | simple | <table><tr><td></td><td>N-starved cells</td><td>P-starved cells</td></tr><tr><td>Total sequences collected</td><td>2,259,219</td><td>1,501,972</td></tr><tr><td>Total signatures</td><td>44,779</td><td>27,722</td></tr><tr><td>Reliable, significant signatures</td><td>27,217</td><td>20,161</td></tr><tr><td>Signatures unique to library</td><td>10,756</td><td>3,700</td></tr></table> |
3458bc2bf3406d0cf5e599a6c9345768822978e835d08c400a1490aef1d720d2.png | simple | <table><tr><td></td><td>All patients (<i>n =</i> 129)</td><td>Trastuzumab-resistant patient (<i>n =</i> 32)</td><td>Trastuzumab-sensitive patients (<i>n =</i> 97)</td><td><i>P</i>-value</td></tr><tr><td>Age at diagnosis</td><td>59 (30-84)</td><td>60 (30-82)</td><td>58 (32-84)</td><td>0.623</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td>0.931</td></tr><tr><td> Male</td><td>96 (74.4%)</td><td>24 (75.0%)</td><td>72 (74.2%)</td><td></td></tr><tr><td> Female</td><td>33 (25.6%)</td><td>8 (25.0%)</td><td>25 (25.8%)</td><td></td></tr><tr><td>Histology</td><td></td><td></td><td></td><td>0.031</td></tr><tr><td> Adeno, WD</td><td>7 (5.4%)</td><td>0 (0%)</td><td>7 (7.2%)</td><td></td></tr><tr><td> Adeno, MD</td><td>76 (58.9%)</td><td>16 (50.0%)</td><td>60 (61.9%)</td><td></td></tr><tr><td> Adeno, PD</td><td>33 (25.6%)</td><td>9 (28.1%)</td><td>24 (24.7%)</td><td></td></tr><tr><td> SRC carcinoma</td><td>13 (10.1%)</td><td>7 (21.9%)</td><td>6 (6.2%)</td><td></td></tr><tr><td>Previous surgery</td><td></td><td></td><td></td><td>0.491</td></tr><tr><td> Yes</td><td>42 (32.6%)</td><td>12 (37.5%)</td><td>30 (30.9%)</td><td></td></tr><tr><td> No</td><td>87 (67.4%)</td><td>20 (62.5%)</td><td>67 (69.1%)</td><td></td></tr><tr><td>Location of tumor</td><td></td><td></td><td></td><td>0.420</td></tr><tr><td> Proximal</td><td>31 (24.0%)</td><td>6 (18.8%)</td><td>25 (25.8%)</td><td></td></tr><tr><td> Distal</td><td>98 (76.0%)</td><td>26 (81.3%)</td><td>72 (74.2%)</td><td></td></tr><tr><td>Peritoneal metastasis</td><td></td><td></td><td></td><td>0.225</td></tr><tr><td> Yes</td><td>45 (34.9%)</td><td>14 (43.8%)</td><td>31 (32.0%)</td><td></td></tr><tr><td> No</td><td>84 (65.1%)</td><td>18 (56.3%)</td><td>66 (68.0%)</td><td></td></tr><tr><td>Liver metastasis</td><td></td><td></td><td></td><td>0.951</td></tr><tr><td> Yes</td><td>53 (41.1%)</td><td>13 (40.6%)</td><td>40 (41.2%)</td><td></td></tr><tr><td> No</td><td>76 (58.9%)</td><td>19 (59.4%)</td><td>57 (58.8%)</td><td></td></tr><tr><td>Bone metastasis</td><td></td><td></td><td></td><td>0.025</td></tr><tr><td> Yes</td><td>15 (11.6%)</td><td>8 (25.0%)</td><td>7 (7.2%)</td><td></td></tr><tr><td> No</td><td>104 (80.6%)</td><td>22 (68.8%)</td><td>82 (84.5%)</td><td></td></tr><tr><td> N/A</td><td>10 (7.8%)</td><td>2 (6.3%)</td><td>8 (8.2%)</td><td></td></tr><tr><td>Lung metastasis</td><td></td><td></td><td></td><td>0.985</td></tr><tr><td> Yes</td><td>16 (12.4%)</td><td>4 (12.5%)</td><td>12 (12.4%)</td><td></td></tr><tr><td> No</td><td>113 (87.6%)</td><td>28 (87.5%)</td><td>85 (87.6%)</td><td></td></tr><tr><td>Performance status</td><td></td><td></td><td></td><td>0.001</td></tr><tr><td> ECOG 0</td><td>72 (55.8%)</td><td>8 (25.0%)</td><td>64 (66.0%)</td><td></td></tr><tr><td> ECOG 1</td><td>42 (32.6%)</td><td>18 (56.3%)</td><td>24 (24.7%)</td><td></td></tr><tr><td> ECOG ≥2</td><td>15 (11.7%)</td><td>6 (18.7%)</td><td>9 (9.2%)</td><td></td></tr><tr><td>Regimen</td><td></td><td></td><td></td><td>0.896</td></tr><tr><td> Herceptin-FP</td><td>17 (13.2%)</td><td>4 (12.5%)</td><td>13 (13.4%)</td><td></td></tr><tr><td> Herceptin-XP</td><td>112 (86.8%)</td><td>28 (87.5%)</td><td>84 (86.6%)</td><td></td></tr><tr><td>HER2 IHC</td><td></td><td></td><td></td><td>0.475</td></tr><tr><td> 2+</td><td>31 (24.0%)</td><td>10 (31.3%)</td><td>21 (21.6%)</td><td></td></tr><tr><td> 3+</td><td>98 (76.0%)</td><td>22 (68.8%)</td><td>76 (78.4%)</td><td></td></tr><tr><td>HER2 amplification index</td><td>7.0 ± 5.9</td><td>7.7 ± 6.3</td><td>4.1 ± 1.4</td><td>0.005</td></tr><tr><td>PTEN expression</td><td></td><td></td><td></td><td>0.017</td></tr><tr><td> Loss</td><td>11 (16.4%)</td><td>5 (38.5%)</td><td>6 (11.1%)</td><td></td></tr><tr><td> Intact</td><td>56 (83.6%)</td><td>8 (61.5%)</td><td>48 (88.9%)</td><td></td></tr><tr><td>PIK3R1 genotype</td><td></td><td></td><td></td><td>0.460</td></tr><tr><td> Variant</td><td>16 (23.2%)</td><td>5 (31.3%)</td><td>12 (22.2%)</td><td></td></tr><tr><td> Wildtype</td><td>53 (76.8%)</td><td>11 (68.8%)</td><td>42 (77.8%)</td><td></td></tr></table> |
ec52e56d699489f62246126c30ba81107ed7e26921c4e60f9d82bb19979b6478.png | simple | <table><tr><td></td><td>CKD (<i>n</i>= 6)</td><td>CKD + pravastatin (<i>n</i>= 5)</td></tr><tr><td>Focal glomerulosclerosis (%)</td><td></td><td></td></tr><tr><td> Normal</td><td>32.9 ± 7.6</td><td>23.4 ± 13.1</td></tr><tr><td> Partial</td><td>48.1 ± 10.6</td><td>62.7 ± 10.4</td></tr><tr><td> Total</td><td>19.0 ± 6.7</td><td>14.0 ± 15.8</td></tr><tr><td>Tubulo-interstitial damage</td><td></td><td></td></tr><tr><td> Fibrosis</td><td>0.78 ± 0.31</td><td>0.85 ± 0.14</td></tr><tr><td> Inflammation</td><td>1.72 ± 0.54</td><td>1.66 ± 0.22</td></tr><tr><td> Atrophy</td><td>1.09 ± 0.65</td><td>0.56 ± 0.09</td></tr></table> |
8c042be04cfcbdfe8303b20069e72ee8f551034c1fcc9512ff23b13b33b2afa7.png | complex | <table><tr><td>Dependent variables:</td><td colspan="2">Complaints of generalised anxiety</td></tr><tr><td></td><td>MEN</td><td>WOMEN</td></tr><tr><td></td><td>B</td><td>B</td></tr><tr><td>Intercept</td><td>-0.027 ***</td><td>-0.004</td></tr><tr><td>Contextual effects</td><td></td><td></td></tr><tr><td>Unemployment rate</td><td>0.032</td><td>0.075</td></tr><tr><td>Median area income (in euros)</td><td>0.245</td><td>1.214</td></tr><tr><td>Density</td><td>-0.081</td><td>0.032</td></tr><tr><td>Individual effects</td><td></td><td></td></tr><tr><td>Social support</td><td>-0.018 ***</td><td>-0.028 ***</td></tr><tr><td>Current employment situation (ref.: paid labour)</td><td></td><td></td></tr><tr><td><i>Retired</i></td><td>0.003</td><td>0.003</td></tr><tr><td><i>Disabled</i></td><td>0.091 ***</td><td>0.101 ***</td></tr><tr><td><i>Unemployed</i></td><td>0.022 ***</td><td>0.022 ***</td></tr><tr><td><i>Househusband/wife</i></td><td>-0.028</td><td>-0.011 *</td></tr><tr><td><i>Student and others</i></td><td>0.032 **</td><td>0.102</td></tr><tr><td>Educational level (ref.: tertiary education)</td><td></td><td></td></tr><tr><td><i>No diploma or primary education</i></td><td>0.008 *</td><td>0.038 ***</td></tr><tr><td><i>Lower secondary</i></td><td>0.009 *</td><td>0.017 ***</td></tr><tr><td><i>Higher secondary</i></td><td>-0.001</td><td>0.010 ***</td></tr><tr><td>Equivalent income of the household (ref.: > 2.500 <i>€</i>)</td><td></td><td></td></tr><tr><td><i>< 750 €</i></td><td>0.018 **</td><td>0.017 *</td></tr><tr><td><i>750 - 1.000 €</i></td><td>0.009</td><td>0.013 *</td></tr><tr><td><i>1.000 - 1.500 €</i></td><td>0.002</td><td>0.005</td></tr><tr><td><i>1.500 - 2.500 €</i></td><td>-0.002</td><td>-0.002</td></tr><tr><td><i>Missing income</i></td><td>-0.008</td><td>-0.011 *</td></tr><tr><td>Age</td><td>-0.002</td><td>-0.002</td></tr><tr><td>Household type (ref.: couple with child(ren))</td><td></td><td></td></tr><tr><td><i>Single</i></td><td>-0.001</td><td>-0.001</td></tr><tr><td><i>Single with child(ren)</i></td><td>-0.010</td><td>0.008</td></tr><tr><td><i>Couple</i></td><td>0.006</td><td>0.009 *</td></tr><tr><td><i>Complex household</i></td><td>0.004</td><td>0.003</td></tr></table> |
74d200590c3ca1ffb3a787fa3d8dc0d5e130fc4eb37b98c32f7a256587f624e5.png | simple | <table><tr><td>Year</td><td>First Author</td><td>No</td><td>Sex</td><td>Age</td><td>Site</td><td>Complications</td><td>Treatment</td><td>Incision</td><td>LOS (days)</td></tr><tr><td>1991 [13]</td><td>Hale</td><td>22</td><td>M</td><td>85</td><td>Sigmoid</td><td>Incarceration</td><td>Hartmann’s + intra-abdominal internal ring closure</td><td>Midline laparotomy</td><td>NA</td></tr><tr><td>2003 [12]</td><td>Tan</td><td>23</td><td>M</td><td>62</td><td>Sigmoid</td><td>Incarceration</td><td>High anterior resection + left orchidectomy + intra-abdominal closure of hernial defect</td><td>Left iliac fossa transverse</td><td>NA</td></tr><tr><td>2003 [7]</td><td>Kouraklis</td><td>24</td><td>M</td><td>79</td><td>Sigmoid</td><td>Perforation</td><td>Hartmann’s + loop colostomy + interval reversal and open hernioplasty</td><td>Left groin</td><td>10</td></tr><tr><td>2003 [16]</td><td>Cervinka</td><td>25</td><td>M</td><td>69</td><td>Sigmoid</td><td>Incarceration</td><td>Sigmoidectomy + anastomosis + defunctioning transverse colostomy + herniorrhaphy (Bassini)</td><td>Left groin</td><td>NA</td></tr><tr><td>2008 [17]</td><td>Slater</td><td>26</td><td>M</td><td>66</td><td>Sigmoid</td><td>Incarceration</td><td>Hartmann’s + left orchidectomy + internal ring closure</td><td>Left groin + midline laparotomy</td><td>NA</td></tr><tr><td>2008 [17]</td><td>Slater</td><td>27</td><td>M</td><td>73</td><td>Sigmoid</td><td>Perforation</td><td>Hartmann’s + left orchidectomy + internal ring closure</td><td>L groin + Left modified Rutherford-Morrison</td><td>NA</td></tr><tr><td>2009 [18]</td><td>Ruiz-Tovar</td><td>28</td><td>M</td><td>67</td><td>Sigmoid</td><td>Perforation without contamination</td><td>Sigmoidectomy and anastomosis + hernioplasty (Lichtenstein)</td><td>Left groin + midline laparotomy</td><td>7</td></tr><tr><td>2010 [19]</td><td>Ko</td><td>29</td><td>M</td><td>84</td><td>Sigmoid</td><td>Perforation</td><td>Hartmann’s + herniorrhaphy</td><td>Laparotomy</td><td>Deceased</td></tr><tr><td>2010 [20]</td><td>Mai</td><td>30</td><td>M</td><td>83</td><td>Sigmoid</td><td>Strangulation</td><td>Hartmann’s + herniorrhaphy</td><td>Lower midline + left groin</td><td>NA</td></tr><tr><td>2011 [5]</td><td>Pernazza</td><td>31</td><td>M</td><td>70</td><td>Caecum</td><td>Incarceration</td><td>Laparoscopic right hemicolectomy + herniorrhaphy</td><td>Laparoscopy + bilateral groin incisions</td><td>5</td></tr><tr><td>2012 [6]</td><td>Carr</td><td>32</td><td>M</td><td>65</td><td>Sigmoid</td><td>Incarceration</td><td>Laparoscopic high anterior resection + open biosynthetic hernioplasty</td><td>Laparoscopy + left groin</td><td>4</td></tr><tr><td>2013 [21]</td><td>Meniconi</td><td>33</td><td>F</td><td>78</td><td>Caecum</td><td>Incarceration</td><td>Open right hemicolectomy + herniorrhaphy</td><td>Midline laparotomy + right groin</td><td>NA</td></tr><tr><td>2013 [22]</td><td>Tan</td><td>34</td><td>M</td><td>63</td><td>Sigmoid</td><td>Perforation</td><td>Hartmann’s + herniorrhaphy</td><td>Midline laparotomy + left groin</td><td>10</td></tr><tr><td>2016 [23]</td><td>Kulasegaran</td><td>35</td><td>M</td><td>66</td><td>Sigmoid</td><td>Perforation + necrotising infection</td><td>Hartmann’s + debridement + staged skin graft</td><td>Left groin + midline laparotomy</td><td>NA</td></tr><tr><td>2016 [24]</td><td>Diao</td><td>36</td><td>M</td><td>48</td><td>Transverse colon</td><td>Perforation</td><td>Transverse colectomy + herniorrhaphy + orchidectomy + partial scrotectomy</td><td>Left groin</td><td>NA</td></tr><tr><td>2017 [25]</td><td>Sharma</td><td>37</td><td>M</td><td>84</td><td>Caecum</td><td>None</td><td>Open right hemicolectomy + herniorrhaphy</td><td>Right transverse</td><td>NA</td></tr><tr><td>2018</td><td>Current report</td><td>38</td><td>M</td><td>83</td><td>Ascending colon</td><td>Incarceration</td><td>Laparoscopic right hemicolectomy + laparoscopic defect closure</td><td>Laparoscopy</td><td>10</td></tr></table> |
ab132861fa58245909a6e4bed997205f54e00913ff46f5332ed2a53c1b54acbf.png | complex | <table><tr><td></td><td>Normotensive pregnancy (<i>n</i> = 3183)</td><td>Gestational hypertension (<i>n</i> = 145) Beta (95% CI)</td><td><i>P</i> value</td><td>Pre-eclampsia (<i>n</i> = 63) Beta (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="6">Retinal arteriolar caliber (SDS)</td></tr><tr><td> Full model</td><td><i>Ref</i></td><td>–0.20 (–0.34, –0.05)</td><td>0.007</td><td>–0.40 (–0.62, –0.19)</td><td>0.0002</td></tr><tr><td colspan="6">Retinal venular caliber (SDS)</td></tr><tr><td> Full model</td><td><i>Ref</i></td><td>0.22 (0.07–0.36)</td><td>0.003</td><td>0.08 (–0.13, 0.30)</td><td>0.45</td></tr></table> |
42680961659dac59e806ee0123b21dbf4f937d94eb9c3464598c90a57e2510ea.png | complex | <table><tr><td rowspan="2">Medium</td><td colspan="5">Time</td></tr><tr><td>0 day</td><td>1 day</td><td>3 days</td><td>5 days</td><td>7 days</td></tr><tr><td>Water</td><td>208.7 ± 12.6</td><td>214.2 ± 10.1</td><td>217.7 ± 9.5</td><td>224.4 ± 10.6</td><td>227.8 ± 13.4</td></tr><tr><td>PBS plus 10% (<i>v</i>/<i>v</i>) FBS</td><td>254.5 ± 5.7</td><td>260.1 ± 4.5</td><td>279.6 ± 7.7</td><td>288.9 ± 10.2</td><td>302.5 ± 9.8</td></tr><tr><td>PBS</td><td>286.6 ± 18.5</td><td>310.6 ± 35.8</td><td>347.0 ± 37.4</td><td>369.6 ± 41.2</td><td>404.4 ± 25.9</td></tr><tr><td>1.0 mol/L NaCl</td><td>542.7 ± 50.4</td><td>784.1 ± 45.7</td><td>1,009.2 ± 66.3</td><td>1,445.4 ± 57.1</td><td>1,667.8 ± 87.0</td></tr></table> |
d67d7d72921715cd03914076708168d36d3d598a24d008ab27c2af03af91cb56.png | complex | <table><tr><td>Cell lines</td><td colspan="4">IC50</td></tr><tr><td></td><td>GEM (μM)</td><td>OSI-027 (μM)</td><td>OSI-027 (μM) + GEM (μM)</td><td>Interaction</td></tr><tr><td>Panc-1</td><td>14.79 (10.34 to 19.20)</td><td>21.93 (17.37 to 26.48)</td><td>OSI8.951 (8.309 to 9.594)GEM0.8951 (0.8309 to 0.9594)</td><td>0.465 synergy</td></tr><tr><td>BxPC-3</td><td>0.7716 (0.6574 to 1.356)</td><td>8.551 (7.913 to9.187)</td><td>OSI 3.041 (2.799 to9.594)GEM 0.3041 (0.279 to 0.959)</td><td>0.749 synergy</td></tr><tr><td>CFPAC-1</td><td>0.6796 (0.6082 to 0.751)</td><td>13.96 (13.06 to 14.85)</td><td>OSI 2.702 (2.554 to2.850)GEM0.2702 (0.2554 to 0.2850)</td><td>0.59 synergy</td></tr></table> |
4413ef9a1fe09853a4c51393d92cd339a0f54f3336cd8914cb0c9526d2361b2c.png | simple | <table><tr><td>Statistical value </td><td>DR: VC</td><td>DR: RMSSD</td><td>DR: max-min</td><td>VR</td><td>Rest: VC</td><td>Rest: RMSSD</td><td>DR: max/min</td><td>PI</td></tr><tr><td>Ancova F</td><td>10.854</td><td>8.492</td><td>9.016</td><td>0.380</td><td>6.512</td><td>0.493</td><td>6.467</td><td>2.70</td></tr><tr><td>p-value</td><td><0.01</td><td><0.04</td><td><0.005</td><td>n.s.</td><td><0.02</td><td>n.s.</td><td><0.02</td><td>n.s.</td></tr></table> |
7cd58f259919390bef4a9b742061d74f296e4937b2e3608de6822f9ffcb338b6.png | complex | <table><tr><td>Target<sup>a</sup></td><td>Nucleotide sequence (5′ to 3′)</td><td>Amplicon size (bp)</td><td>Reference</td></tr><tr><td rowspan="2"><i>cfb</i><sup>b</sup></td><td>F: CACACATGCTGTTGGAGTTCAGTTGA</td><td rowspan="2">138</td><td>This study</td></tr><tr><td>R: ACGAAGTCGACAGCATCACACGAAA</td><td></td></tr><tr><td rowspan="2"><i>erm</i>(A)/(TR)</td><td>F: CCGGCAAGGAGAAGGTTATAATGA</td><td rowspan="2">190</td><td>Otaguiri et al. [5]</td></tr><tr><td>R: GCATTCACCCGTTGACTCATTTCC</td><td></td></tr><tr><td rowspan="2"><i>erm</i>(B)</td><td>F: GCTCTTGCACACTCAAGTCTCGAT</td><td rowspan="2">117</td><td>Otaguiri et al. [5]</td></tr><tr><td>R: ACATCTGTGGTATGGCGGGTAAGT</td><td></td></tr><tr><td rowspan="2"><i>mef</i>(A/E)</td><td>F: GCGATGGTCTTGTCTATGGCTTCA</td><td rowspan="2">225</td><td>Otaguiri et al. [5]</td></tr><tr><td>R: AGCTGTTCCAATGCTACGGAT</td><td></td></tr><tr><td rowspan="2"><i>RNaseP</i></td><td>F: AGATTTGGACCTGCGAGCG</td><td rowspan="2">64</td><td>WHO [27]</td></tr><tr><td>R: GAGCGGCTGTCTCCACAAGT</td><td></td></tr><tr><td rowspan="2">IGS1</td><td>F: GTCATTTCAGCTGGCGCCATCGATAC</td><td>260</td><td>Tavares et al. [32]</td></tr><tr><td>R: TTGCCGCATAACGCATCTTAGCCA</td><td></td><td></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.